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BACKGROUND Thrombotic disease is rare but significant in women of reproductive age.
Thrombosis and thromboembolism are the most common causes of maternal death in the
United Kingdom. Pre-eclampsia is associated with increase in immediate and lifetime risk of
adverse thrombotic events. Both pregnancy and the follicular phase are associated with
arterial thrombosis and myocardial infarction. Modulation of haemostatic mechanisms in
reproductive physiology and disease is not well understood. Outwith pregnancy, stimulated
tissue plasminogen activator (t-PA) release, platelet activation, arterial stiffness and
circulating endothelial progenitor cell (EPC) number are established indicators of vascular
pathology and prognosis.
AIMS (i) To compare endogenous fibrinolysis between pregnant women and non-pregnant
control women, (ii) To make serial measurements of reproductive hormones, inflammatory
mediators, platelet and monocyte activation, arterial stiffness and circulating EPCs
throughout the normal menstrual cycle, healthy pregnancy, and pregnancy affected by pre¬
eclampsia.
METHODS (i) Endogenous fibrinolytic capacity was assessed using forearm venous sampling
and plethysmography during intra-arterial infusion of bradykinin (a known stimulant of
endothelial t-PA release). Healthy women in the third trimester were recruited from antenatal
clinics. Healthy volunteers were studied in their follicular phase, (ii) Platelet-monocyte
aggregates and surface markers of platelet and monocyte activation were assessed with flow
cytometry. Reproductive hormones, inflammatory mediators (soluble intercellular adhesion
molelcule-l (ICAM-1), interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-a)) and
soluble markers of platelet activation were measured by enzyme-linked immunosorbent
assay (ELISA). Arterial stiffness was derived using pulse wave analysis (PWA) and pulse
wave velocity (PWV). Circulating EPCs were assessed by flow cytometry and cell culture.
All measurements were taken longitudinally in three different populations: healthy women
during a single menstrual cycle (4 time points), healthy pregnant women (4 time points and
post-partum) and women with pre-eclampsia (at diagnosis and post-partum).
RESULTS (i) Pregnant women had more plasminogen activator inhibitor type 1 (PAI-1)
antigen and lower active t-PA plasma concentrations than non-pregnant women,
(ii) Pregnant women had greater platelet and monocyte activation, plasma soluble ICAM-1
and IL-6 than non-pregnant women. There was no difference in platelet activation or
inflammatory mediators between healthy and pre-eclamptic pregnant women. Systemic
arterial stiffness varies during the menstrual cycle. In pregnancy both systemic and central
arterial stiffness are lowest during the second trimester. Arterial stiffness was greater in pre¬
eclampsia and this persisted post-partum, despite blood pressure returning to normal.
Concentration of EPCs (cytometry) varied during the menstrual cycle and was greatest in the
follicular phase. Endothelial progenitor cell colony formation was reduced in healthy
pregnancy compared to the follicular phase. There was no difference in either EPC assay
between healthy and pre-eclamptic pregnant women.
CONCLUSIONS Important constituents of thrombotic and inflammatory activity are observed
to vary with normal changes in reproductive status. No difference was observed in these
factors between healthy pregnant and pre-eclamptic women. Greater arterial stiffness was
observed in pre-eclamptic women, also continuing after pregnancy. This may contribute to
the increased immediate and lifetime risk of vascular disease in these women. Variation in
circulating EPCs during the menstrual cycle may be due to a role in endometrial
angiogenesis.
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ABBREVIATIONS
AcLDL acetylated low-density lipoprotein
AIx augmentation index
ANOVA analysis of variance
APC allophycocyanin
BD Becton Dickinson
bpm beats per minute
BMI body mass index
CD cluster of differentiation
CFU-EPCs colony forming unit-endothelial progenitor cells
CV coefficient of variation
D day
DAPI 4',6-Diamidino-2-phenylindole dihydrochloride




ECCM EndoCult™ complete culture medium
ECM extra cellular matrix
EDTA Ethylenediaminetetraacetic acid
ELISA Enzyme-Linked Immunosorbent Assay
EPC endothelial progenitor cell
ER oestrogen receptor




FSH follicle stimulating hormone
G-CSF granulocyte-colony stimulating factor





HLA human leucocyte antigen
HSCs haematopoietic stem cells
HUVECs human umbilical vein endothelial cells
ICAM-1 intercellular adhesion molecule-1
Ig immunoglobulin
IL interleukin
ISSHP International Society for the Study of Hypertension in
Pregnancy
IU international units
JAM junctional adhesion molecule




m/s metres per second
Mac-1 membrane-activated complex-1
MCP monocyte chemo tactic protein
MFI mean fluorescent intensity
mL millilitre
NF-kp nuclear factor kappa |3
NP non-pregnant
PAF platelet activating factor
PAI-1 plasminogen activator inhibitor type 1
PBMCs peripheral blood mononuclear cells




PSGL-1 P-selectin glycoprotein ligand-1
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PWA pulse wave analysis
PWV pulse wave velocity
RANTES Regulated upon Activation, Normal T-cell Expressed, and
Secreted
RNA ribonucleic acid
RPMI Rosewell Park Memorial Institute
SDF-1 stromal cell-derived factor-1
SEM standard error of the mean
SNP sodium nitroprusside
SSC side-scatter
sys BP systolic blood pressure
TM thrombomodulin
TNF-a tumour necrosis factor alpha
t-PA tissue plasminogen activator
UEA-1 Ulex europaeus agglutinin-1
VCAM-1 vascular cell adhesion molecule-1
VEGF vascular endothelial growth factor
VSMCs vascular smooth muscle cells
vWF von Willebrand factor
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The endothelium plays a central role in vascular homeostasis. Female sex hormones
affect vascular health, with oestrogens in particular having protective effects on
vascular structure and function. During the reproductive years, female sex steroids
fluctuate cyclically during the menstrual cycle and increase dramatically in
pregnancy. Thrombotic disease is rare but significant in women of reproductive age.
For example: myocardial infarction is more common in the follicular phase of the
menstrual cycle, pregnancy is associated with an increased risk of arterial and venous
thrombosis, and women with pre-eclampsia have an increase in immediate and
lifetime risk of adverse thrombotic events. The mechanisms linking reproductive
processes and thromboembolic disease are not well understood. Outwith pregnancy,
stimulated tissue plasminogen activator (t-PA) release, platelet activation, circulating
endothelial progenitor cell (EPC) number and arterial stiffness are established
indicators of vascular pathology and prognosis. The effect of the menstrual cycle,
normal and pre-eclamptic pregnancy upon specific areas of vascular health;
thrombosis, angiogenesis and arterial stiffness, using the markers described above is
the subject of this thesis. The background is presented below.
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1.1 THE VASCULAR ENDOTHELIUM
The vascular endothelium is a metabolic organ forming a dynamic interface between
blood and tissues. Comprised of a monolayer of cells it is central to the regulation of
blood vessel tone and permeability; acts as a non-adhesive surface for leucocytes and
platelets and produces important factors in the regulation of fibrinolysis and blood
flow.
The term 'endothelial dysfunction' is widely used to imply disturbance of normal
homeostatic pathways, predisposing to vasoconstriction, platelet activation and
thrombosis. In many clinical studies it is assessed by endothelium-dependent
vasomotion [McCarthy et al, 1993], However, solely assessing function by
endothelium-dependent vasomotion is restrictive and inaccurate, as altered
vasomotion may not reflect other capacities of the endothelial cell, such as t-PA
release. For example, both smokers and hypertensive patients have impaired
endogenous t-PA release but preserved endothelium-dependent vasomotion
[Hrafnkelsdottir et al, 1998; Pretorius et al, 2002; Hrafnkelsdottir et al, 2004b].
Recognising differing states of endothelial cell activation, where some pathways may
be up-regulated and others inhibited will aid understanding of the role of the
endothelium in different pathologies.
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1.1.1 Endothelial cell activation
Endothelial cell activation was defined in 1988 as "a quantitative change in the level
of expression of certain gene products (proteins) that in turn, endow endothelial cells
with new capacities to perforin new functions" [Pober, 1988]. Endothelial cell
activation encompasses many interlinked responses such as the immunoregulatory
cytokine interleukin (IL)-l stimulating thrombin production. There are five main
components of endothelial cell activation: loss of vascular integrity; expression of
leucocyte adhesion molecules (P-selectin, E-selectin, intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1); secretion
of cytokines (IL-1, IL-6, IL-8, monocyte chemo tactic protein (MCP)); pro-
thrombotic changes; and up-regulation of human leucocyte antigen (HLA) molecules
(Figure 1).
Changes associated with Endothelial Cell Activation
Figure 1. Changes associated with endothelial cell activation.
vWF - von Willebrand factor; TM - thrombomodulin; PAF - platelet activating factor; PAI-1 -
plasminogen activator inhibitor type 1; IL - interleukin. Adapted from Hunt BJ, 2002 [Hunt BJ, 2002].
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The loss of vascular integrity and expression of leucocyte adhesion molecules results
in leucocyte tethering and subsequent migration into underlying tissues. In addition
to being a target for cytokine action as a result of infectious and non-infectious
inflammatory states, the endothelium is a source of cytokines, particularly IL-1 and
IL-6 and the chemo attractants IL-8 and MCP, further potentiating the inflammatory
response. The pro-thrombotic effects of endothelial cell activation are due to loss of
antithrombotic effects and expression of thrombotic molecules and are described in
detail below.
1.1.2 Impaired endothelium-dependent vasomotion
The ability of acetylcholine to induce relaxation of vascular smooth muscle is
dependent on endothelial cells, endothelium-dependent relaxation. Damage to, or
removal of the endothelium results in impaired relaxation of the vascular smooth
muscle to acetylcholine, though it still responds to glyceryl trinitrate. Endothelium-
dependent relaxation is in part mediated by nitric oxide, continuous basal release of
which from the vascular endothelium maintains resting tone. Impaired endothelium-
dependent relaxation is associated with several disease states, including





The endothelium plays a central role in haemostasis, through its regulation of
coagulation and fibrinolysis. In a healthy state it produces the anticoagulants
thrombomodulin, protein S, tissue factor pathway inhibitor and heparin sulphate
proteoglycans as well as inhibitors of platelet aggregation [Jin et al, 2005].
Disturbances in normal endothelial function secondary to injury or inflammation can
cause it to become pro-coagulant, through down-regulation of its anticoagulant
functions; increased secretion of platelet activating factor, von Willebrand factor
(vWF) and fibronectin, as well as increased tissue factor expression [Rosenberg and
Aird, 1999; van Hinsbergh, 2001], The role of the endogenous fibrinolytic system is
to protect the circulation from intravascular fibrin formation and thrombosis.
Tissue plasminogen activator
Tissue plasminogen activator is a 68kDa serine protease synthesised and released,
both constitutively and faculatively by the endothelium. The pathways that regulate
release are poorly described, though facultative release is thought to involve G-
coupled protein receptors and intracellular calcium signalling. Factors stimulating
release include factor Xa and thrombin from the clotting cascade, as well as
bradykinin [Emeis, 1992; Brown et al, 1997], The synthesis of t-PA varies with
anatomical site, reflecting heterogeneity in endothelial cell function. The capacity of
the endothelium to secrete t-PA is large; continuous release can be stimulated for
many hours and concentrations in the forearm approach those achieved by systemic
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thrombolytic therapy [Witherow et al, 2002], Once released by the endothelium,
t-PA catalyses the conversion of plasminogen (which circulates in molar excess) to
plasmin, which in turn degredates fibrin to soluble fibrin degredation products. The
plasma half-life of t-PA is approximately 5 minutes and it is predominately cleared
by the liver [Narita et al, 1995].
Little circulating t-PA is functionally active, as the majority is bound to the serine
protease inhibitors, mostly plasminogen activator inhibitor type 1 (PAI-1)
[Nordenhem and Wiman, 1998]. The proportion of active t-PA in the circulation
varies inversely with PAI-1 concentrations, as PAI-1 circulates in molar excess of
t-PA and complex formation between the t-PA and PAI-1 is rapid, thus limiting
circulating active t-PA (Figure 2).
Figure 2. PAI-1 binds most t-PA in plasma. Only unbound fractions are active. Other protease
inhibitors include PAI-2, which is produced by the placenta in pregnancy.
PAI-1 - plasminogen activator inhibitor type 1; t-PA - tissue plasminogen activator. Adapted from
Oliver et al, 2005 [Oliver et al, 20051.
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To achieve effective thrombolysis, quick local release of t-PA is required. The
relative balance between plasma t-PA and PAI-1, and the acute release of t-PA from
the endothelium determines the efficacy of endogenous fibrinolysis during
intravascular thrombus formation or endothelial injury [Oliver et al, 2005], The local
capacity for acute endothelial t-PA release is not reflected by basal plasma t-PA
concentrations [Hrafnkelsdottir et al, 2004a], which highlights the importance of
assessing acute local endothelial t-PA for its pathophysiological relevance.
Clinical relevance
Impaired t-PA release has been demonstrated in the forearm of cigarette smokers and
hypertensive subjects who are at increased risk of thrombotic disease [Newby et al,
1999; Ridderstrale et al, 2006], In stable coronary heart disease patients, reduced
acute t-PA release predicts future cardiovascular events [Robinson et al, 2007],
Gender differences exist in acute endothelial t-PA release with middle-aged women
releasing more than men [Stauffer et al, 2005]. The hypercoaguable state of
pregnancy is associated with increased basal plasma concentrations of PAI-1 and
PAI-2 [Hellgren, 2003], due in part to their production by the placenta [Vassalli et al,
1991], However, acute endothelial t-PA release has not been fully evaluated in
pregnancy.
Assessment ofacute endothelial t-PA release
The facultative release of t-PA by the endothelium can be demonstrated in humans in
vivo, by use of several clinical models using infusions of bradykinin and substance P
to stimulate release. Systemic release can be measured following intravenous
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infusion of these agents but is not thought to represent local t-PA activity due to the
confounding factors of clearance and PAI-1 complex formation. The venous
occlusion test, which measures increased concentrations of pooled t-PA in venous
plasma in an upper or lower limb has been used but is now surpassed by the
combined technique of venous occlusion together with intra-arterial infusions of
stimulant drugs. The most common method used in clinical research involves
infusions of substance P, bradykinin or desmopressin into the brachial artery and
collecting outflowing venous blood from both the infused and non-infused arms. Net
release of t-PA can be calculated from the concentration difference in plasma t-PA
antigen and activity between arms, the haematocrit (Hct) and forearm blood flow
(FBF) and is described in more detail in Chapter 2. This method is highly
reproducible and provides an accurate assessment of stimulated t-PA release as well
as endothelium-dependent and independent vasomotion [Newby et al, 2002].
1.2.2 Interaction of platelets and monocytes
Platelets are critical to haemostasis through clot formation following activation of the
coagulation pathway. In addition platelets mediate inflammation through interactions
with circulating leucocytes and the endothelium, together with the release of platelet-
derived chemokines [Henn et al, 1998; Levi et al, 2003].
Platelets may either become activated in the circulation by cytokines including IL-1
and IL-6 associated with systemic inflammatory or thrombotic events, or by
interactions with activated endothelium [Levi et al, 2003]. In the non-activated state
the endothelium prevents adhesion of platelets to the vessel wall by release of nitric
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oxide, prostacyclin and cyclooxygenase-2 [Jin et al, 2005], As described above,
endothelial cell activation results in a pro-thrombotic endothelial phenotype with the
release of vWF and the up-regulation of tissue factor and adhesion molecules such as
ICAM-1. These changes further promote platelet-endothelial interactions and
subsequent platelet activation [Rosenberg and Aird, 1999; van Hinsbergh, 2001],
Platelet-endothelial cell binding and platelet release of IL-1|3 results in further
endothelial cell activation via nuclear factor kappa (J (NF-k|3) activation, with
subsequent up-regulation of adhesion molecules on the endothelial cell, including
ICAM-1 and P-selectin as well as release of MCP-1, IL-6 and 8, vWF and matrix
metalloproteinases [Hawrylowicz et al, 1991]. Thus platelet adhesion results in a
pro-inflammatory endothelium.
When platelets become activated, conformational changes occur in the glycoprotein
(GP) allb(33 (GP lib Ilia) and in the integrin a2|31 resulting in exposure of the
fibrinogen and collagen binding sites, respectively. These changes mediate firm
adhesion of the platelet to the endothelium. In addition, exposure of the a-granule
membrane protein, P-selectin on the platelet surface occurs together with cluster of
differentiation (CD)40 ligand (CD40L/CD154) and tumour necrosis factor super
family 14 expression [Henn et al, 1998; Michelson, 2006]. The activated platelet
binds secreted platelet proteins, thrombospondin and multimerin to its surface and
releases inflammatory mediators including IL-1 (3 and platelet factor (PF)4 [van Gils
et al, 2009],
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Adherent platelets recruit monocytes
Adherent, activated platelets on the endothelial monolayer also recruit monocytes.
This happens directly between P-selectin expressed on the activated platelet and P-
selectin glycoprotein ligand-1 (PSGL-1) constitutively expressed on the monocyte
[Kuijper et al, 1998]. Interaction of these surface molecules also induces monocyte
expression of membrane-activated complex-1 (Mac-1) (CD1 lb/CD 18) which
promotes further monocyte to platelet binding through its association with GPlb and
junctional adhesion molecule (JAM)-c on platelets [Neumann et al, 1999]. The
CD40-CD40 ligand dyad also mediates further platelet-monocyte interactions.
Indirectly, chemokines released by the activated platelet such as PF4 and Regulated
upon Activation, Normal T-cell Expressed, and Secreted (RANTES) also recruit
monocytes, promoting adhesion to the vessel wall [Lindmark et al, 2000].
Circulating activated platelets bind leucocytes
System inflammatory or thrombotic conditions can result in circulating activated
platelets, binding to leucocytes, predominately monocytes to form complexes:
known as circulating platelet-monocyte aggregates (Figure 3). This interaction is
predominately due to P-selectin on platelets, binding to PSGL-1 on monocytes
[Sarma et al, 2002], with stabilisation occurring through monocyte Mac-1 and
platelet GPlb. The formation of platelet-monocyte aggregates depends mostly on
platelet activation and is considered to be a sensitive marker of in vivo platelet
activation [Michelson et al, 2001]. Importantly, platelet-monocyte aggregates have
multiple functional consequences [van Gils et al, 2009],
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Figure 3. Monocytes form multiple conjugates with platelets. Whole unfragmented platelets (green)
are bound to monocytes (red). Unbound platelets arc also clearly visible. Reproduced with permission
from Sarma et al, 2002 [Sarma et al, 2002].
Monocyte activation and interaction with the endothelium
Platelet-monocyte aggregates have increased adhesive and transmigrate capacity
compared to platelet-free monocytes [van Gils et al, 2009]. Binding of platelets to
monocytes, through P-selectin-PSGL-1 and also CD40-CD40L, together with the
action of platelet-derived chemokines results in monocyte activation, with shedding
of L-selectin. Platelet-monocyte interactions also increase NF-k|3 activity within the
monocyte with subsequent release of pro-inflammatory mediators including tumour
necrosis factor (TNF)-a, IL-8, MCP-1, 1L-1|3 and tissue factor [Neumann et al,
1997; Li et al, 2008]. Finally, increased expression and activity of Bi and B2
(Mac-1) integrins increase the adhesive capacity of monocytes which in turn affects
their ability to tether to endothelial cells [da Costa Martins et al, 2004] and decreases
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their rolling velocity, secondary to L-selectin shedding. Together, these result in
increased contact of the monocyte with endothelial cells and exposure to chemokines
and adhesion molecules. RANTES, IL-8 and MCP-1 released by platelets and
endothelial cells promote the arrest of rolling monocytes, and endothelial cell
expression of integrins such as ICAM-1 binding to Mac-1 on monocytes cause stable
adhesion of the monocyte to the endothelium [Gerszten et al, 1999], Subsequent to
stable adhesion on the endothelium, monocytes transmigrate into the sub-endothelial
space.
Clinical relevance
Platelet, monocyte and endothelial cell activation are closely linked. Interaction of
activated platelets with monocytes, either within the circulation or on the endothelial
surface results in monocyte activation. The activated monocyte becomes more
adhesive, migratory, pro-inflammatory and pro-coagulant and causes further
endothelial, platelet and monocyte activation. Platelet-monocyte aggregates as
markers of platelet activation are elevated in vascular pathologies such as myocardial
infarction and stroke and are increasingly considered to be a cardiovascular risk
factor [Furman et al, 1998]. Establishing the effect of reproductive processes on
platelet and monocyte activation may help link thromboembolic disease and
reproductive processes.
Assessment ofplatelet- monocyte aggregates, platelet and monocyte activation
The technique of flow cytometry, described in detail in Chapter 2, allows the
detection of specific activation-dependent changes on the platelet surface as well as
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their interactions with other cells including monocytes. Platelets are extremely
susceptible to ex vivo activation by sampling and handling methods. The use of flow
cytometry allows evaluation of in vivo platelet and monocyte activation in whole
blood [Michelson et al, 2000]. Using this technique, the expression of platelet
surface P-selectin, monocyte surface CD40 and CDllb and the formation of
circulating platelet-monocyte aggregates can be quantified. These are considered
highly sensitive and physiologically relevant markers of platelet [Michelson et al,
2001] and monocyte activation [Shi and Simon, 2006].
1.3 ANGIOGENESIS
The discovery of endothelial progenitor cells has generated considerable interest in
the field of vascular biology. These cells arise from a population of circulating
mononuclear cells and have the capacity to form new blood vessels and contribute to
vascular repair. Circulating EPC numbers are reduced in patients with cardiovascular
risk factors and in the presence of endothelial dysfunction, but are increased in
response to ischaemia, oestrogens and drug therapy. They have been studied in
pathologies from cardiovascular and renal disease to rheumatoid arthritis and pre¬
eclampsia.
1.3.1 Characterisation of circulating epcs
Endothelial progenitor cells are characterised by their expression of both
haematopoietic and mature endothelial cell antigens, and by their ability to
proliferate, migrate and differentiate into mature cell types. Asahara et al exploited
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two antigens shared by endothelial cells and haematopoietic stem cells (HSCs) to
isolate putative EPCs from peripheral blood [Asahara et al 1997], CD34 is expressed
by most mature endothelial cells [Fina et al, 1990] as well as all HSCs but is lost by
haematopoietic cells as they differentiate [Civin et al, 1984], Kinase insert domain
receptor (KDR), the extracellular domain of vascular endothelial growth factor
(VEGF) receptor [Shalaby et al, 1995], is also expressed by both early HSCs and
endothelial cells but is lost on haematopoietic cell differentiation [Matthews et al,
1991]. CD34 positive (+) and KDR+ cells isolated from peripheral blood leucocytes
form vascular structures in vitro and incorporate into the vessel wall in experimental
models of neovascularisation [Asahara et al, 1997],
Co-expression of CD34 and KDR has been used in a number of experimental and
clinical studies to identify circulating EPCs. No surface marker unique to endothelial
progenitors has been identified and so it remains difficult to distinguish EPCs from
mature endothelial cells that have been swept into the circulation and haematopoietic
cells. CD 133 is expressed by haematopoietic cells, but not by mature endothelial
cells. Identification of CD133, KDR and CD34 co-expression may differentiate
between circulating mature and progenitor endothelial cells [Peichev et al, 2000],
The rarity of EPCs in peripheral blood (100-200 cells mL"1) has made their study
difficult.
Alternative methods have been described for the characterisation and quantification
of EPCs based on the culture of endothelial cells from circulating mononuclear cells.
A number of functional assays have been reported, most involving the isolation of
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peripheral blood mononuclear cells by density centrifugation of blood and
subsequent culture on fibronectin coated plates. After 5 to 7 days in culture, adherent
colonies are seen, where spindle shaped cells emerge from a cluster of round cells
(colony forming unit-endothelial progenitor cells (CFU-EPCs)). These adherent cells
display a variety of endothelial-like properties including the uptake of acetylated
low-density lipoprotein (AcLDL) and staining with a lectin of Ulex europaeus
(UEA-1), (specific for endothelial cells in a variety of tissues binding to the
carbohydrate moiety a-L-fucose [Stephenson et al, 1986]).
Studies addressing the origin of EPCs have demonstrated that monocytes express
endothelial lineage markers such as KDR and can differentiate into endothelial cells
[Schmeisser et al, 2001]. Rehman et al, found that the majority of CFU-EPCs
expressed monocyte markers such as CD 14, Mac-1, and CD 11c, suggesting that
peripheral blood EPCs are derived from monocyte-like cells [Rehman et al, 2003],
The concept that functional endothelial cells may originate from a CD 14+progenitor
is supported by reports that mature endothelial cells from human umbilical vein
express CD 14 [Jersmann et al, 2001] and that isolated CD14+ cells can improve
neovascularisation after mouse hind limb ischaemia [Urbich et al, 2003]. Figure 4
outlines two potential ways that endothelial cells might arise from HSCs via myeloid


















/_ j CD 14
CD34
CD14
Figure 4. Possible pathways by which endothelial cells may arise from haematopoietic stem cells.
Haemangioblasts give rise to circulating haematopoetic stem cells of myeloid or endothelial
progenitor subtypes, with endothelial cells potentially derived from either pathway.
KDR - Kinase insert domain receptor; CD - cluster of differentiation; EPC - endothelial progenitor
cell. Reproduced with permission from Robb et al, 2007 [Robb et al, 2007].
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In this emerging field, many different methods have been used to characterise and
quantify putative endothelial progenitors, preventing straightforward comparison.
Reduced levels of both phenotypic [Schmidt-Lucke et al, 2005] and functional EPCs
[Werner et al, 2005] (Table 1) predict adverse outcome in patients with coronary
artery disease. Whilst questions remain as to the origin and phenotype of EPCs,
evidence that they contribute to vascular repair and neoangiogenesis in animal
models is compelling.
TABLE 1 Characteristics of endothelial progenitor cells
Phenotypic • Cell-surface expression of haematopoietic stem-cell (CD34,
CD133) and endothelial cell antigens (KDR)
Functional • Produce characteristic colonies and tubular structures on
fibronectin in vitro
• Migrate and incorporate into areas of vascular damage in vivo
• Differentiate into mature endothelial cells
CD - cluster of differentiation; KDR - kinase insert domain receptor.
1.3.2 Mobilisation and differentiation of epcs
Integrity of the vascular endothelium is a dynamic equilibrium between endothelial
degeneration and repair [Karter et al, 2004], The concept of a pool of endothelial
progenitors in the bone marrow, capable ofmoving to effect angiogenesis or vascular
repair in response to ischaemia or vascular injury is supported by both in vitro and in
vivo studies. In a mouse model, Asahara et al demonstrated differentiation of donor
bone marrow cells into endothelial cells and their subsequent incorporation into the
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vasculature during processes such as ovulation, wound healing, recovery from hind
limb ischaemia and neoplasia [Asahara et al, 1999].
The postulated factors responsible for mobilisation of EPCs from the bone marrow
are the subject of an intense search. Such a factor might form a therapeutic strategy
to enhance vascular repair. EPCs are released in the context of acute ischaemic
injury, such as myocardial infarction [Leone et al, 2005; Massa et al, 2005] and
following vascular injury as a consequence of coronary artery bypass grafting [Gill et
al, 2001]. Vascular endothelial growth factor and stromal cell-derived factor-1 (SDF-
1), both released from ischaemic tissue, are thought to be important factors in the
mobilisation of EPCs. Other cytokines such as granulocyte-colony stimulating factor
(G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) mobilise
both haematological progenitors and EPCs. These have been used for many years to
harvest progenitors for autologous bone marrow transplantation in the context of
haematological malignancy. However, they also induce a pro-inflammatory state that
may limit their therapeutic potential.
Mechanisms of EPC mobilisation in conditions other than ischaemia may be more
relevant to understanding the role of EPCs in healthy women. The effect of
oestrogens in maintaining endothelial function may be related to EPC mobilisation
and enhanced vascular repair. In a rat carotid injury model, exogenous oestradiol
accelerates re-endothelialisation and attenuates medial thickening via mobilisation
and proliferation of bone marrow-derived EPCs. This response was absent in
endothelial nitric oxide synthase knock out animals [Iwakura et al, 2003], Recent
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mouse studies with oestrogen receptor (ER) a and (3 knockout animals demonstrate
roles for both receptors in EPC-mediated neovascularisation in response to
ischaemia. In addition, ERa messenger ribonucleic acid (RNA) expression was
higher than ER)3 messenger RNA expression in EPCs. Vascular endothelial growth
factor expression was significantly down regulated on EPCs from ERa knockout
mice compared with EPCs from wild type animals [Hamada et al, 2006],
1.3.3 Clinical relevance
Reduced circulating EPC levels are observed when established cardiovascular risk
factors are present suggesting a role for EPCs in the maintenance of endothelial
function. Decreased numbers of EPCs have been demonstrated in cigarette smokers
[Vasa et al, 2001] and in patients with diabetes mellitus [Tepper et al, 2002] or
rheumatoid arthritis [Grisar et al, 2005]. Hill et al [2003] observed a strong
correlation between the Framingham cardiovascular risk score (which uses
cardiovascular risk factors to predict future risk of coronary artery disease [Wilson et
al, 1987]) and circulating EPCs numbers. Endothelial progenitor cell numbers
predicted systemic endothelial function more accurately than the Framingham risk
score [Hill et al, 2003]. Furthermore, lower levels of EPCs are associated with
adverse outcome in patients with coronary artery disease [Schmidt-Lucke et al, 2005;
Werner et al, 2005]. As described, EPC mobilisation and function is affected by
inflammation, hormonal regulation and endothelial function. These factors are
pivotal to many reproductive processes, including menstruation, healthy pregnancy
and complications of pregnancy such as pre-eclampsia.
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1.3.4 Assessment of circulating epcs
Due to a lack of consensus on the definitive EPC phenotype a variety of surface
markers are in use to assess this progenitor population. Increasingly EPCs are
quantified by surface expression of phenotypic markers (CD34+CD133+KDR+) or
their ability to form colonies within an endothelial progenitor cell assay [Hill et al,
2003]. Relatively few clinical studies have either used both approaches or compared
EPC phenotype and function. Both methods are described in detail in Chapter 2.
1.4 ARTERIAL COMPLIANCE AND STIFFNESS
The compliance of a vessel is the amount by which it will increase in volume for a
given increase in distending pressure and is determined by the elastic properties of
the vessel wall. Distensibility is the proportionate increase in volume per unit
increase in distending pressure.
COMPLIANCE = AV / AP
Where AV is the increase in volume and AP the increase in pressure.
DISTENSIBILITY = [AV/V] / AP
As compliance depends on the diameter of the vessel, distensibility is more closely
related to the elastic properties of the vessel. A larger artery may have greater
compliance than a smaller artery due to its larger diameter, even though its intrinsic
elasticity may be lower. The term 'arterial stiffness' is often used to represent the
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inverse of distensibility when describing the reduction in compliance in a vessel,
which dilates very little even when exposed to a large distending pressure.
Vascular compliance has important influences on circulatory haemodynamics. The
compliance of the aorta and large arteries accommodates blood ejected from the left
ventricle in systole, reducing after load and preventing excessive rises in systolic
pressure. In diastole, when distending pressure falls, aortic contraction ensures
increased flow to the peripheral and coronary circulations. A poorly compliant or
'stiff vessel will cause excessive rise in blood pressure with systole and a
precipitous fall in diastole. Thus compliance has effects on systemic haemodynamics
in systole, and diastole but is also important for its transmission of pressure
throughout the vascular tree. When a forward pressure wave propagates through the
vascular tree, it arrives at peripheral arteries at a later time during systole. In addition
this pressure wave is reflected at various points, mostly by small arteries resulting in
reflected waves travelling back towards the heart. The total pressure in the
vasculature at any point is the sum of the forward and reflected waves. In a
compliant aorta, reflected waves arrive back during diastole with the effect of
increasing early diastolic pressure which is thought to be favourable, especially with
regard to coronary perfusion. A poorly compliant or 'stiff aorta will result in faster
travel of forward and reflected wave, with a greater proportion of reflected waves
arriving in systole, augmenting systolic blood pressure with detrimental effects
[Laurent et al, 2006; Hunt, 2002],
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1.4.1 Arterialwall structure
The intrinsic elasticity of the artery wall is determined by the individual components,
endothelial, smooth muscle and fibroblast cells within extra cellular matrix (ECM).
The endothelium releases locally active mediators such as nitric oxide, which have
immediate vasoactive properties and longer lasting trophic effects on vascular
smooth muscle cells (VSMCs). Vascular smooth muscle cells actively control wall
tension and also synthesise major structural components of the vascular wall. The
ECM comprises more than 60% of the intimal volume and is made up of collagen
and elastin, embedded in glycoproteins and proteoglycans. The ECM is increasingly
recognised as a dynamic structure, acting as a store for growth factors and containing
the enzymes, matrix metalloproteinases. Both are thought to affect cellular growth
and proliferation with resulting reorganisation of the ECM [Dollery et al, 1995;
Taipale and Keski-Oja, 1997]. In muscular arteries, compliance is greatly affected by
smooth muscle tone, with a decrease in tone associated with an increase in
compliance. In larger elastic arteries such as the aorta, compliance is less dependent
on vascular smooth muscle tone than the intrinsic elasticity of the ECM.
1.4.2 Clinical relevance
Increased arterial stiffness is an independent predictor of organ damage and
cardiovascular outcomes [Saba et al, 1993; Booth et al, 2004; Weber et al, 2005].
Within normotensive pregnancy, aortic stiffness is inversely associated with birth
weight, more than mean arterial pressure, suggesting that increased arterial
compliance may be a better representation of maternal adaptation to pregnancy than
blood pressure [Elvan-Taspinar et al, 2005]. Arterial stiffness is widely assessed in
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observational studies to further understand the mechanisms underlying
haemodynamic changes in clinical conditions and increasingly used to examine
responses to pharmacocological and non-pharmacocological interventions.
1.4.3 Assessment of arterial compliance and stiffness
Arterial compliance can be determined in several ways; high-resolution ultrasound
can be used to measure changes in vessel diameter throughout the cardiac cycle,
together with tonometry to determine pressure to calculate the compliance of
segments of the arterial tree. Two other methods, pulse wave analysis (PWA) and the
gold standard measurement, pulse wave velocity (PWV) and are in common use and
are described in detail in Chapter 2.
1.5 THE MENSTRUAL CYCLE
The normal regular menstrual cycle is about 26 to 35 days in length. It is controlled
by the hypothalamus and pituitary glands, and is divided simplistically into two
phases by the occurrence mid-cycle of ovulation. The first half of the cycle is the
follicular phase and the second half the luteal phase (Figure 5). The start of the cycle
is defined by menstruation, the process of shedding of the functional layer of the
endometrium. This has been described as an inflammatory event with local
up-regulation of cytokines, together with recruitment of leucocytes [Critchley et al,
2001]. At this point, the early follicular phase, systemic levels of both oestradiol and
progesterone are low. The mid and late follicular phases are characterised by
gradually increasing levels of oestrogen produced by the developing follicle. This is
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followed by the lutenising hormone (LH) surge and ovulation. The early luteal phase
is characterised by slightly lower concentrations of oestrogen and high levels of
progesterone. In the absence of pregnancy, progesterone levels fall following the
demise of the corpus luteum and menstruation follows.
Figure 5. Cyclical variation in ovarian hormones during the menstrual cycle.
LH - lutenising hormone; FSH - follicle stimulating hormone. Adapted from Simmen et al 2006
[Simmen et al, 2006],
1.5.1 Thrombosis
Although rare in pre-menopausal women, arterial thrombotic events do occur in
some women and incidence appears to be affected by menstrual cycle phase. During
menstruation, when circulating oestradiol concentrations are lowest, the incidence of
effort and variant angina are increased [Lloyd et al, 2000; Kawano et al, 2001] as is
the incidence ofmyocardial infarction [Mukamal et al, 2002],
Little data exists for the effect of the menstrual cycle, upon endogenous fibrinolysis
or platelet activation, in the absence of exogenous hormones. Systemic levels of t-PA
and PAI-1 have been measured throughout the menstrual cycle and found not to vary
[Koh et al, 2005], The capacity of the endothelium to release t-PA has been assessed
at different stages of the cycle using a venous occlusion test. The late luteal phase
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and the menstrual phase of the cycle were both associated with a significant fall in
fibrinolytic capacity compared to the other phases of the cycle [Siegbahn et al,
1989]. Both the above studies measured platelet function in vitro and found no
cyclical variation [Siegbahn et al, 1989; Koh et al, 2005], Both venous occlusion to
examine fibrinolytic capacity and in vitro assays of platelet activation have been
surpassed by the more sensitive and reproducible tests of forearm venous
plethysmography and flow cytometry of whole blood described above. At the outset
of this project, neither had been used to examine the effects of the menstrual cycle.
1.5.2 Angiogenesis
Growth of endometrial vasculature in preparation for implantation begins in the
proliferative phase and continues in the secretory phase of the menstrual cycle. This
physiological angiogenesis is thought to occur primarily through elongation and
intussusception of existing small vessels [Gargett and Rogers, 2001], Sprouting is
important in placentation and is also a feature of angiogenesis associated with
pathology such as ischaemia [Reynolds and Redmer, 2001] (Figure 6). Asahara et al
have implicated a role for EPCs in physiological endometrial angiogenesis where
EPCs were demonstrated within vasculature and stroma of the endometrium and
myometrium after induced ovulation in mice [Asahara et al, 1999], These animal
studies are supported by clinical studies in women demonstrating that stromal and
endothelial endometrial cells can originate from donor-derived bone marrow cells








Figure 6. Proposed mechanisms by which endothelial progenitor cells (EPCs) may contribute to
angiogenesis in human endometrium. Mature resident endothelial cells (purple) and proliferating
resident mature endothelial cells (blue). Circulating EPCs (yellow) may incorporate into endothelial
monolayer at points of elongation and intussusception, or proliferate to form new micro vessels
(sprouting). Circulating EPCs may have a supportive paracrine effect on adjacent mature endothelial
cells, through the release of angiogenic factors including vascular endothelial growth factor (VEGF).
EPCs release VEGF both in in vitro and in in vivo murine studies [Urbich et at, 2005], Reproduced
with permission from [Robb et al, 2007],
Local factors including oestradiol, TNF-a, IL-6, VEGF and ICAM-1 are implicated
in the regulation of endometrial angiogenesis [Jabbour et al, 2006]. Many of these
factors also appear to be involved in EPC mobilisation and trafficking in mouse
models [Iwakura et al, 2003; Hamada et al, 2006; Iwakura et al, 2006] and human
studies [Naiyer et al, 1999; Kalka et al, 2000]. At the commencement of this
research, no studies had assessed the effect of the menstrual cycle on circulating
levels of EPCs in human subjects.
1.5.3 Arterial compliance and stiffness
Oestrogen and progesterone both have effects on arterial structure and function
[Natoli et al, 2005]. In the pre-pubertal and post-menopausal years when female sex
steroids are low, women have stiffer arteries than age-matched men [Waddell et al,
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2001; Ahimastos et al, 2003], During the menstrual cycle, female sex steroids
fluctuate cyclically, though the available data on the effect of these fluctuations on
arterial stiffness is conflicting. Previous studies demonstrate either no change
[Willekes et al, 1997] or an increase in compliance in the ovulatory phase compared
to the follicular and luteal phase [Giannattasio et al, 1999; Williams et al, 2001].
These studies are not easily comparable because of differing methodologies
employed, sample population characteristics, and timing of sampling. Therefore, the
aim of the studies undertaken in this thesis was to address these issues by measuring
arterial stiffness with a sensitive, reproducible technique in a well-characterised
population at clearly defined time-points.
1.6 HEALTHY PREGNANCY
Pregnancy necessitates cardiovascular adaptation to sustain the developing foetus.
Initially, peripheral vascular resistance falls resulting in an increase in cardiac output
and plasma volume expands [Ginsburg and Duncan, 1967; Ueland et al, 1969; Pirani
et al, 1973], In normal pregnancy, there is enhanced endothelial function and
reactivity with greater production of endothelium-derived vasodilators [Goodman et
al, 1982; Williams et al, 1997; Anumba et al, 1999a], Flow-mediated dilatation of
the brachial artery increases with the gestational week suggesting maintenance of
endothelial vascular function [Dorup et al, 1999],
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1.6.1 Inflammatory state
Endothelium-dependent vasodilatation is preserved in spite of the systemic
inflammatory response associated with normal pregnancy. There is increased
production of pro-inflammatory cytokines, including IL-6, IL-12, and TNF-a with
associated leucocytosis. The neutrophil count rises steadily throughout gestation, to
peak at term [Austgulen et al, 1994; Rebelo et al, 1995; Melczer et al, 2003; Sacks et
al, 2003]. As well as being a pro-inflammatory state, normal pregnancy is associated
with increased insulin resistance and hyperlipidaemia, controlled by hormonal
changes. Pregnancy might be considered a 'stress' test for the maternal vascular
endothelium [Sattar and Greer, 2002],
1.6.2 Thrombosis
The hypercoagulable state of pregnancy helps protect women from potentially
catastrophic haemorrhage during placentation and the post-partum period [Hellgren,
2003], However, this predisposes women to thrombosis and thromboembolism, the
leading causes ofmaternal mortality in the United Kingdom [Lewis 2005], The risks
of venous and arterial thromboembolism are both increased 4-fold in pregnancy.
Moreover in the post-partum period, these risks are up to 20-fold higher [James et al,
2007], In addition, many complications of pregnancy, such as placental abruption,
pre-eclampsia and foetal growth restriction are either caused or exacerbated by the
hypercoagulable state [Gilabert et al, 1995],
The pro-thrombotic state of pregnancy has been attributed to marked alterations in
the coagulation and fibrinolytic system, with increased plasma concentrations of
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coagulation factors VII, VIII, X, vWF and fibrinogen as well as reductions in plasma
protein S concentrations. Free, active unbound protein S concentrations are reduced
secondary to increased levels of its binding protein, complement component C4b
[Flellgren, 2003]. During pregnancy, changes in the fibrinolytic system include
increased basal plasma concentrations of both t-PA and its principal inhibitor, PAI-1
[Flellgren, 2003]. Plasma levels of PAI-2, also produced by the placenta, rise
dramatically in the third trimester. Tissue plasminogen activator activity during
pregnancy has been shown to be reduced compared to non-pregnant women, using
the venous occlusion test [Stegnar et al, 1993], though the authors acknowledged in a
later publication that the technique 'needs improvement in order to be potentially
clinically useful'. The pro-thrombotic state begins with conception, aggravated
further in late gestation as the gravid uterus partially compresses the inferior vena
cava, causing venous stasis in the lower limbs. Disturbances in coagulation and
fibrinolysis persist post-partum and make take up to 8 weeks to return to pre¬
conception values [James et al, 2007].
1.6.3 Angiogenesis
The uterine vasculature undergoes dramatic remodelling during pregnancy. In
addition to vasodilatation of the uterine artery, remodelling ofmaternal spiral arteries
provides a large vascular bed perfusing the placental intervillous space with maternal
blood [Brosens et al, 1967], During placentation, this remodelling is mediated by
interstitial and endovascular trophoblast invading maternal vessels [Pijnenborg et al,
2006], During the wave of trophoblast invasion, maternal spiral artery endothelium is
extensively damaged and then repaired. This results in a fresh layer of endothelium
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[Pijnenborg et al, 2006], The repair is thought to be effected by local endothelial
cells though it is plausible that circulating EPCs are involved.
At the commencement of this research, circulating EPCs in normal human pregnancy
had been examined in two cross-sectional studies. Different methods had been used
to characterise and quantify putative endothelial progenitors, preventing
straightforward comparisons between the studies. The first, by Sugawara et al
[2005a] studied circulating EPCs in the peripheral blood of twenty pregnant women.
They observed greater numbers of CFU-EPCs at greater gestational age which also
correlated with serum oestradiol concentrations [Sugawara et al, 2005a].
Oestrogens are known to have vasculoprotective effects, in part due to increasing
production of nitric oxide and by decreasing reactive oxygen species [Mendelsohn
and Karas, 1999]. Oestrogens also mobilise EPCs from the bone marrow in vivo.
They inhibit the senescence of EPCs and stimulate VEGF production in vitro
[Strehlow et al, 2003; Imanishi et al, 2005a]. Mobilisation of EPCs may be an
important mechanism by which oestrogens protect the vascular endothelium during
pregnancy. The second study by Gussin et al [2002] supported this hypothesis. They
cultured peripheral blood mononuclear cells from non-pregnant and pregnant
women. Early outgrowth endothelial cells were formed from both groups. Late
outgrowth cells, which have a higher proliferative potential, were only formed by the
cells from pregnant women. The authors initially hypothesised that these cells were
of foetal origin and their original intention was to optimise the culture of foetal cells.
To identify foetal cells, they stained for X and Y-chromosomes and discovered that
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none of the colonies contained foetal cells. They concluded that endothelial cells
were of maternal origin and that pregnancy is associated with mobilisation of EPCs
into the circulation [Gussin et al, 2002], Prospective studies following women
through gestation would provide more information about EPCs in pregnancy.
1.6.4 Arterial compliance and stiffness
Successful pregnancy relies on adequate cardiovascular adaptation. The initial effect
of pregnancy increasing arterial compliance is well documented in both animal and
human studies [Hart et al, 1986; Poppas et al, 1997; Slangen et al, 1997; Edouard et
al, 1998; Smith et al, 2004; Mersich et al, 2005], This increased arterial compliance
may aid adaptation to the increased cardiac output by preventing excessive rise in
systolic blood pressure.
This altered compliance is likely to be driven by altered endothelial function and
vascular smooth muscle tone, but in large arteries such as the aorta, by remodelling.
Dramatic remodelling of the uteroplacental circulation in pregnancy has been
intensively studied and described. Matrix metalloproteinases have a role in both
spiral artery remodelling and pathological remodelling of the cardiovascular system.
However the remodelling or restructuring of larger arteries in pregnancy has not been
studied to the same extent. Information that exists is largely confined to animal
studies although the increase in aortic diameter in pregnant women and further
increases with parity suggest that pregnancy causes intrinsic modifications of the
arterial wall [Hart et al, 1986; Easterling et al, 1991],
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1.7 PREECLAMPSIA
Pre-eclampsia, occurring in 2 to 7% of first pregnancies with 20 to 25% recurrence is
the most common medical complication of pregnancy. The disease, characterised by
hypertension and proteinuria, is a significant cause of maternal and perinatal
morbidity and mortality worldwide [Stone et al, 1994; Hauth et al, 2000].
Epidemiological data suggest an increased maternal risk of hypertension, coronary
and cerebrovascular disease in later life [Wilson et al, 2003].
1.7.1 Pathogenesis
Hypertension and proteinuria in pre-eclampsia are measurable endpoints of the
disease but despite recent advances, the pathogenesis of pre-eclampsia still remains
unclear. Predisposing risk factors for the development of pre-eclampsia include
genetic predisposition as well as pre-existing medical complications such as obesity,
chronic hypertension and diabetes mellitus. Several theories on the pathogenesis of
pre-eclampsia exist and the role of the placenta is pivotal. Deficient placentation
(decreased trophoblast invasion and subsequent spiral artery remodelling) is seen
histologically in most women with pre-eclampsia [Brosens et al, 1972; Pijnenborg et
al, 1991]. In addition, pre-eclampsia is associated with reduced vascular integrity,
endothelial cell activation, impaired endothelium-dependent vasodilatation and
activation of the coagulation system.
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Two main theories have been proposed:
1) The two-stage model of pre-eclampsia: reduced placental blood flow,
secondary to abnormal placentation or pre-existing maternal microvascular
disease results in a poorly perfused placenta. The placenta then releases a
circulating factor or factors into the circulation, which target the maternal
endothelium leading to the endothelial cell activation and impaired
endothelium-dependent vasomotion [Roberts and Lain, 2002].
2) The continuum theory of inflammatory response to trophoblast debris:
in this theory, pre-eclampsia is an exaggeration of the inflammatory response
characteristic of normal pregnancy. The exaggerated response is thought to
be secondary to increased trophoblast debris from a poorly perfused or larger
placenta or due to increased maternal susceptibility [Redman and Sargent,
2000],
1.7.2 Endothelial cell activation
Vascular cellular adhesion molecule-1, ICAM-1, E-selectin, endothelin-1, cellular
fibronectin and soluble markers of endothelial dysfunction are raised in the blood of
women with pre-eclampsia. Some are evident before the clinical features of the
disease [Taylor et al, 1991; Schiff et al, 1992; Kraayenbrink et al, 1993; Higgins et
al, 1998; Bretelle et al, 2001]. Other markers of endothelial cell activation including
asymmetric dimethylarginine (an endogenous inhibitor of nitric oxide synthesis)
[Savvidou et al, 2003] also rise before clinical symptoms appear.
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1.7.3 Impaired endothelium-dependent vasodilatation
Despite the pathogenesis being still under debate, resistance arteries from women
with pre-eclampsia exhibit impaired endothelium-dependent vasodilatation
[McCarthy et al, 1993], Women with pre-eclampsia are more likely to have impaired
uterine artery doppler waveforms [Campbell et al, 1983] and reduced flow-mediated
dilatation of the brachial artery at 23 to 25 weeks gestation, suggesting that
alterations in endothelial function precede pre-eclampsia [Savvidou et al, 2003],
Impaired endothelium-dependent vasodilatation persists beyond pregnancy in
women who have had pre-eclampsia [Lampinen et al, 2006],
1.7.4 Circulating anti-angiogenic factors
The link between deficient placentation and endothelial cell activation in pre¬
eclampsia has been attributed to a circulating factor. It has previously been
demonstrated that serum from women with pre-eclampsia is cytotoxic to human
umbilical vein endothelial cells (HUVECs) in culture and that plasma from women
with pre-eclampsia impairs the normal vasodilatory responses of myometrial vessels
to bradykinin [Rodgers et al, 1988; Hayman et al, 2001], Despite intensive
investigation, the factor or factors are still elusive. Candidates include circulating
anti-angiogenic factors such as endoglin and soluble fms-like tyrosine kinase 1 and
syncytiotrophoblast micro fragments [Levine et al, 2006].
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1.7.5 Thrombosis
Thrombosis and pre-eclampsia are intertwined. In pre-eclampsia, there is extension
of the hypercoagulable state of pregnancy with intravascular coagulation. Women
with pre-eclampsia are at an increased risk of arterial and venous thromboses
[Kobayashi et al, 1999], In addition, women with a history of hypercoaguability,
manifested by previous thromboembolism are at increased risk of pre-eclampsia
[Robertson et al, 2006]. Both PAI-1 and t-PA are elevated in the blood of pregnant
women who develop pre-eclampsia before clinical symptoms appear, with t-PA
correlating with the degree of proteinuria [Belo et al, 2002; Roes et al, 2002], It is
often assumed that pre-eclampsia is accompanied by platelet activation. However,
the existing literature is controversial with studies demonstrating that platelet
activation may be increased [Konijnenberg et al, 1997; Harlow et al, 2002;
Bagamery et al, 2005] or unchanged [Holthe et al, 2005] compared to normal
pregnancy.
Within the placenta, increased synthesis of PAI-1 [Estelles et al, 1998] is associated
with aberrant fibrin deposition and the development of vaso-occlusive lesions within
the placenta [Ma et al, 2002]. Acute atherosis in the placental bed, with lipid-laden
foam cells is similar to atherosclerosis found elsewhere in the vascular tree, out with
pregnancy. Thrombotic risks are not confined to pregnancy. Women with a history of
pre-eclampsia have increased risks of venous and arterial thromboembolism in later
life compared to women with uncomplicated pregnancies [van Walraven et al, 2003;
Ray et al, 2005].
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1.7.6 Angiogenesis
Pre-existing conditions associated with endothelial dysfunction, such as
hypertension, renal disease, and diabetes, increase the risk of developing pre¬
eclampsia. Although there are extensive studies reporting decreased levels of EPCs
or abnormal function of EPCs in men and non-pregnant women with these
conditions, there are few available data about EPCs in pre-eclampsia. Sugawara et al
[2005b] demonstrated decreased numbers of CFU-EPCs and increased senescence of
EPCs in patients with pre-eclampsia compared to gestationally matched controls.
[Sugawara et al, 2005b]. It is likely that EPC function is more important than
quantity, and ideally a subsequent study of EPCs in pre-eclampsia would assess
number and function prospectively prior to the onset of disease.
1.7.7 Arterial compliance and stiffness
Current clinical practice relies on the measurement of brachial blood pressure as a
screening and diagnostic test for pre-eclampsia. Elowever, because of the
amplification of pulse pressure between central and peripheral arteries, peripheral
blood pressure is not an accurate reflection of central aortic pressure [Wilkinson et
al, 2001a]. Central pressures are more closely associated with intermediate
cardiovascular outcomes than brachial pressures in non-pregnant and pregnant
populations [Jondeau et al, 1999; Roman et al, 2007], The techniques of pulse wave
analysis mentioned briefly above enable the non-invasive determination of central
arterial pressure and stiffness from the radial artery waveform. Use of this technique
in women with pre-eclampsia may further help our understanding of the disease and
if central pressures and changes in arterial stiffness could be detected before a rise in
brachial blood pressure, the technique may have use as a screening tool.
1.8 SUMMARY
This thesis concerns aspects of vascular function in the menstrual cycle, normal and
pre-eclamptic pregnancies. By assessing different areas of vascular function;
thrombosis, angiogenesis and arterial stiffness, the effect of varying reproductive
states on the vasculature can be further understood. Stimulated t-PA release, platelet
activation, circulating EPC number and arterial stiffness are all useful indicators for
assessing these areas of vascular function. The above overview of these markers,
together with their pathophysiological and clinical relevance provides the
background to the following hypotheses.
1.9 HYPOTHESES AND AIMS
1.9.1 Thrombosis
Endogenous fibrinolysis
It was hypothesised that the pro-thrombotic state of pregnancy would be reflected in
impaired capacity of the endothelium to release t-PA, in response to stimulation with
bradykinin (Chapter 3).
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The aim of this research was to compare endogenous fibrinolysis between pregnant
women and non-pregnant control women using the sensitive technique of forearm
occlusion venous plethysmography.
Platelet and monocyte activation
It was hypothesised that menstruation as well as the pro-thrombotic and
inflammatory state of pregnancy would be reflected in increased in vivo platelet and
monocyte activation and that this would be further increased in pre-eclampsia
(Chapter 4).
The aim of this research was to make serial measurements of platelet and monocyte
activation, throughout the normal menstrual cycle, healthy pregnancy, and pregnancy
affected by pre-eclampsia using both cellular (platelet-monocyte aggregates, platelet
surface P-selectin expression, monocyte CD40 and CDllb expression) and soluble
(soluble P-selectin and soluble CD40L) markers of activation.
1.9.2 Angiogenesis
It was hypothesised that EPCs are mobilised during inflammatory reproductive
processes involving endothelial repair, specifically that: -
(i) Circulating EPC numbers and function (assessed by flow cytometry and
CFU-EPC assay) would vary during the menstrual cycle, healthy pregnancy and in
pregnancies complicated by pre-eclampsia.
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(ii) Circulating EPC numbers and function would correlate with serum hormone
levels (oestradiol and progesterone) and measures of inflammation, IL-6, TNF-a,
soluble ICAM-1 and VEGF.
The aim of this research was to make serial measurements of number and function of
circulating EPCs together with circulating sex steroids and inflammatory mediators
throughout the normal menstrual cycle, healthy pregnancy, and pregnancy affected
by pre-eclampsia (Chapter 5).
1.9.3 Arterial compliance and stiffness
It was hypothesised that both central and systemic arterial stiffness will be altered in
the fluctuating hormonal milieu of the menstrual cycle and pregnancy and the
hypertensive state of pre-eclampsia (Chapter 6).
The aim of this research was to make serial measurements of reproductive hormones,
central and systemic arterial stiffness throughout the normal menstrual cycle, healthy




All materials, reagents and cell lines used are detailed in Appendix 1.
Recipes for reagents are provided in Appendix 2.
2.1 SUBJECT RECRUITMENT
2.1.1 Ethical approval and consent
Approval from the Lothian Local Research Ethics Committee (Reference numbers
04/S1103/40 and 05/S1104/48) was granted for all the experimental work described
in this thesis. Two clinical studies were performed. The first (study 1) involved non¬
pregnant and healthy pregnant women, who underwent venous occlusion
plethysmography (described below) and is detailed in chapter 3. The second (study
2) involved non-pregnant, healthy pregnant and pre-eclamptic women, who
underwent venepuncture and arterial stiffness studies (described below) and is
detailed in chapters 4,5 and 6. Women participated in either study 1 or study 2.
Written information was provided and informed consent obtained from all study
participants. All studies were undertaken in accordance with the Declaration of
Helsinki.
2.1.2 Non-pregnant women
Healthy non-pregnant, nulligravida women with at least a two-month history of
normal regular menstrual cycles were recruited from the University of Edinburgh
staff and student populations. Exclusion criteria included the use of hormonal
contraception, current or past heavy menstrual bleeding or dysmennorhoea, current
or past hypertension, diabetes mellitus, and the use of regular medication other than
antacids, inhaled medication for asthma or vitamin supplementation. Non-pregnant




Healthy primigravida women were recruited from community antenatal clinics.
Exclusion criteria included current or past hypertension, diabetes mellitus, and the
use of regular medication other than antacids, inhaled medication for asthma or
vitamin supplementation. Pregnant women participated either in study 1 (Reference
number 04/S1103/40) or in study 2 (Reference number 05/S1104/48).
Primigravida women presenting with pre-eclampsia were recruited from the
Obstetric unit, The Royal Infirmary of Edinburgh. Pre-eclampsia was defined by
International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria
|Brown et al, 20011 as a systolic blood pressure of 140 mmHg and a diastolic
pressure (Korotkoff V) of 90 mmHg on at least two occasions after the 20th week of
pregnancy in a previously normotensive woman and proteinuria (2+ on dipstick or an
Albumin: Creatinine Ratio >30 mg/mmol). Exclusion criteria for women with
pre-eclampsia included diabetes mellitus and multiple pregnancy. Women with pre¬
eclampsia were divided into pre-term and term groups on diagnosis being made
before or after 34 weeks gestation respectively. This division was made due to its
accepted use in the literature for early and late-onset pre-eclampsia [Egbor et al,
20061. Women with pre-eclampsia participated in study 2 only (Reference number
05/S 1104/48).
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2.2 ARTERIAL STIFFNESS STUDIES
The following sensitive and reproducible methods [Wilkinson et al, 1998; Oliver and
Webb, 2003] were used to provide measures of systemic and central arterial stiffness
in accordance with the recommendations made by the Expert Consensus document
on arterial stiffness [Laurent et al, 2006].
All studies were performed in a quiet, temperature controlled room (22-25°C) within
the Wellcome Trust Clincal Research Facility. Subjects rested in the supine position
or 30° left-lateral position (to avoid vena cava compression by the uterus) for non¬
pregnant and pregnant subjects, respectively. Blood pressure and heart rate were
recorded in duplicate using an automated sphygmomanometer (Micro life 3BTO-A)
validated for use in pregnancy and pre-eclampsia [Reinders et al, 2005], following a
30-minute rest period. During this rest period, venepuncture was performed for
platelet and monocyte activation studies (chapter 4) and for endothelial progenitor
cell studies (chapter 5).
2.2.1 Pulse wave analysis
Pulse wave analysis was performed using micromanometer applanation tonometry of
the radial artery at the wrist and the SphygmoCor system, in accordance with the
manufacturer's recommendations (www.atcormedical.com/technical notes.htm).
Pulse wave analysis derives an aortic pulse pressure waveform from the radial artery
wave via a mathematical transfer function. The arterial pressure waveform is a
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composite of the forward pressure wave created by ventricular contraction and a
reflected wave generated by peripheral vascular resistance. The augmentation index
(AIx), which is the difference between the second and first systolic peaks, expressed
as a percentage of the pulse pressure, is a measure of systemic arterial stiffness and









(sys BP - dias BP)
x 100
diastole time
Figure 7. Average aortic pulse waveform from a young person. Augmentation index, expressed as a
percentage, is the proportion of the pulse pressure, which is due to the reflected pulse wave.
AIx - augmentation index; sys BP - systolic blood pressure; dias BP - diastolic blood pressure.
At least two independent waveform analyses were obtained from each subject.
Nursing staff, specifically trained in the technique from the Wellcome Trust Clinical
Research Facility, performed all vascular measurements. These were only accepted
on meeting SphygmoCor quality control criteria (average pulse height si00 units,
pulse height variation <5%, diastolic variation <5%, quality index s80%).
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2.2.2 Pulse wave velocity
The same micromanometer and SphygmoCor system were used to assess carotid-
femoral PWV, and carotid-radial PWV by applanation tonometry. The PWV was
determined by sequential acquisition of pressure waveforms from the carotid,
femoral and radial arteries. The timing of these waveforms was compared with that
of the R wave on the simultaneously recorded electrocardiogram. The computer
software measured the time delay automatically. The distance travelled by the pulse
wave between the carotid artery and the femoral artery was measured in a straight
line using a pair of compasses to reduce the influence of altered body contours due to
pregnancy. The proximal distance was measured from the sternal notch to the
sampling site on the carotid artery and the distal distance was measured from the
sternal notch to the sampling site on the femoral artery (Figure 8). The carotid-to-
femoral path length was estimated by subtracting the proximal from the distal
distance.
Pulse wave velocity was then calculated as the ratio of the distance travelled by the
pulse wave and the foot-to-foot time delay between the pulse waves, expressed in
metres per second (m/s). For carotid-radial PWV the distal distance was measured






Figure 8. Distance travelled by the pulse wave between the carotid and femoral arteries. The
proximal distance is measured between the suprasternal notch and the sampling point over the carotid
artery. The distal distance is measured from the suprasternal notch to the sampling point over the
femoral artery. A pair of compasses were designed and made to measure this in all subjects.
Arterial blood pressure varies with respiration so the average of ten successive
measurements was used in the analyses to cover a complete respiratory cycle. For
each subject, a total of two consecutive waveform recordings were obtained. The
mean of these two readings were used in further analyses. Again, nursing staff
specifically trained in the technique, performed all vascular measurements.
Measurements were only accepted on meeting SphygmoCor quality control criteria
(Standard deviation (metres per second (m/s)) < 6% of the mean time).
2.3 VENOUS OCCLUSION PLETHYSMOGRAPHY
The basic methodology of venous occlusion plethysmography was first described in
1909 and, when combined with intra-arterial drug administration it is considered the
gold standard technique for assessing vascular function in humans in vivo [Wilkinson
and Webb, 2001b]. The technique is most often performed in the forearm, though it
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can also be done in the lower limb. The underlying principle is as follows: brief
interruption of venous drainage from the forearm, without affecting arterial inflow
results in an increase in forearm volume. This increase is linear and proportional to
arterial blood inflow, until venous pressure rises towards occluding pressure. At rest,
approximately 70% of total forearm blood flow (FBF) is through skeletal muscle,
most of the remainder is through the skin. Blood flow in the hand is different;
therefore exclusion of the hand from the model is standard practice. If the hand is not
excluded, the blood flow is nonlinear.
2.3.1 Method
Studies were carried out in a quiet temperature controlled room (22-25°C). The study
was conducted in the supine position for non-pregnant women but pregnant women
had a slight left-lateral tilt to minimise caval compression by the gravid uterus. Blood
pressure and heart rate were recorded throughout the study using a semi-automated
noninvasive oscillometric sphygmomanometer (OMRON 705 IT).
Both arms were positioned above the level of the right atrium to allow adequate
venous drainage, with the elbows resting on foam pads and the hands supported on
pillows. Inflatable cuffs were placed around both wrists and upper arms. The wrist
cuffs were inflated to 200 mmHg (above systolic pressure) to exclude the hands from
the circulation. The upper cuffs were inflated to 40 mmHg (above venous pressure,
but below diastolic pressure). The upper cuffs were inflated for 7 seconds at a time
and then deflated for 3 seconds to allow venous emptying. The wrist cuffs were
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inflated for 3 minutes at a time and for at least 60 seconds before flow measurements
were analysed, to allow FBF to stabilise. Mercury-in-silastic strain gauges were
placed at the widest part of each forearm and connected to a plethysmograph.
Change in forearm volume results in a corresponding change in circumference
detected as an alteration in electrical resistance and thus potential difference. The
gauge lengths were equal to the resting arm circumference (measured at the start of
the study), so that changes in limb volume were directly proportional to the change
in resistance. Venous occlusion plethysmography provides a measure of blood flow
to that part of the forearm enclosed by the two cuffs, expressed as millilitre (mL) per
100 mL of forearm volume per minute. Within subject reproducibility for FBF,
















Figure 9. (2.3)The effect of an intra-arterial infusion of substance P on forearm blood flow. A) Intra¬
arterial saline infusion. B) Intra-arterial substance P infusion. Substance P produces a marked increase
in blood flow in the infused arm, as illustrated by the increase in the slope of the tracing. Adapted
from Wilkinson and Webb, 2001b [Wilkinson and Webb, 2001b].
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At the start of the study, unilateral brachial artery cannulation with a 27-standard
wire gauge steel needle was performed under controlled conditions [Wilkinson and
Webb, 2001b], using local anaesthesia. Venous cannulae (17-gauge) were inserted
into large subcutaneous veins of the antecubital fossae of both arms for collection of
venous effluent (Figure 10). This allowed for the study of the local actions of drugs
in the forearm vascular bed. Drugs were given at doses 10 to 100 times below those
causing systemic effect, because FBF is approximately 100 times lower than cardiac
output. The non-infused arm acts as a control to take into account any minor changes
in both arms affecting blood flow such as emotional response, change in temperature.
Wrist Cuff Strain Gauge Venous Cannula
Figure 10. Photograph of subject demonstrating placement of cuffs, mercury-in-silastic strain
gauges, arterial needle and venous cannulae.
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2.3.2 Data analysis
Plethysmographic data and net t-PA release were determined as described previously
[Newby et al, 1997; Oliver et al, 2005]. Data were extracted from the Chart data files
and FBFs were calculated for individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel version 11.3). Recordings from the first 60 seconds after
wrist cuff inflation were not used because of the reflex vasoconstriction this causes.
The last five linear flow recordings in each 3-minute measurement period were
calculated and averaged for each arm. Estimated net release of t-PA activity and
antigen was defined as the product of the infused forearm plasma flow (based on the
haematocrit (Elct), and the infused forearm blood flow, (FBF)) and the concentration
difference between the infused ([t-PA]inf) and non-infused ([t-PA]N0n-inf) arms:
Estimated net t-PA release = FBF x (1-Hct) x ([t-PA]inf-[t-PA]Non-inf)
The t-PA/PAI-1 ratio was calculated from the respective antigen concentrations.
2.4 SAMPLE COLLECTION
2.4.1 Venous blood within forearm venous plethysmography studies
Venous blood (10 mL) was drawn simultaneously from both arms at baseline and at
defined points in the study protocol (Chapter 3) into acidified buffered citrate
(Stabilyte tubes) and into sodium citrate (for t-PA and PAI-1 assays, respectively).
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Samples were kept on ice before being centrifuged at 2000 g for 30 minutes at 4°C.
Platelet-free plasma was decanted and stored at -80°C before assay.
2.4.2 Venous blood from all other studies
Peripheral venous blood was drawn from a large antecubital vein with a 19-gauge
needle using minimal tourniquet pressure. Care was taken to ensure a smooth blood
draw as previously described [Harding et al, 2007].
The first 3 mL of venous blood were discarded. Thereafter 3 mL of blood were
collected in a tube containing the direct thrombin inhibitor D-phenylalanine-L-
prolyl-L-arginine chloromethyl ketone (75 pM, PPACK). This was chosen for its
reliable anticoagulation without cation chelation (which reduces platelet-leukocyte
interactions in vitro) or causing platelet activation [Harding et al, 2007], Then 25 mL
of blood were collected in tubes containing Ethylenediaminetetraacetic acid (EDTA)
(1.6 mg/mL), and 10 mL in tubes containing sodium citrate. Finally 10 mL of blood
were collected in serum gel tubes. Initial processing of samples occurred within 5
minutes of phlebotomy. Plasma was separated by centrifugation (2000 x g for
30 min) from blood anticoagulated with EDTA and sodium citrate. Serum was
prepared from blood collected in the serum gel tubes. Plasma and serum samples
were stored at -80°C until analysis. Five millilitres of blood anticoagulated with
EDTA were sent to the hospital haematology laboratory for automated calculation of
the full blood count differential.
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2.5. FLOW CYTOMETRIC ANALYSIS
Flow cytometry is a technique that allows rapid measurements to be performed on
single cells as they flow in a fluid stream past a sensing point. The important feature
is that measurements are made on each cell in turn, not just as average values for the
population. In the subsequent studies we have utilised flow cytometry to identify sub
populations of cells in human venous blood and the subsequent cell surface
expression of different molecules. We performed immunolabelling of cells in whole
blood through incubation with combinations of fluorescent-conjugated antibodies.
Thereafter samples were fixed (with, or without lysis of erythrocytes) until analysis.
A laser flow cytometer was used. The laser light source illuminates cells within the
sample of interest in addition to producing specific wavelength to excite the
fluorescent dyes. Photon detectors collect the scattered and fluorescent light
generated by the cells passing through an illuminating beam. These in turn convert
photon pulses into electronic signals, which can be displayed graphically as
histograms or dot plots. The following protocols (detailed in Appendix 3) have been
developed and validated by our group and used in various study areas [Harding et al,
2004; Robinson et al, 2006; Harding et al, 2007; Tura et al, 2007],
2.5.1 Platelet-monocyte aggregates
Platelet-monocyte aggregates are sensitive markers of platelet activation with
important functional consequences [Michelson et al, 2001].
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Immunolabelling was performed at exactly 5 minutes to minimise ex vivo platelet
activation. All antibodies were used at 1:20 concentration in flow buffer
(Appendix 2.) To quantify platelet-monocyte aggregates, 60 pL aliquots of whole
blood, (anticoagulated with PPACK) were incubated with 60 pL of antibodies
against CD 14, CD42a and isotype matched controls for 20 minutes in darkness at
room temperature. Thereafter samples were fixed and the red cells lysed by the
addition of 500 pL of FACS-Lyse solution. Samples were stored at 4°C in the dark
until analysis. Samples were analysed using a Becton Dickinson (BD) FACSCalibur
Flow Cytometer equipped with a 488 nm wavelength laser within 12 hours of
labelling. Monocytes were identified by their forward and side scatter properties and
CD 14 expression. Two thousand, five hundred cells were collected. Platelet-
monocyte aggregates were defined as monocytes positive for the platelet marker
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Figure 11. Representative flow cytometric analysis of platelet-monocyte aggregates from non¬
pregnant subject. Monocytes were labelled with CD (cluster of differentiation) 14-PE (phycoerythrin)
and platelets with CD42a-FITC (fluorescein isothiocyanate). (a) Monocytes were identified by their
characteristic forward- and side-scatter properties. Monocyte population in 'gated' oval, (b) A
histogram of gated events was created, with a second gate placed over the CD14-bright monocytes. A
total of 2,500 CD14-bright monocytes were collected for analysis, (c) A quadrant plot of CD14-bright
monocytes against an appropriate Ig (immunoglobulin)Gl isotype control was used to set a marker to
allow for non-specific binding and autofluorescence. (d) A second quadrant plot of CD14-bright
monocytes against CD42a was then used to determine the percentage of monocytes positive for
CD42a.
SSC - side-scatter; FSC - forward-scatter; FL - fluorescence parameter.
69
2.5.2 Platelet surface p-selectin expression
Platelets rapidly express P-selectin on their cell surface when activated [van Gils et
al, 2009],
Immunolabelling was performed at exactly 5 minutes to minimise ex vivo platelet
activation. All antibodies were used at 1:20 concentration in flow buffer (Appendix
2). To quantify platelet surface P-selectin, 5 pL aliquots of whole blood
(anticoagulated with PPACK) were incubated with 45 pL of antibody against
CD42a, CD62P and isotype matched controls for 20 minutes in darkness at room
temperature before samples were fixed by the addition of 1450 pL of 1%
paraformaldehyde (Appendix 2). Light scatter and CD42a expression identified
platelets, and 7500 cells collected.
2.5.3 Monocyte activation
CDllb and CD40 expression are markers of activated monocytes [van Gils et al,
2009],
Immunolabelling was performed at exactly 5 minutes to minimise ex vivo platelet
activation. All antibodies were used at 1:20 concentration in flow buffer (Appendix
2). Monocyte CD40 and CD1 lb expression were evaluated by incubation of 60 pL
of whole blood (anticoagulated with PPACK) with 60 pL of antibody against CD 14,
CD40 and CD1 lb for 20 minutes in darkness at room temperature, before 500 pL of
FACS-Lyse was added. Light scatter and CD 14 expression identified monocytes.
2500 cells were collected.
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Results are expressed as percentage of positive cells. Monocyte CDllb expression
was quantified using mean fluorescent intensity (MFI) due to its constitutive
presence. Analyses were performed using Flowjo software (Tree Star, Inc. Oregon,
USA).
2.5.4 Endothelial progenitor cells
To quantify endothelial progenitor cells, defined as cells co-expressing CD34,
CD 133 and VEGF receptor 2 (KDR); three-colour flow cytometry was used. In early
studies, isotype-matched negative control antibodies were compared with unstained
samples. Since these did not differ, unstained samples were used to establish positive
stain boundaries for CD34 and CD133 expression [Tura et al, 2007]. For KDR
expression, the appropriate isotype control immunoglobulin (Ig)Gl was used.
Two hundred millilitre aliquots of whole blood, (anticoagulated with EDTA) were
incubated with 5 pL aliquots of mouse anti-human CD34-fluorescein isothiocyanate
(FITC), mouse anti-human CD133-phycoerythrin (PE), mouse monoclonal anti-
human VEGF receptor 2 (KDR)-allophycocyanin (APC) and mouse IgGl isotype
control-APC for 20 minutes in the dark at room temperature. Samples were stained
with none, single, double and triple antibodies over the sequence, none, CD34,
CD 133, KDR or IgGl isotype control in a 5 tube panel. Thereafter, samples were
fixed and erythrocytes lysed by the addition of 200 pL ofUTI-Lyse reagent A. After
10 minutes, 2 mL of UTI-Lyse reagent B were added. Ten minutes later, cells were
washed and separated by centrifugation at 1500 x g for 5 minutes at room
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temperature. The supernatant was decanted and 1 mL of phosphate buffered saline
(PBS) without cations added. The washing process was repeated as before and
finally cells were resuspended by adding 500 pL of PBS to each tube.
Samples were stored in darkness at room temperature until flow cytometric analysis
within 12 hours of labelling. Analysis was performed on a BD FACSCalibur Flow
Cytometer equipped with 488 nm and 635 nm wavelength lasers connected to an
Apple Macintosh computer equipped with CellQuest software. Consistent with
protocols for the identification of rare cells [Donnenberg and Donnenberg, 2007],
distilled water was run between each sample and a low flow rate (12 pL/min) was
used to minimise coincident events. The flow cytometer was calibrated and
compensated at frequent intervals with calibration beads and software appropriate for
the flurocromes employed, in accordance with the manufacturer's recommendations.
The identical stored collection settings were used for all samples. For each sample,
80,000 events were acquired in the lymphocyte region (as determined by
characteristic forward- and side-scatter profile), but all events were saved for
analysis.
Data was saved as listmode files and transferred to another Apple Macintosh
computer for detailed analysis, using Flowjo software. Boolean gating was employed
(Figure 12). Endothelial progenitor cells were identified by the co-expression of
CD34, CD133, and KDR antigens and quantified as a percentage of total leucocytes.
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Absolute numbers were determined through multiplication using the total white
count and triple positive leucocytes expressed as number of cells per litre of blood.
Figure 12. Flow cytometric analysis of endothelial progenitor cells in whole blood. Cells were
labelled with CD (cluster of differentiation)34-FITC (fluorescein isothiocyanate), CD133-PE
(phycoerythrin), KDR-APC (kinase insert domain receptor-allophycocyanin) or Ig
(immunoglobulin)Gl-APC. Representative forward- and side-scatter properties (cell size and
granularity) of leucocytes in whole blood. Debris was excluded by primary gate R1. Events within R1,
CD34 positive events within gate R2. CD 133 positive events within gate R3 and KDR positive events
within R4. Boolean gating used to identify cells present in all 3 gates, R2, R3 and R4 ('triple-positive'
cells).
SSC - side-scatter; FSC - forward-scatter; FL - fluorescence parameter.
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2.6 IN VITRO CULTURE
All cells were maintained at 37°C, 5% C02 with 95% humidity.
2.6.1 CFU-EPC assay
Based on the assay described by Hill et al [Hill et al, 2003], functional EPCs were
quantified using the EndoCult™ CFU-EPC assay and commercial kit reagents
according to the manufacturer's recommendations.
Venous blood samples (10 mL anticoagulated with EDTA) were diluted 1:1 with
sterile PBS without cations and layered onto 15 mL of Histopaque. Samples were
then spun at 1050 x g for 20 minutes at room temperature and the intermediate
opaque mononuclear layer collected. The peripheral blood mononuclear cells
(PBMCs) were washed twice with PBS, once with EndoCult™ complete culture
medium (ECCM, Appendix 2) and 5 x 106 cells resuspended in 2 mL of ECCM.
Cells were then plated at 2 mL/well in a 6-well fibronectin-coated plate and
incubated at 37°C, 5% C02 with 95% humidity for 2 days. The non-adherent cells
were then harvested, and transferred in fresh ECCM to a 24-well fibronectin-coated
plate at 1 x 106 cells/mL/well for a further 3 days. Colonies (CFU-EPCs), were
defined using the published method as a central core of "round" cells surrounded by
elongated "sprouting" cells at the periphery (Figure 13). Colonies were counted in a
minimum of 2-wells per sample by observers unaware of the subjects' clinical
profiles and the results expressed as mean numbers of CFU-EPCs per 1 x 106 cells
plated.
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Figure 13. A Typical colony forming unit with a characteristic core of round cells and sprouting
spindle cells at the periphery (xlOO magnification).
2.6.2 Human umbilical vein endothelial cells (huvecs)
Dr C. Shaw, Department of Cardiovascular Research, The University of Edinburgh
kindly provided these. Human umbilical vein endothelial cells (HUVECs) were
cultured onto 4-well plain glass chamber slides at a density of 7xl05 cells in
endothelium growth medium 2 before being fixed in methanol and stained as below.
2.6.3 HT-29, Human colon adenocarcinoma cell line
Dr S Bader, Edinburgh Cancer Research Centre, The University of Edinburgh kindly
donated these cells. Cells were cultured in Rosewell Park Memorial Institute (RPMI)
medium supplemented with 5% foetal calf serum until 80% confluence was achieved




To confirm endothelial cell lineage, colonies were stained directly using acetylated
low density lipoprotein (LDL) and co-stained with lectin (UEA-1) as previously
described [Kalka et al, 2000], Cells were incubated with l,l'-dioctadecyl-3,3,3',3'-
tetramethylcarbocyanine-labelled acetylated LDL (Dil-AcLDL); 1:100 in ECCM for
4 hours, washed in PBS and fixed with ice-cold methanol for 10 minutes. Colonies
were stained for 1 hour with FITC-labelled lectin from UEA-1 (1:100 in PBS),
counterstained with 4',6-Diamidino-2-phenylindole dihydrochloride (DAPI) and
mounted with Permafluor.
For CD 105 (endoglin) and CD 146 staining, fixed colonies were permeabilised and
blocked in a solution of 10% goat serum, 1% bovine serum albumin and 0.02%
IGEPAL/NP40. Next, colonies were incubated with primary murine monoclonal
antibodies against human CD105 (1:500) or CD146 (1:200) for 2 hours at room
temperature. A secondary polyclonal goat anti-mouse biotinylated antibody was
added for 30 minutes followed by streptavidin-Alexa Fluor 546 or streptavidin-Alexa
Fluor 488 for 1 hour in the dark. Nuclei were counterstained and colonies mounted
as above. Between each step the slides were washed with PBS for 5 minutes. Human
umbilical vein endothelial cells were used as positive controls for all of the
endothelial markers. Staining was performed without the primary antibody as a
negative control for each antibody. In addition the HT-29 human colon cell-line was
used as a negative control for the endothelial markers. Phase-contrast images of the
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same CFU-EPCs were used to confirm colony morphology. All images are
representative of at least three different subjects (Figure 14).
2.7.2 CONFOCAL MICROSCOPY AND IMAGE ANALYSIS
A Zeiss 'LSM 510 Meta' confocal microscope, with x40 oil immersion objective
was used to visualise the stained cells. Image capture was performed with LSM 510
meta-analysis computer software. Detection gain and offset setting were established
on the positive controls and the same levels used on the CFU-EPCs and respective
negative controls. Images for all antibodies were captured at single slices through the
colonies. Z-stack images were also captured providing a 3D image of the colony
through reconstitution of serial image captured at preset intervals.








Figure 14. Characterisation of CFU-EPCs (colony forming unit-endothelial progenitor cells). Live
CFU-EPCs exposed to Dil-AcLDL (l,r-dioctadecyl-3,3,3',3'-tetramethylcarbocyanine-labellcd
acetylated low-density lipoprotein) (A), stained with FITC (fluorescein isothiocyanate)-lectin (Ulex
europaeus agglutinin-1) (B), nuclear counter stain DAP1 (4',6-Diamidino-2-phenylindole
dihydrochloride) (C) and merged image (D). Fixed CFU-EPCs immunostained for the endothelial cell
marker CD (cluster of differentiation) 105 (E), nuclear counterstain (F) merged image (G) and for
CD146 (H), nuclear counterstain (1) and merged (J), (x 40 magnification)
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2.8 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
ELISAs can quantify the amount of a given protein in a solution, through comparison
with a standard curve created from samples containing known concentrations. Most
of the assays performed in this project were sandwich ELISAs.
A sandwich ELISA uses plates coated with an antibody raised against one epitope of
the substance to be measured. The solution of interest, or the standard, is then added,
and the immobilised antibody binds the substance. After washing away unbound
substances, an enzyme-linked antibody specific for the substance to be measured is
added to the wells. Following a wash to remove any unbound antibody-enzyme
reagent, a substrate solution is added to the wells. After an incubation period, during
which amplifier solutions are sometimes added, colour develops in proportion to the
amount of substance bound in the initial step. The reaction is stopped with sulphuric
acid solution and the absorbance measured by spectrophotometry.
Standard curves were constructed. Assays were validated by performing serial
dilutions of a sample and confirming that when the absorbance was plotted a linear
response was obtained which was parallel to the standard curve. Assay precisions
were calculated using the formula "standard deviation/mean x 100" to give the
coefficient of variation (%CV).
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2.8.1 Soluble p-selectin elisa
A soluble P-selectin assay kit was used, containing plates pre-coated with capture
antibody, and all required reagents and buffers (Appendix 1). Samples, controls and
standards (100 pL) were diluted in dilutant provided and applied to each well.
Diluted conjugate (sheep polyclonal antibody to recombinant human soluble P-
selectin conjugated to horseradish peroxidase) (100 pL) was added to each well and
incubated at room temperature for 1 hour. Plates were washed three times with wash
buffer. Substrate (tetramethylbenzidine) was applied to each well (100 pL) and
incubated at room temperature for 15 minutes. One hundred microlitres of stop
solution was then added to each well and the plate read on a microplate reader
(Thermomax, Molecular Devices, CA. USA) within 30 minutes. The intra-assay CV
was 4.9%; the inter-assay CV was 7.9% and the detection limit of the assay was 0.5
ng/mL.
2.8.2 CD40 ligand elisa
A CD40 ligand assay kit was used, containing plates pre-coated with capture
antibody, and all required reagents and buffers (Appendix 1). Samples, controls and
standards (200 pL) were diluted in dilutant provided and applied to each well.
Diluted conjugate (polyclonal antibody to recombinant human CD40L conjugated to
horseradish peroxidase) (200 pL) was added to each well and incubated at room
temperature for 2 hours. Plates were washed four times with wash buffer. Substrate
(200 pL) was applied to each well and incubated at room temperature for 30 minutes
in the dark. Fifty microlitres of stop solution was then added to each well and the
plate read on a microplate reader within 30 minutes. The intra-assay CV was 4.5%;
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the inter-assay CV was 6.0% and the detection limit of the assay was 4.2 pg/mL.
2.8.3 IL-6 elisa
An IL-6 assay kit was used, containing plates pre-coated with capture antibody, and
all required reagents and buffers (Appendix 1). Samples, controls and standards
(200 pL) were diluted in dilutant provided and applied to each well and incubated at
room temperature for 2 hours. Plates were washed 6 times with wash buffer. Diluted
conjugate (polyclonal antibody to IL-6 conjugated to alkaline phosphatase) (200 pL)
was added to each well and incubated at room temperature for 2 hours. Plates were
washed a further 6 times with wash buffer. Substrate (lyophilized NADPH) (50 pL)
was applied to each well and incubated at room temperature for 1 hour. Fifty
microlitres of amplifier solution was applied to each well and incubated at room
temperature for 30 minutes. Fifty microlitres of stop solution (sulfuric acid) was then
added to each well and the plate read on a microplate reader within 30 minutes. The
intra-assay CV was 6.9%; the inter-assay CV was 6.5% and the detection limit of the
assay was 0.039 pg/mL.
2.8.4 TNF-a elisa
A tumour necrosis factor-a assay kit was used, containing plates pre-coated with
capture antibody, and all required reagents and buffers (Appendix 1). Samples,
controls and standards (250 pL) were diluted in dilutant provided and applied to each
well and incubated at room temperature for 3 hours. Diluted conjugate (polyclonal
antibody to TNF-a conjugated to alkaline phosphatase) (200 pL) was added to each
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well and incubated at room temperature for 2 hours. Plates were washed six times
with wash buffer. Substrate (lyophilized NADPH) (50 pL) was applied to each well
and incubated at room temperature for 1 hour. Fifty microlitres of amplifier solution
was applied to each well and incubated at room temperature for 30 minutes. Fifty
microlitres of stop solution (sulfuric acid) was then added to each well and the plate
read on a microplate reader within 30 minutes. The intra-assay CV was 3.1%; the
inter-assay CV was 7.3% and the detection limit of the assay was 0.1 pg/mL.
2.8.5 Soluble icam-1 elisa
A soluble ICAM-1 assay kit was used, containing plates pre-coated with capture
antibody, and all required reagents and buffers (Appendix 1). Diluted conjugate
(antibody to soluble ICAM-1 conjugated to horseradish peroxidase) (100 pL) was
added to each well. Samples, controls and standards (100 pL) were diluted in dilutant
provided and applied to each well and incubated at room temperature for 1.5 hours.
Plates were washed 6 times with wash buffer. Substrate (100 pL) was applied to each
well and incubated at room temperature for 30 minutes. One hundred microlitres of
stop solution was then added to each well and the plate read on a microplate reader
within 30 minutes. The intra-assay CV was 3.3%; the inter-assay CV was 6.0% and
the detection limit of the assay was 0.35 ng/mL.
2.8.6 VEGF-elisa
A vascular endothelial growth factor assay kit was used, containing a single plate
pre-coated with capture antibody, and all required reagents and buffers (Appendix 1).
Samples, controls and standards (200 pL) were diluted in dilutant provided and
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applied to each well and incubated at room temperature for 2 hours. Plates were
washed three times with wash buffer. Diluted conjugate (antibody to VEGF
conjugated to horseradish peroxidase) (200 pL) was added to each well and
incubated at room temperature for 2 hours. Plates were washed three times with wash
buffer. Substrate (200 pL) was applied to each well and incubated at room
temperature for 25 minutes. Fifty microlitres of stop solution was then added to each
well and the plate read on a microplate reader within 30 minutes. The intra-assay CV
was 6.5% and the detection limit of the assay was 9.0 pg/mL
2.8.7 T-PA ANTIGEN AND ACTIVITY ELISA
Plasma t-PA antigen and activity were determined using a commercially available
combined assay kit, containing plates pre-coated with capture antibody that does not
interfere with t-PA functional activity, and all required reagents and buffers
(Appendix 1). In the first step of this assay, t-PA and t-PA-PAI-1 complexes are
bound to the plate and active non-complexed t-PA is thereafter quantified using a
solution of Glu-plasminogen, fibrinogen fragments and a synthetic substrate, which
reacts with plasmin formed in the reaction to yield a coloured reaction product. The
second part of this assay is used to determine the total amount of t-PA antigen bound
to the plate through the use of a horseradish peroxidase-labelled monoclonal
antibody.
Samples, controls and standards (100 pL) were diluted in dilutant provided and
applied to each well and incubated at 4°C overnight. Plates were washed three times
with wash buffer. Plasminogen activator detection mixture (200 pL) was added to
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each well and incubated at 37°C for 1 hour. The plate was read on a microplate
reader. Thereafter the plate was washed three times with wash buffer. Diluted
conjugate (antibody to t-PA conjugated to horseradish peroxidase) (100 pL) was
added to each well and incubated at 37°C for 1 hour. Plates were washed three times
with wash buffer. Substrate (100 pL) was applied to each well and incubated at room
temperature for 10 minutes. One hundred microlitres of stop solution was then added
to each well and the plate read on a microplate reader within 30 minutes. The inter-
and intra-assay CVs were 9.8% and 5% respectively. The detection limit of the assay
was 0.05 units/mL for t-PA activity and 0.1 ng/mL for t-PA antigen.
2.8.8 PAI-1 ANTIGEN ELISA
Plasminogen activator inhibitor type 1 antigen was determined using a commercially
available combined assay kit, containing plates pre-coated with capture antibody
(monoclonal anti-PAI-1), and all required reagents and buffers (Appendix 1).
Samples, controls and standards (200 pL) were diluted in dilutant provided and
applied to each well and incubated at 37°C for 1 hour. Plates were washed four times
with wash buffer. Diluted conjugate (antibody to PAI-1 conjugated to horseradish
peroxidase) (200 pL) was added to each well and incubated at 37°C for 1 hour.
Plates were washed four times with wash buffer. Substrate (200 pL) was applied to
each well and incubated at room temperature for 30 minutes. Fifty microlitres of stop
solution was then added to each well and the plate read on a microplate reader within
15 minutes. The intra-assay CV was 5.0%; the inter-assay CV was 6.5% and the
detection limit of the assay was 0.5 ng/mL.
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2.8.9 PAI-1 ACTIVITY ELISA
Plasminogen activator inhibitor type 1 activity was determined using a commercially
available assay kit, containing plates pre-coated with capture antibody (recombinant
t-PA), and all required reagents and buffers (Appendix 1). Samples, controls and
standards (200 pL) were diluted in dilutant provided and applied to each well and
incubated at room temperature for 1 hour. Plates were washed five times with wash
buffer. Diluted conjugate (antibody to PAI-1 conjugated to horseradish peroxidase)
(200 pL) was added to each well and incubated at room temperature for 1 hour.
Plates were washed five times with wash buffer. Substrate (200 pL) was applied to
each well and incubated at room temperature for 5 minutes. Fifty microlitres of stop
solution was then added to each well and the plate read on a microplate reader within
30 minutes. The intra-assay CV was 5.5%; the inter-assay CV was 7.5% and the
detection limit of the assay was <0.1ng/mL.
2.9 AUTOMATED IMMUNOASSAYS
2.9.1 Oestradiol
Oestradiol was measured in serum using the automated Abbott Architect Integrated
system within the Clinical Biochemistry Department, The Royal Infirmary of
Edinburgh. A chemiluminescent microparticle immunoassay was performed on
samples. Serum samples from pregnant subjects were manually diluted prior to
placement in the machine. The intra-assay CV was <7%; the inter-assay CV was <6
% and the detection limit of the assay was 10 pg/mL.
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2.9.2 Progesterone
Progesterone was measured in serum using the automated ADVIA Centaur®
Immunoassay system within the Clinical Biochemistry Department, The Royal
Infirmary of Edinburgh. A chemiluminescent microparticle immunoassay was
performed on samples. Serum samples from pregnant subjects were manually diluted
prior to placement in the machine. The intra-assay CV was <7 %; the inter-assay CV
was % and the detection limit of the assay was 0.67 nmol/L.
2.9.3 Lutenising hormone
Lutenising Hormone was measured in serum using the automated Abbott Architect
Integrated system within the Clinical Biochemistry Department, The Royal Infirmary
of Edinburgh. A chemiluminescent microparticle assay was performed on samples.
The intra-assay CV was < 3%; the inter-assay CV was < 3% and the detection limit
of the assay was 0.07 mlU/mL.
2.9.4 Follicle-stimulating hormone (fsh)
Follicle-stimulating hormone was measured in serum using the automated Abbott
Architect Integrated system within the Clinical Biochemistry Department, The Royal
Infirmary of Edinburgh. A chemiluminescent microparticle assay was performed on
samples. The intra-assay CV was < 3%; the inter-assay CV was < 2.7% and the
detection limit of the assay was 0.05 mlU/mL.
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2.10 STATISTICAL ANALYSIS
Continuous variables are reported as mean±standard error of the mean (SEM).
Continuous variables were analysed using the Kolmogorov-Smirnov test for
normality. Statistical analyses were performed using one and two-way analysis of
variance (ANOVA) with repeated measures and Bonferroni's post-tests for multiple
comparisons or two-tailed Student's /-test where appropriate. Friedman analyses and
Mann-Whitney tests were used for non-parametric data. Correlation coefficients
were calculated using Pearson or Spearman analyses for parametric and non-
parametric data respectively. All calculations were performed using GraphPad Prism.
Statistical significance was taken at 5%.
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3.1 INTRODUCTION
Pregnancy is recognised as a hypercoagulable state that protects women from
potentially catastrophic haemorrhage during placentation and the post-partum period
[Hellgren, 2003]. However, this predisposes women to thrombosis and
thromboembolism [Lewis 2005] with many complications of pregnancy either being
caused or exacerbated by the hypercoagulable state [Gilabert et al, 1995],
The pro-thrombotic state of pregnancy has been attributed to marked alterations in
the coagulation and fibrinolytic system, including increased plasma concentrations of
t-PA and its principal inhibitor, PAI-1 [Hellgren, 2003]. The relative balance
between plasma t-PA and PAI-1, and the acute release of t-PA from the endothelium
determines the efficacy of endogenous fibrinolysis [Oliver et al, 2005]. Basal plasma
t-PA concentrations do not reflect the local capacity for acute endothelial t-PA
release [Hrafnkelsdottir et al, 2004], This underscores the importance of assessing
acute local endothelial t-PA release, which is of greater pathophysiological
relevance.
No studies have previously assessed the acute endothelial release of t-PA during
pregnancy. The aim of work presented in this Chapter was, therefore, to assess
whether impairment of acute endogenous fibrinolytic capacity contributes to the pro-
thrombotic consequences of pregnancy.
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3.2 METHODS
All materials and reagents used are detailed in Appendix 1.
3.2.1 Subject recruitment
Women were identified, recruited and consented to this study (study 1, Reference
number 04/S1103/40), as described in section 2.1.
Non-pregnant women
Healthy pre-menopausal nulliparous women (n=20) with at least a 2-month history
of normal regular menstrual cycles were recruited to the study. Exclusion criteria
included the use of hormonal contraception, current or past heavy menstrual bleeding
or dysmennorhoea, current or past hypertension, diabetes mellitus, and the use of
regular medication other than antacids, inhaled medication for asthma or vitamin
supplementation as detailed in section 2.1.2.
Pregnant women
Healthy primigravida women with an uncomplicated pregnancy (n=10) were
recruited in the third trimester of pregnancy. Exclusion criteria included current or
past hypertension, diabetes mellitus, and the use of regular medication other than





Women attended for a single visit in the mid-follicular phase (day 9.8±0.3) of their
menstrual cycle.
Pregnant women
Women attended for a single visit during the third trimester of pregnancy (week
36±1).
3.2.3 Study protocol
Women abstained from alcohol, caffeine and tobacco for 24 hours and fasted for
4 hours prior to attendance. Prior to commencement of the study, height and weight
were measured to allow calculation of body mass index (BMI).
Studies were carried out in a quiet temperature controlled room (22-25°C). The study
was conducted in the supine position for non-pregnant women but pregnant women
had a slight left-lateral tilt to minimise caval compression by the gravid uterus. Blood
pressure and heart rate were recorded throughout the study using a semi-automated
noninvasive oscillometric sphygmomanometer.
Venous occlusion plethysmography
Forearm blood flow was measured in the infused and non-infused arms by venous
occlusion plethysmography using mercury-in-silastic strain gauges as described in
section 2.3.1, in conjunction with intra-arterial drug administration, detailed below.
90
Intra-arterial drug administration
All women underwent unilateral brachial artery cannulation with a 27-standard wire
gauge steel needle as described in section 2.3.1. All studies commenced with a
20-minute saline infusion. Following this the following drugs (dilutions detailed in
Appendix 2) were infused in a randomised order:
Bradykinin (endothelium-dependent vasodilator that stimulates the release of t-PA)
was infused at 100, 300 and 1000 pmol/min and sodium nitroprusside (endothelium-
independent vasodilator that does not stimulate release of t-PA) was infused at 2, 4
and 8 pg/min. The two vasodilators were separated by a 20-minute saline infusion
and given in a randomised order (Figure 15).
Assessment of acute t-PA release
Venous cannulae were inserted into large subcutaneous veins of the antecubital fossa
in both arms. Blood (10 mL) was drawn simultaneously from both arms at baseline
and after each dose of bradykinin into acidified buffered citrate (for t-PA assays) and
into citrate (for PAI-1 assays) (Figure 15). Samples were collected, processed and










Normal Saline (SNPpg min-1) Normal Saline \ End
H 1 1 h-
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! t ! 1
Sampling for t-PA and PAI-1
Figure 15. Schematic diagram demonstrating the intra-arterial drug administration protocol and time
points for venous blood sampling for t-PA and PAI-1 assays. Bradykinin and sodium nitroprusside
were given in a randomised order within each study.
SNP - sodium nitroprusside; t-PA - tissue plasminogen activator; PAI-1 - plasminogen activator
inhibitor type 1.
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3.2.4 Measurement of t-pa and pai-i antigen and activity
concentrations
Plasma t-PA antigen and activity and PAI-1 antigen and activity concentrations were
measured in plasma using commercially available enzyme-linked immunosorbent
assays as detailed in sections 2.8.7-9.
3.2.5 Measurement of circulating hormones
At the commencement of the study, venous blood (10 mL) was collected in a serum
gel tube, centrifuged and serum samples were stored at -80°C until analysis. Serum
concentrations of oestradiol and progesterone were measured in all women.
Luteinizing hormone and FSH were also measured in the healthy non-pregnant
women. All hormones were measured by automated chemiluminescent microparticle
assays as described in section 2.9.1-4.
3.2.6 Data analysis
Plethysmographic data and net t-PA release were determined as described in section
2.3.2.
3.2.7 Statistical analysis
Continuous variables are reported as mean±SEM using ANOVA with repeated
measures and two-tailed Student's t-test where appropriate.
All calculations were performed using GraphPad Prism, (GraphPad Software, USA).




Due to technical problems, one pregnant woman and three non-pregnant women
were unable to complete the complex vascular studies. Pregnant (n=9) and non¬
pregnant (n=17) women were well-matched for age (26±3 versus 27±1 years,
p=0.67) and BMI (24±1 kg m"2 versus 24±1 kg m"2, p=0.77). Serum hormonal assays
confirmed that the non-pregnant women were studied in the mid-follicular phase of
their menstrual cycle. All pregnant women had uncomplicated pregnancies and
delivered at term (mean gestational age at delivery of 40±1 weeks) with average
birth weights (3,144±186 g). Three pregnant and three non-pregnant women were
unable to complete the fibrinolytic studies due to technical problems with
simultaneous venous access leaving a final study group of six pregnant and fourteen
non-pregnant women for fibrinolytic analysis. These women were well-matched for
age (26±4 versus 27±2 years, p=0.94), BMI (24±1 kg m"2 versus 24±1 kg m"2,
p=0.85) and current smoking status (2/6 versus 3/14, p=0.6).
3.3.2 Vasomotor function
There were no differences in resting systolic (122±3 versus 116±2 mmHg, p=0.14)
or diastolic blood pressure (76±3 versus 73±2 mmHg, p=0.39) between pregnant and
non-pregnant women. Similarly, there was no difference in basal infused (3.1 ±0.5
versus 2.1±0.2 mL"1 100 mL"1 min"1, p=0.07) or non-infused (2.4±0.4 versus
1.8±0.2 mL"1 100 mL"1 min"1, p=0.11) forearm blood flow between pregnant and non-
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pregnant women. However, consistent with a hyperdynamic circulation, pregnant
women had increased resting heart rates compared to non-pregnant women (80±3
versus 67±2 bpm, p=0.002).
There was a dose-dependent increase in forearm blood flow with bradykinin
(p<0.0001 for both) and sodium nitroprusside (p<0.002 for both).
Endothelium-dependent and endothelium-independent vasodilatation was similar
between the two groups of women (p=0.6 and p=0.8 respectively, two-way ANOVA
with repeated measures; Table 2).
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TABLE2.Absoluteforearml odl wrespons stendoth lium-dependentanind pen nvasodilators Healthynon-pregnantwomeltpregn two Bradykinin pmolmin"101003 00 FBF mL"1100mL"1min"1 Non-infusedarm2.0±0.231 83 1 626 73 . Infusedarm2.8±0.410.1±1.03 2 29.1± .9*3 9 6.75.3 2 58 7 4 Healthynon-pregnantwomeltpregna SodiumNitroprusside pgmin"1024824 FBF mL"1100L"1in Non-infusedarm2.4±0.45319 1 13 27 04 Infusedarm3.7±0.910.6±1 23.1 .416 0± .9*4 0 2 51 2 64 8 3.2* Dataexpressedmean±SEM.*p<0.0001forbradykinin,p=0. 2d.sodiumnitropr si e(pr g tn- eg antg psr s ctively)o -wa ANOVA. FBF-forearmbloodl w;SEMstandardrrorftheme n;ANOVAanalysisv riance.
3.3.3 Fibrinolytic function
Baseline plasma PAI-1 antigen concentrations were higher in pregnant women
(77.1±12.4 versus 21.5±9.8 ngmL"1 in non-pregnant women, p=0.004, unpaired
Student's t-test; Table 3) whilst apparently higher plasma t-PA antigen
concentrations did not achieve statistical significance (13.5±2.4 versus
7.5±2.0 ngmL"1 respectively, p=0.10, unpaired Student's t-test). Consistent with this,
t-PA/PAI-1 ratios (0.2±0.1 versus 0.6±0.1, p=0.02) and plasma t-PA activity
concentrations (0.17±0.02 versus 0.58±0.06 IU mL'VmL, p<0.0004, unpaired
Student's Mest) were lower in pregnant women.
Bradykinin caused a dose-dependent increase in plasma t-PA antigen and activity
concentrations in the infused arm of both pregnant and non-pregnant women
(p<0.005 for all; Table 3). The increase in t-PA activity was greater in the non¬
pregnant women (p=0.02 versus pregnant, two-way ANOVA; Figure 16).
Bradykinin increased the net release of t-PA antigen and activity in both pregnant
women and non-pregnant women (p<0.05 for all; Table 3). Both net release of active
t-PA and plasma t-PA/PAI-1 ratios were markedly reduced in pregnant women
(p<0.05 for both; Table 3 and Figure 17). Compared with the non-pregnant women,
the area under the curve for net active t-PA release was reduced by
36% in the pregnant women.
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TABLE3.Plasmat-pandpai-intigenac vityconcentratio sibo hf r a ms Healthynon-pregnantwome(n=14)
Healthypregnantwome(n=6)
BradykininInfusio (pmolin"1) t-PAAntigen,gmL"1 Non-infusedarm Infusedarm t-PAActivityIUmL"1 Non-infusedarm Infusedarm
7.45±2.0 6.95±2.0 0.58±0.06 0.5±0.06
100 7.6±2.0 8.6±2.0 0.6±0.08 1.6±0.19
300 0.8±0.09 2.8±0.4
1000
8.0±2.39 8 12.2±2.56.0±3.0* 1.1±0.14 4.3±0.6*
13.5±2.4 12.3±2.9 0.17±0.02 0.51±0.32
100 13.6±2.6 13.4±2.8 0.26±0.06 0.51±0.1
300 14.6±3.0 14.4±2.5 0.43±0.2 1.3±0.15
1000 15.8±3.2 20.0±2.2* 0.53±0.12 2.4±0.31*
PAI-1Antigen,gmL" Non-infusedarm Infusedarm PAI-1Activity,ngmL"1 Non-infusedarm Infusedarm
21.5±9.8 19.2±7.7 2.1±1.8 1.36±1.0
23.2±10.3 18±7.3 l.4±1.0 1.31±1.0
23±10 19±7 1.1±0.9 1.9±1.7
26.9±10 19.8±7.4 1.1±0.8 1.1±0.9
77.1±12 4 72.6±9.0 5.7±1.4 5.7±1.5
71.8±6.3 87.1±16.3 6.1±1.7 5.9±1.7
80.5±11.4 82.8±14 6.2±1.7 5.8±1.7
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Figure 16. Plasma tissue plasminogen activator (t-PA) activity concentrations in the infused (solid
symbols and lines) and non-infused (open symbols and dashed lines) arms of pregnant (n=6, circles)
and non-pregnant (n=14, squares) women during intra-arterial bradykinin infusion. Plasma t-PA
activity increased in the infused arm of both pregnant and non-pregnant women (p<0.001 for both,
one-way analysis of variance (ANOVA) but was greater in non-pregnant women (*p=0.02 versus
pregnant women, two-way ANOVA).
IU - international units.
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Figure 17. Ratio of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1
(PAI-1) in the infused (solid symbols and lines) and non-infused (open symbols and dashed lines)
arms of pregnant (n=6, circles) and non-pregnant (n=14, squares) women during intra-arterial
bradykinin infusion. Plasma t-PA/PAI-1 ratios were markedly lower in pregnant women (p=0.04,
versus non-pregnant women, two-way analysis of variance (ANOVA)).
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3.4 DISCUSSION
In the third trimester of pregnancy, these results demonstrate that there is marked
perturbation of the fibrinolytic system. There was a marked increase in basal plasma
PAI-1 concentrations leading to a reduction in t-PA activity and t-PA/PAI-1 ratios,
consistent with previous work [Koh et al, 2002; Coolman et al, 2006]. For the first
time, acute endothelial t-PA release has been assessed in pregnant women. Despite
normal vasomotor responses, there was a marked reduction in bradykinin-induced
release of active t-PA that was primarily attributable to an excess of PAI-1. This
leads to the conclusion that elevated plasma PAI-1 concentrations and inadequate
active t-PA release contribute to the pro-thrombotic consequences of pregnancy.
3.4.1 Perturbations of fibrinolysis in pregnancy
Pregnancy is associated with a marked elevation in plasma PAI-1 concentrations
that, in this study, were 4- to 5-fold higher than age-matched non-pregnant women
and comparable to concentrations found in previous studies [Chappell et al, 2002],
Although there appeared to be a modest concomitant rise in t-PA antigen, this was
unable to compensate for the dominance of PAI-1 as demonstrated by the adverse
effect on the ratio of t-PA to PAI-1. Thus, whilst being able to stimulate the release
of substantial amounts of t-PA from the endothelium using intra-arterial bradykinin,
the overwhelming effect of PAI-1 markedly inhibited the plasma activity of both
basal and stimulated t-PA. This marked shift in fibrinolytic potential, and the
associated dramatic reduction in active t-PA, will have major pro-thrombotic
consequences for pregnant women.
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During pregnancy, PAI-1 is produced by placental vasculature, trophoblast and
decidua in addition to endothelium and activated platelets [Ginsburg et al, 1986;
Schatz and Lockwood, 1993; Fitzpatrick and Graham, 1998], The affinity of PAI-1
for t-PA is 1000 times greater than that of PAI-2, which is also produced by the
placenta [Vassalli et al, 1991]. The placenta therefore plays a major role in
regulating the fibrinolytic balance during pregnancy. In pregnancies complicated by
placental dysfunction, the reduction in fibrinolytic capacity is even more pronounced
[Greer, 2003]. For example, in pre-eclampsia, increased placental synthesis of PAI-1
[Estelles et al, 1998] is associated with aberrant fibrin deposition and the
development of vaso-occlusive lesions within the placenta [Ma et al, 2002].
Moreover, the hypofibrinolytic polymorphic gene mutations of PAI-1, for example
the 4G/4G and 4G/5G mutations, which cause an increase in placental PAI-1 gene
expression and plasma levels, are independent risk factors for the development of
pre-eclampsia [Yamada et al, 2000; Glueck et al, 2001].
Pregnancy is also associated with an increased risk of systemic thrombotic events
including thromboembolism and myocardial infarction. Although rare (6 per 100,000
pregnancies), the age-adjusted incidence of acute myocardial infarction is increased
4-fold by pregnancy and is associated with a significant mortality rate [James et al,
2006]. With increasing maternal age, the overall incidence of myocardial infarction
is rising (30 per 100,000 in those over 40 years) and is likely to represent an
increasing patient group in contemporary cardiovascular practice.
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Acute myocardial infarction in women has several features that distinguish it from
those seen in men [Davies, 2000], In 50% of women, myocardial infarction results
from plaque erosion rather than rupture and, in some instances, endothelial erosion
and coronary thrombosis can occur in the absence of atherosclerosis [Arbustini et al,
1999]. Thus, thrombosis and pro-thrombotic states are more likely to be implicated
in the pathogenesis of acute myocardial infarction in women and this may be
mediated through changes in fibrinolytic function.
This current study has demonstrated a reduction of bradykinin-induced release of
active t-PA and t-PA/PAI-1 ratio in normal pregnancy compared to non-pregnant
women. This is consistent with a study by Stegnar et al [Stegnar et al, 1993], that
demonstrated reduced t-PA activity in pregnant, compared with non-pregnant,
women after the venous occlusion test. This finding also mirrors that of a previous
study in which it was demonstrated that current smokers had elevated basal plasma
PAI-1 concentrations, that were associated with reduced basal and stimulated active
t-PA, compared to non-smokers [Newby et al, 2001]. Coronary thrombosis
[Doll et al, 2004] is one of the major causes of sudden cardiac death in both smokers
[Burke et al, 1997] and myocardial infarction during pregnancy [Davies, 2000], The
alteration in fibrinolytic function that has been demonstrated may therefore provide a
common pathogenic mechanism underlying coronary thrombosis in both patient
populations. Moreover, it may in part explain the strong association of myocardial
infarction with hypertension during pregnancy. Superimposing the added stress of
hypertension on blood vessels already weakened by the haemodynamic stresses of
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pregnancy may augment the reduction in t-PA and t-PA/PAI-1 ratio in response to
endothelial damage [Hrafnkelsdottir et al, 2004].
Bradykinin is a powerful stimulus for endothelial t-PA release and has been used in
this study and by other investigators to assess this aspect of endothelial function
[Brown et al, 1999; Brown et al, 2000; Mills et al, 2007], Bradykinin is not only an
inflammatory mediator but is also released during the contact phase of coagulation
when high-molecular weight kininogen is cleaved by kallikrein to produce a
disulphide-linked light and heavy chain [Schiffman et al, 1980; Reddigari and
Kaplan, 1988]. This liberation of bradykinin may represent an important negative
feedback loop in which bradykinin-induced t-PA release inhibits thrombus formation
within the vascular lumen when localised endothelial denudation occurs. Indeed,
bradykinin may also contribute to the regulation of basal release of t-PA and that
associated with angiotensin-converting enzyme inhibition [Pretorius et al, 2003],
Thus, whilst bradykinin was used in this study as a physiological tool to probe the
effects of pregnancy, it may also have a pathophysiological role in the pathway of
acute t-PA release as has been demonstrated in cardiovascular disease in non¬
pregnant patients [Cruden and Newby, 2005].
3.4.2 Vasomotor function
The study design allowed the assessment of peripheral vasomotor function of women
in pregnancy in addition to the dynamic fibrinolytic capacity. Whilst not the primary
aim, this study demonstrates that, despite the major hyperdynamic changes of
pregnancy, endothelial and vascular smooth muscle vasomotor function was
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preserved and comparable to normal non-pregnant women. Consistent with these
findings, Anumba and colleagues [Anumba et al, 1999b] have previously reported
unaltered nitric oxide sensitivity and endothelium-independent vasodilatation during
pregnancy. However, they did find a modest impairment of endothelium-dependent
vasodilatation to serotonin. Whether this reflects differential alterations in signalling
pathways, or a true alteration in endothelial function, remains to be determined. This
highlights the importance of assessing different aspects of vascular function in order
to determine the overall effect of pregnancy on the vasculature.
3.5 SUMMARY
In conclusion, pregnancy is associated with major perturbations of endogenous
fibrinolytic capacity that is due an overwhelming increase in plasma PAI-1
concentrations and an inadequate release of active t-PA. These pro-thrombotic
effects may, in part, explain the increased risk of arterial and venous thrombosis both
systemically and locally within the foeto-placental unit in pregnant women.
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CHAPTER 4
THE INFLUENCE OF THE MENSTRUAL CYCLE,




Inflammation and haemostasis underpin many reproductive processes including
menstruation, healthy and complicated pregnancies. Circulating platelets and their
interactions with monocytes and the endothelium play a key role in mediating
thrombotic and inflammatory events in health and disease. Activated platelets
express P-selectin on their cell surface and form aggregates with leucocytes,
predominately monocytes [Sarma et al, 2002], The formation of platelet-monocyte
aggregates has important functional consequences. These include the expression and
release of cytokines, chemokines, adhesion molecules and tissue factor by
monocytes. In addition, monocyte adhesion and subsequent interaction with the
endothelium is promoted.
Platelets are extremely susceptible to ex vivo activation by sampling and handling
methods. The use of flow cytometry is a sensitive technique to evaluate in vivo
platelet and monocyte activation in whole blood. Using this technique, the
expression of platelet surface P-selectin, monocyte surface CD40 and CD1 lb and the
formation of circulating platelet-monocyte aggregates can be quantified. These are
considered highly sensitive markers of platelet [Michelson et al, 2001] and monocyte
activation [Shi and Simon, 2006],
Establishing whether there is variation in platelet and monocyte activation during the
menstrual cycle, in normal and pre-eclamptic pregnancies may further our
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understanding of pregnancy and its complications and perhaps inform the temporal
link between thromboembolic disease and reproductive processes.
The aim of this research was to determine the influence of the menstrual cycle,
normal and pre-eclamptic pregnancies on platelet and monocyte activation using
both cellular (platelet-monocyte aggregates, platelet surface P-selectin expression,
monocyte CD40 and CD1 lb expression) and soluble (soluble P-selectin and soluble
CD40L) markers of activation.
4.2 METHODS
All materials, reagents and cell lines used are detailed in Appendix 1.
4.2.1 Subject recruitment
Women were identified, recruited and consented to this study (study 2, Reference
number 05/S1104/48), as described in section 2.1.
Non-pregnant women
Healthy pre-menopausal non-smoking nulliparous women (n=16) with at least a
2-month history of normal regular menstrual cycles were recruited to the study.
Exclusion criteria included the use of hormonal contraception, current or past heavy
menstrual bleeding or dysmennorhoea, current or past hypertension, diabetes
mellitus, and the use of regular medication other than antacids, inhaled medication
for asthma or vitamin supplementation as detailed in section 2.1.2.
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Pregnant women
Healthy, non-smoking primigravida women with an uncomplicated pregnancy
(n=30) or with pre-eclampsia (n=16) were recruited in the first trimester of
pregnancy or at diagnosis respectively. Women were given a minimum of 24 hours
to consider participating in the study. Exclusion criteria are detailed in section 2.1.3.
4.2.2 Visit schedule
Women abstained from alcohol, caffeine and tobacco for 12 hours and fasted for
4 hours prior to attendance. Blood pressure and heart rate were recorded in duplicate
using an automated sphygmomanometer following a 15 minute left-lateral or supine
rest for pregnant subjects (at every visit) and non-pregnant (at first visit, Day (D) 1-
3) respectively. Height and weight were also measured to allow calculation ofBMI.
Women with pre-eclampsia continued to take their antihypertensive medication as
prescribed. This is detailed in section 4.3.1.
Non-pregnant women
Women attended for four visits during a single menstrual cycle (D 1-3 (early
follicular), D 6-8 (mid-follicular)), D 13-15 (peri-ovulatory) and D 20-22 (mid-
luteal)).
Pregnant women
Women with uncomplicated pregnancies attended for four visits during pregnancy at
16, 24, 32 and 37 weeks and at 7 weeks post-partum. Women with pre-eclampsia
attended following diagnosis and at 7 weeks post-partum.
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4.2.3 Sample collection
At each visit, peripheral venous blood was drawn from a large antecubital vein with
a 19-gauge needle using minimal tourniquet pressure, as described in section 2.4.2.
Care was taken to ensure a smooth blood draw as described previously [Harding et
al, 2007],
Initial processing of all samples occurred within 5 minutes of phlebotomy, with
immunolabelling performed at exactly 5 minutes to minimise ex vivo platelet
activation. Plasma and serum were prepared and stored as described in section 2.4.2
for subsequent analysis of circulating hormones and markers of platelet activation.
Following venepuncture, arterial stiffness studies were performed, detailed in
Chapter 6.
4.2.4 Flow cytometric analysis of platelet and monocyte activation
Platelet-monocyte aggregates
Staining was performed on whole blood using directly conjugated monoclonal
antibodies, on all samples as detailed in section 2.5.1.
Platelet surface P-selectin expression
Staining was performed on whole blood using directly conjugated monoclonal
antibodies, on all samples as detailed in section 2.5.2.
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Monocyte CD40 and CDllb expression
Staining was performed on whole blood using directly conjugated monoclonal
antibodies, on all samples as detailed in section 2.5.3.
4.2.5 Measurement of soluble markers of platelet activation
Circulating P-selectin and soluble CD40L concentrations were measured in plasma
using commercially available enzyme-linked immunosorbant assays as described in
sections 2.8.1 and 2.8.2 respectively.
4.2.6 Measurement of circulating hormones
Serum concentrations of oestradiol and progesterone were measured in all women.
Lutenizing hormone and follicle-stimulating hormone were also measured in the
healthy non-pregnant women. All hormones were measured by automated
chemiluminescent microparticle assays as described in section 2.9.1-4.
4.2.7 Statistical analysis
The distribution of data was determined using the Kolmogorov-Smirnov test for
normality. Continuous variables are reported as mean±SEM for parametric data.
Statistical analyses were performed using paired and unpaired two-tailed
Student's /-tests. For multiple comparisons, one-way ANOVA with repeated
measures was used. All calculations were performed using GraphPad Prism,





In six of sixteen non-pregnant women, ovulation could not be confirmed leaving a
final study group of ten women with a confirmed regular ovulatory cycle (cycle
length 28±0.4 days; luteal phase serum progesterone >30 nmol/L). All women (age,
31.4±2.0 years) were of normal body composition (BMI, 23.4±0.7 kg/m2). Baseline
systolic and diastolic blood pressures and heart rate, measured at D 1-3 of the cycle,
were 110±2 mmHg, 67±2 mmHg and 60±2 bpm, respectively.
Pregnant subjects
In the healthy pregnant group, four of thirty women developed complications in their
pregnancy, for example intra-uterine growth restriction, pre-term labour or pre¬
eclampsia and a further five were unable to complete the full schedule of visits,
leaving a final study group of twenty-one women for analysis. In the pre-eclamptic
group, women were categorised according to gestation at presentation, into pre-term
(n=8; mean 30 (range 24-34 weeks)) and term (n=8; mean 38 (range 36-40 weeks).
Women with pre-eclampsia were delivered earlier than women with uncomplicated
pregnancies and had offspring of lower birth weight (Table 4).
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There was no difference in first trimester blood pressures between women with
healthy and pre-eclamptic pregnancies (113±2/69±2 mmHg versus 117±3/73±2
mmHg, p>0.9). As expected women, with pre-term and term pre-eclampsia had
higher blood pressures at the time of study compared to those women with
uncomplicated pregnancies, at similar gestations (pre-term pre-eclampsia, 30 weeks
(n=8) at presentation versus healthy pregnancy, 32 weeks (n=21) 140±2/87±2 mmHg
versus 112±1/69±1 mmHg respectively; term pre-eclampsia, 38 weeks (n=8) at
presentation versus healthy pregnancy, 37 weeks (n=21) 146±2/95±2 mmHg versus
116±1/75±1 mmHg respectively; all p<0.002). The pre-eclamptic women were no
longer hypertensive at the post-partum visit, but still had higher blood pressures than
the women with uncomplicated pregnancies (pre-eclampsia post-partum (n=T6)
123±3/77±2 mmHg versus healthy pregnancy post-partum (n=21) 113±1/69±1
mmHg; both p<0.002).
Medication use
In women with pre-term pre-eclampsia, five were taking regular labetalol and
nifedipine, two were taking regular methyldopa and nifedipine, and one was
receiving no anti-hypertensive therapy. Seven of these women received antenatal
betamethasone. In women with term pre-eclampsia, one was taking regular labetalol
with the remaining seven women not receiving anti-hypertensive therapy. None
received antenatal betamethasone. Post-partum, out of the original sixteen women
who had developed pre-eclampsia, only three women were taking labetalol, and one,
methyldopa.
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4.3.2 Effect of themenstrual cycle on platelet activation
To investigate the effect of cyclical variation in ovarian hormones on platelet
activation: platelet-monocyte aggregates, platelet surface P-selectin expression,
plasma soluble P-selectin and soluble CD40L concentrations were measured
longitudinally over a single menstrual cycle in healthy non-pregnant women. None
of these measures of platelet activation varied during the menstrual cycle (p>0.08 for
all, one-way ANOVA with repeated measures; Figures 18, 19, 20 and 21). There was
no correlation between platelet-monocyte aggregates, surface or soluble P-selectin or
soluble CD40L and circulating concentrations of oestrogen or progesterone at any
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Figure 18. Platelet-monocyte aggregates do not vary during the menstrual cycle, (p=0.09, one-way
ANOVA with repeated measures). Data (non-pregnant women, n=10) expressed as mean±SEM.
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Figure 19. Platelet surface expression of P-selectin does not vary during the menstrual cycle,
(p=0.08, one-way ANOVA with repeated measures). Data (non-pregnant women, n=10) expressed as
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Figure 20. Plasma concentrations of soluble P-selectin (ngmL"') do not vary during the menstrual
cycle, (p=0.7, one-way ANOVA with repeated measures). Data (non-pregnant women, n=10)
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Menstrual cycle (day)
Figure 21. Plasma concentrations of soluble CD40 ligand (pgmL"1) do not vary during the menstrual
cycle, (p=0.6, one-way ANOVA with repeated measures). Data (non-pregnant women, n=10)
expressed as mean±SEM. CD - cluster of differentiation; ANOVA - analysis of variance; SEM -
standard error of the mean.
4.3.3 Effect of the menstrual cycle on monocyte activation
To investigate the effect of cyclical variation in ovarian hormones on monocyte
activation, monocyte CD40 and CDllb expression were measured longitudinally
over a single menstrual cycle in healthy non-pregnant women. Neither of these
measures of monocyte activation varied during the menstrual cycle (p>0.3 for both,
one-way ANOVA with repeated measures; Figures 22 and 23). There was no
correlation between monocyte CD40 or CDllb expression and circulating
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Figure 22. Monocyte CD40 expression does not vary through the menstrual cycle, (p=0.3, one-way
ANOVA with repeated measures). Data (non-pregnant women, n=10) expressed as mean±SEM.
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Figure 23. Monocyte CD1 lb expression (MFl), does not vary through the menstrual cycle, (p=0.8,
one-way ANOVA with repeated measures). Data (non-pregnant women, n=10) expressed as
mean±SEM. CD - cluster of differentiation; MFI - mean fluorescent intensity; ANOVA - analysis of
variance; SEM - standard error of the mean.
4.3.4 Effect of pregnancy on platelet activation
To investigate the effect of healthy pregnancy on platelet activation: platelet-
monocyte aggregates, platelet surface P-selectin expression, plasma soluble P-
selectin and CD40L concentrations were quantified longitudinally during healthy
pregnancy and compared to the mean of the values obtained across the menstrual
cycle from the ten non-pregnant women.
Platelet-monocyte aggregates did not vary significantly during healthy pregnancy

































▼ Healthy non-pregnant n= 10
Healthy pregnant n= 21
□ Pre-term pre-eclamptic n= 8
□ Term pre-eclamptic n= 8
□ PP pre-eclamptic n= 16
NP 16 24 32 37 +7 PP
Gestation (weeks)
Figure 24. Influence of normal and pre-eclamptic pregnancy on platelet-monocyte aggregates.
Platelet-monocyte aggregates increased by 24 weeks gestation, compared to the non-pregnant women
(p=0.02, two-tailed, unpaired Student's /-test). Platelet-monocyte aggregates did not vary with
gestation (p=0.28, one-way ANOVA with repeated measures), but did decrease post-partum (p=0.02,
37 weeks versus post-partum). Platelet-monocyte aggregates were not significantly different in
women with pre-eclampsia. Data expressed as mean±SEM.
NP - non-pregnant; PP - post-partum; ANOVA - analysis of variance; SEM - standard error of the
mean.
Platelet surface and plasma soluble P-selectin increased with gestation during healthy
pregnancy (p<0.0001, one-way ANOVA with repeated measures; Figures 25 and
26). Compared to the non-pregnant women, platelet-monocyte aggregates, platelet
surface P-selectin expression and plasma soluble P-selectin concentrations were all
higher in healthy pregnancy by 24 weeks gestation (26.4±2.5% versus 20.2±1.4%;
4.7±0.6% versus 3.0±0.3% and 47.1±3.0 ngmL"' versus 38.6±1.6 ngmL"1,
respectively; p<0.02 for all, two-tailed unpaired Student's f-test). Platelet-monocyte
aggregates, platelet surface P-selectin expression and plasma soluble P-selectin
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concentrations all decreased post-partum (p<0.02 for all, two-tailed paired Student's
/-test), although platelet surface P-selectin and plasma soluble P-selectin
concentrations remained elevated 7 weeks post-partum compared to the non¬
pregnant women (4.0±0.4% versus 3.0±0.3% and 49.6±4.0 ngmL"1 versus
38.6±1.6 ngmL"1, respectively; p<0.03 for both, two-tailed unpaired Student's /-test).
Gestation (weeks)
Figure 25. influence of normal and pre-eclamptic pregnancy on platelet surface P-selectin
expression. Platelet surface P-selectin expression increased by 24 weeks gestation, compared to the
non-pregnant women (p=0.005, two-tailed unpaired Student's /-test), varied with gestation (p<0.001,
one-way ANOVA with repeated measures), and decreased post-partum (p<0.001, 37 weeks versus
post-partum, two-tailed paired Student's /-test). Expression was not significantly different in pre¬
eclampsia. Data expressed as mean±SEM.

















▼ Healthy non-pregnant n= 10
Healthy pregnant n= 21
□ Pre-term pre-eclamptic n= 8
□ Term pre-eclamptic n= 8
□ PP pre-eclamptic n= 16
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16 24 32 37 +7 PP
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Figure 26. Influence of normal and pre-eclamptic pregnancy on the concentration of soluble P-
selectin in plasma. Plasma concentrations of soluble P-selectin (ngmL"1) increased by 24 weeks
gestation, compared to the non-pregnant women (p=0.007, two-tailed unpaired Student's /-test),
varied with gestation (p<0.001, one-way ANOVA with repeated measures), and decreased post¬
partum (p<0.02, 37 weeks versus post-partum, two-tailed paired Student's /-test). Plasma
concentrations were not significantly different in pre-eclampsia. Data expressed as mean±SEM.
NP - non-pregnant; PP - post-partum; ANOVA - analysis of variance; SEM - standard error of the
mean.
Compared to non-pregnant women, plasma soluble CD40L concentrations were
lower in pregnancy at mid gestation (64.8±5.3 pgmL"1 versus 85.5±3.1 pgmL"1, 24
weeks versus non-pregnant women, p=0.0007, two-tailed unpaired Student's /-test;
Figure 27). Levels fell from 16 to 24 weeks (p<0.01, Bonferroni's post-test) before
rising at term. Soluble CD40L concentrations continued to rise post-partum (p=0.03,
two-tailed paired Student's /-test) and were higher than non-pregnant levels at 7
weeks post-partum (101.2±7.6 pgmL"1 versus 85.5±3.1 pgmL" , 7 weeks post-partum
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Figure 27. Influence of normal and pre-eclamptic pregnancy on the concentration of soluble CD40
ligand in plasma. Plasma concentrations of soluble CD40 ligand (pgmL"') were lower at 24 weeks
than in non-pregnant women (p=0.0007, two-tailed unpaired Student's Mest) varied with gestation
(p=0.01, one-way ANOVA with repeated measures), falling between 16 and 24 weeks (p<0.01,
Bonferroni's post-test) and increased post-partum (p=0.03; 37 weeks -versus post-partum, two-tailed
paired Student's Mest). Plasma concentrations were not significantly different in pre-eclampsia. Data
expressed as mean±SEM.
NP - non-pregnant; PP - post-partum; CD - cluster of differentiation; ANOVA - analysis of variance;
SEM - standard error of the mean.
There was no difference in any of the variables measured between pre-term or term
pre-eclamptic and healthy pregnant women. Although the post-partum data is
combined graphically for the women with pre-eclampsia, there was no difference in
any of the variables measured between women with pre-term or term pre-eclampsia
at the post-partum visit (two-tailed unpaired Student's /-tests; p>0.05 for all; Figures
24, 25, 26 and 27).
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4.3.6 Effect of pregnancy on monocyte activation
To investigate the effect of healthy pregnancy on monocyte activation; monocyte
CD40 and CDllb expression were quantified longitudinally during healthy
pregnancy and compared to the mean of the values obtained across the menstrual
cycle from the ten non-pregnant women.
Monocyte CD40 expression was lower at 16 weeks in healthy pregnant women, than
in non-pregnant women (41.5±3.3% versus 57.7±2.8%, p=0.0009, two-tailed
unpaired Student's /-test), then increased with gestation (p<0.0001, one-way
ANOVA with repeated measures) and decreased post-partum (37 weeks versus post¬
partum, 62.6±3.4% versus 45.0±2.7%, pO.OOOl, two-tailed paired Student's /-test).
Post-partum levels were lower than in the non-pregnant women (45.0±2.7% versus
57.7±2.8%, p=0.006, two-tailed unpaired Student's /-test). Monocyte CD40
expression was not significantly different in pre-eclampsia. Although the post¬
partum data is combined graphically for the women with pre-eclampsia, there was no
difference in levels of expression between women with pre-term or term pre¬
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Figure 28. Influence of normal and pre-eclamptic pregnancy on monocyte CD40 expression
Monocyte CD40 expression was lower at 16 weeks than in non-pregnant women (p=0.0009, two-
tailed unpaired Student's /-test) varied with gestation (p<0.0001, one-way ANOVA with repeated
measures), rising between 16 and 32, 16 and 37, 24 and 37 weeks (p<0.01 for all, Bonferroni's post-
test) and decreased post-partum (p<0.0001; 37 weeks versus post-partum, two-tailed paired Student's
/-test). CD40 expression was not significantly different in pre-eclampsia. Data expressed as
mean±SEM.
NP - non-pregnant; PP - post-partum; CD - cluster of differentiation; SEM - standard error of the
mean.
In contrast, monocyte CD1 lb expression was greater in healthy pregnant women, at
16, 24 and 37 weeks than in non-pregnant women (69.1±7.5, 57.2±4.6 and 59.6±4.9
versus 43.9±3.3 MFI, p<0.02 for all, two-tailed unpaired Student's /-tests), though it
did not vary significantly with gestation (p=0.06, one-way ANOVA with repeated
measures). Levels of expression fell post-partum (37 weeks versus post-partum,
59.6±4.9 versus 47.9±3.3 MFI, p=0.02; two-tailed paired Student's /-test), returning
to non-pregnant levels. CD1 lb expression was greater in women with pre-term pre-
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eclampsia than women with healthy pregnancies at 32 weeks gestation (73.8±7.2
versus 50.8±3.0 MFI, p=0.001, two-tailed unpaired Student's t-test), but not
significantly different in women with term pre-eclampsia, or post-partum compared
to healthy pregnant women. Although the post-partum data is combined graphically
for the women with pre-eclampsia, there was no difference in CD lib expression
between women with pre-term or term pre-eclampsia at the post-partum visit (two-
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□ Pre-term pre-eclamptic n= 8
□ Term pre-eclamptic n= 8
□ PP pre-eclamptic n= 16
H h
NP 16 24 32 37 +7 PP
Gestation (weeks)
Figure 29. Influence of normal and pre-eclamptic pregnancy on monocyte CDllb expression.
Monocyte CDllb expression was greater at 16, 24 and 37 weeks gestation than in non-pregnant
women (p<0.02 for all, two-tailed unpaired Student's Mests). It did not vary significantly with
gestation (p=0.06, one-way ANOVA with repeated measures), but fell post-partum (p=0.02; 37 weeks
versus post-partum, two-tailed paired Student's /-test). CD1 lb expression was greater in pre-term pre¬
eclamptic pregnancies than healthy pregnancy at 32 weeks gestation (p=0.001, two-tailed unpaired
Student's /-test), but not significantly different in term pre-eclampsia, or post-partum. Data expressed
as mean±SEM.
NP - non-pregnant; PP - post-partum; CD - cluster of differentiation; MFI - mean fluorescent
intensity; SEM - standard error of the mean.
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4.4 DISCUSSION
This longitudinal study has demonstrated that platelet-monocyte aggregates, in
conjunction with other markers of platelet activation, are increased in the third
trimester of pregnancy compared to the non-pregnant state. In addition, it has
demonstrated that both surface expression of platelet P-selectin and soluble plasma
concentration increase with gestation. However, none of the markers of platelet
activation were affected by the menstrual cycle or pre-eclampsia. A novel finding of
this study was that plasma soluble CD40L did not increase in a similar manner to the
other markers of platelet activation, but paradoxically fell during normal pregnancy
between 16 and 24 weeks. In a similar pattern monocyte CD40 expression was also
decreased at 16 weeks gestation. CD1 lb was elevated in healthy pregnancy, reflecting
increased monocyte activation, and levels were higher in samples from women with
pre-term pre-eclampsia. This leads to the conclusion that both platelet and monocyte
activation contribute to the prothrombotic state during pregnancy but that systemic
platelet activation is not a feature of established pre-eclampsia.
4.4.1 Platelet and monocyte activation within the menstrual cycle
Given that during the menstrual and early follicular phase of the cycle, the priority is
to secure haemostasis and prevent excessive blood loss, it was anticipated that an
increase in platelet activation would be detected at this time. However, in the current
study there was no variation in platelet or monocyte activation during the menstrual
cycle. These findings appear to differ from the only previous study on platelet-
leukocyte activation during the menstrual cycle by Rosin et al [2006], They found
that platelet-leukocyte aggregates peaked mid-cycle, corresponding to ovulation
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[Rosin et al, 2006]. A variety of factors may account for these seemingly discrepant
findings, but in particular, the differing methodologies employed between their study
and this one. Rosin et al [2006] used a small gauge butterfly needle for venesection,
collected the blood into citrated tubes for flow cytometry and undertook initial
processing within 20 minutes of sampling. It has been recently demonstrated that all
these factors have a marked effect on platelet-monocyte aggregation [Harding et al,
2007]. The formation of platelet-monocyte aggregates is calcium dependent and will
therefore be inhibited by anticoagulation with citrate. Moreover, the small gauge
needle used by Rosin et al [2006] may have caused artifactual platelet activation,
particularly if there was a long connecting tube between the needle and citrated
collecting tube. Finally, platelet-monocyte aggregates increase in a time-dependent
manner in vitro. Rosin and colleagues [Rosin et al, 2006] may not have processed
their samples until 20 minutes after original venepuncture. In contrast, this current
study used a large needle for venesection, employed a direct thrombin inhibitor as an
anticoagulant, and immunolabelled all samples at exactly 5 minutes after collection.
This is the first study to examine surface expression ofmonocyte CD40 and CD1 lb in
the menstrual cycle. Previous studies addressing monocyte activation within the
menstrual cycle have focused on measuring plasma concentrations, or basal and
stimulated cytokine and chemokine release from monocytes [Angstwurm et al, 1997;
Brannstrom et al, 1999; Willis et al, 2003; Timmons et al, 2005]. The results are
conflicting, with greater cytokine and chemokine release (IL-6, TNF-a) from
monocytes in the luteal versus follicular phase [Willis et al, 2003] (stimulated TNF-
a), and follicular versus luteal phase [Angstwurm et al, 1997] (plasma IL-6)
[Brannstrom et al, 1999] (plasma TNF-a), or no change [Timmons et al, 2005]
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(plasma IL-6). However, plasma concentrations of cytokines and chemokines are an
indirect method of assessing moncyte activation, as they may also be released from
other cells, for example, endothelial cells release IL-6. Assessing monocyte surface
expression of molecules, in whole blood, using flow cytometry provides a more
sensitive assessment of in vivo monocyte activation status. Although monocytes are
known to be activated by both oestradiol and progesterone, and express oestrogen
receptors, [Li et al, 1993; Ben-Hur et al, 1995] in this longitudinal study no clear
effect of cycling ovarian hormones on CD40 or CD1 lb expression was found.
4.4.2 Platelet and monocyte activation within healthy pregnancy
Pregnancy is associated with a hypercoagulable state with an increased risk of both
venous and arterial thromboembolism [Simpson et al, 2001]. However the
contribution that platelets make to this pro-inflammatory, thrombotic state is less clear
with some studies reporting increased activation [Gerbasi et al, 1990; Janes and
Goodall, 1994] while others reporting no change [Romero et al, 1988; Gatti et al,
1994; Star et al, 1997], Using both cellular and soluble markers of platelet activation
this study demonstrates a gestational increase in platelet activation compared to the
non-pregnant state. This longitudinal study adds to and supports the recent cross-
sectional study of Holthe and colleagues [Holthe et al, 2005] in which they
demonstrate an increase in platelet-leukocyte aggregates at a single time point during
the third trimester compared to matched controls sampled at a single unspecified
time-point during the menstrual cycle.
Previous cross-sectional studies in pregnancy have used a variety of different
techniques including platelet aggregation [Yamazaki et al, 1979; Markham et al,
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1991; Holthe et al, 2005], platelet fibrinogen activation [Faraday et al, 1997;
Heilmann et al, 2007], P-selectin expression [Karalis et al, 2005, Borzychowski et al,
2006] and platelet count [Larsen et al, 1996], By using a complementary panel of
cellular and circulating markers of platelet activation, the current study suggests that
pregnancy is a state of continued in vivo platelet activation. In addition, the
longitudinal study design provides important insights into platelet activation in
varying hormonal states in pregnant and non-pregnant women.
Consistent with the finding of increased platelet activation in pregnancy, there is
increased expression of monocyte CDllb in healthy pregnancy. Activated platelets,
binding to monocytes up-regulate CDllb expression and promote inflammatory
cytokine release. These findings are consistent with previously published data, which
demonstrate an increase in CDllb in the third trimester of pregnancy [Sacks et al,
1998] but no change with gestation [Luppi et al, 2002]. It has been proposed that
increased systemic monocyte activation may be involved in the initiation of labour,
[Luppi et al, 2004], However, the findings from this study suggest that activation
occurs earlier in gestation, though trafficking of these monocytes may be altered near
term.
4.4.3 Platelet and monocyte activation and pre-eclampsia
Pre-eclampsia is associated with systemic endothelial dysfunction and often local
thrombotic changes within the placenta. Although it is often assumed that the
inflammatory milieu of pre-eclampsia is accompanied by platelet activation, the
existing literature is controversial with studies demonstrating that platelet activation
may be increased [Konijnenberg et al, 1997; Harlow et al, 2002; Bagamery et al,
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2005] or unchanged [Holthe et al, 2005; Acar et al, 2007; Lok et al, 2007] compared
to normal pregnancy. It was not possible to demonstrate a difference in platelet
activation in any of the measures in this study between the subjects with pre¬
eclampsia and healthy pregnant women. These findings are consistent with the cross-
sectional study by Holthe et al [2005] which reported no difference in platelet-
leukocyte aggregates between normal pregnancy and pre-eclampsia [Holthe et al,
2005], but do not support their earlier study of increased basal P-selectin expression
on platelets from women with pre-eclampsia [Holthe et al, 2004a], The finding that
plasma P-selectin concentrations are unchanged, support those of Lok et al [2007].
The present study is limited by the lack of data for women prior to the development of
pre-eclampsia. The increased capacity for platelets to aggregate following in-vitro
stimulation is more pronounced at earlier gestations, in women destined to develop
pre-eclampsia, with the difference reducing during the third trimester [Felfernig-
Boehm et al, 2000], These results do not exclude a role for platelet activation prior to
the development of pre-eclampsia or the presence of local platelet activation at the
foeto-maternal interface, but we could not find evidence of increased systemic platelet
activation in established pre-eclampsia above that caused by pregnancy.
This research demonstrates that pre-term pre-eclampsia is associated with an increase
in monocyte CD lib expression compared to healthy normotensive pregnant women
at similar gestations. This finding is supportive of previously published work that
demonstrates increased CDllb expression [Holthe et al, 2004b], cytokine and
chemokine release form the monocytes of pre-eclamptic women [Luppi and Deloia,
2006]. Interestingly, no associated platelet activation was demonstrated, suggesting
involvement of other stimulatory pathways. In addition, this up-regulation was not
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seen in the term-pre-eclamptic women, which may reflect a difference in the
pathogenesis of pre-eclampsia in these women.
4.4.4 CD40-CD40 ligand dyad in pregnancy
A novel finding of this study is that plasma soluble CD40L concentrations were lower
in pregnant women at mid gestation, falling from 16 to 24 weeks and then gradually
rising during the third trimester. This pattern was also reflected in monocyte CD40
expression. There was no difference in either soluble CD40L concentration or
monocyte CD40 expression in women in the third trimester (both with and without
pre-eclampsia) compared to non-pregnant women. However, soluble CD40L
concentrations increased and monocyte CD40 expression decreased, post-partum in
both groups of women. This gestational variation in soluble CD40L concentrations
and monocyte CD40 expression has not been reported previously. As soluble CD40L
is predominately released by activated platelets, an increase was expected as other
markers of platelet activation were elevated. This lack of correlation between soluble
CD40L and platelet bound or soluble P-selectin might reflect different aspects of
platelet biology and has reported in patients outwith pregnancy [Blann et al, 2005],
Our study adds to the findings of a previous cross-sectional study, which
demonstrated that soluble CD40L concentrations were lower during pregnancy
compared to the non-pregnant state [Oron et al, 2006]. However, unlike this current
study, Oron and Mellembakken reported increased soluble CD40L concentrations in
pre-eclampsia [Mellembakken et al, 2001; Oron et al 2006]. This again is most
probably due to methodological differences. Pre-analytical conditions, sampling
technique and storage have a clear effect on soluble CD40L concentrations and are
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not yet standardised for this marker. Oron et al [2006], measured soluble CD40L
concentrations in serum, which are higher than in plasma, less stable and more
vulnerable to sample processing [Mason et al, 2005; Weber et al, 2006]. Although
Mellembakken et al [2006] measured plasma soluble CD40L, this was following
preparation and centrifugation of platelet rich plasma. The study presented in this
chapter, measured plasma soluble CD40L with minimal processing and risk of ex vivo
platelet activation.
No studies have examined the effect of monocyte CD40 expression in pregnancy. A
limitation of our study is that there is no available data on the surface expression of
CD40L on platelets. Following previously published flow cytometric techniques,
surface CD40L expression was studied but we were unable to find a monoclonal
antibody that detected specific immunoreactivity above a matched i sotype control.
However, over 95% of circulating soluble CD40L is thought to be derived form
platelets and its function is reported to be preserved between the membrane bound
and soluble form [Danese and Fiocchi, 2005; Li et al, 2008],
Unlike direct markers of platelet and monocyte activation, the CD40-CD40 ligand
dyad is more complex and has other pro-inflammatory functions. It is expressed on a
wide variety of immune cells, is involved in humoral and cellular immunity through
lymphocyte activation and differentiation, and thymic selection. There is extensive
research to support the central role of the soluble biologically active CD40L molecule
in immune responses, the development of autoimmunity and in inflammatory
disorders [van Kooten, 2000], Given the paradoxical suppression of CD40L and
monocyte CD40 compared to the other markers of platelet activation and monocyte
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CD lib, it is likely that the CD40-CD40 ligand dyad may have other, perhaps
immunomodulatory roles, such as at the materno-foetal interface that are not yet fully
characterised in pregnancy.
4.5 SUMMARY
In summary, this chapter has demonstrated using sensitive flow cytometric techniques
that normal pregnancy is associated with platelet and monocyte activation that
increases with gestation. In addition, systemic platelet activation does not appear to be
a feature of the menstrual cycle or established pre-eclampsia. Monocyte activation
does appear to be associated with pre-term pre-eclampsia but is unaltered by the
varying hormonal milieu of the menstrual cycle. A novel variation in the CD40-CD40
ligand dyad in pregnancy is also described.
Although the requirement to process samples immediately for flow cytometric studies
poses logistical challenges, future areas of research would focus on both platelet and
monocyte activation in the first trimester of pregnancy and ideally in women prior to
the development of pre-eclampsia.
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CHAPTER 5
THE INFLUENCE OF THE MENSTRUAL CYCLE, PREGNANCY
AND PRE-ECLAMPSIA ON CIRCULATING
ENDOTHELIAL PROGENITOR CELLS
Robb AO, Mills NL, Smith IBJ, Short A, Tura-Ceide 0,
Barclay GR, Blomberg A, Critchley HOD, Newby DE, Denison FC
Influence ofmenstrual cycle on circulating endothelial progenitor cells.
Human Reproduction 2009;24 (3):619-625.
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5.1 INTRODUCTION
Endothelial progenitor cells are circulating mononuclear cells derived from the bone-
marrow, which have the potential to proliferate, migrate and differentiate into mature
endothelial cells. Increasingly they are recognised as having an important role in
mediating vascular endothelial repair and angiogenesis [Urbich and Dimmeler,
2004]. Their mobilisation and function is affected by inflammation, hormonal
regulation and endothelial dysfunction. Indeed, these three factors, as well as
endothelial repair, are pivotal to many reproductive processes including
menstruation, healthy pregnancy and complications of pregnancy such as pre¬
eclampsia.
Currently there is a lack of consensus on the definitive EPC phenotype with a variety
of surface markers and functional assays being used to assess this progenitor
population. This makes comparison between different clinical studies difficult.
Although groups are increasingly quantifying EPCs by surface expression of
phenotypic markers (CD34+CD133+KDR+), the CFU-EPC assay represents a
functional assessment that quantifies the ability of putative endothelial progenitors to
form colonies [Hill et al, 2003], To date relatively few clinical studies have either
used both approaches or compared EPC phenotype and function.
The aim of this research was to determine the influence of the menstrual cycle,
normal and pre-eclamptic pregnancy on the number and function of circulating
EPCs, and to investigate how their number and function vary with cyclical variation
of circulating sex steroids or inflammatory mediators. We hypothesised that EPCs
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are mobilised during inflammatory reproductive processes involving endothelial
repair. In this chapter we address the following hypotheses:
(i) Circulating EPC numbers and function (assessed by flow cytometry and
CFU-EPC assay) would vary during the menstrual cycle, healthy pregnancy and in
pregnancies complicated by pre-eclampsia.
(ii) Circulating EPC numbers and function would correlate with serum hormone
levels (oestradiol and progesterone) and measures of inflammation, IL-6, TNF-o:,
soluble ICAM-1 and VEGF.
It was anticipated that the results of these investigations could contribute to our
understanding of the role of EPCs in common reproductive events.
5.2 METHODS
All materials, reagents and cell lines used are detailed in Appendix 1.
5.2.1 Subject recruitment
Women were identified, recruited and consented to this study (study 2, Reference
number 05/S1104/48), as described in section 2.1.
Non-pregnant women
Healthy pre-menopausal non-smoking nulliparous women (n=16) with at least a
2-month history of normal regular menstrual cycles were recruited to the study.
Exclusion criteria are detailed in section 2.1.2.
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Pregnant women
Healthy, non-smoking primigravida women with an uncomplicated pregnancy
(n=30) or with pre-eclampsia (n=16) were recruited in the first trimester of
pregnancy or at diagnosis respectively. Women were given a minimum of 24 hours
to consider participating in the study. Exclusion criteria are detailed in section 2.1.3.
5.2.2 Visit schedule
Women abstained from alcohol, caffeine and tobacco for 12 hours and fasted for
4 hours prior to attendance. Blood pressure and heart rate were recorded in duplicate
using an automated sphygmomanometer following a 15 minute left-lateral or supine
rest for pregnant subjects (at every visit) and non-pregnant (at first visit, D 1-3)
respectively. Height and weight were also measured to allow calculation of BMI.
Women with pre-eclampsia continued to take their antihypertensive medication as
prescribed. This is detailed in section 5.3.1.
Non-pregnant women
Women attended for four visits during a single menstrual cycle (D 1-3 (early




Women with uncomplicated pregnancies attended for four visits during pregnancy at
16, 24, 32 and 37 weeks and at 7 weeks post-partum. Women with pre-eclampsia
attended following diagnosis and at 7 weeks post-partum.
5.2.3 Sample collection
At each visit, peripheral venous blood was drawn from a large antecubital vein as
described in section 2.4.2. Venous blood collected in tubes containing EDTA was
used for the CFU-EPC assay (10 mL) and for flow cytometry (2 mL). The full blood
count differential was obtained from a 5 mL sample of EDTA-anticoagulated blood
processed by the hospital haematology laboratory. Plasma and serum were prepared
and stored as described in section 2.4.2 for subsequent analysis of circulating
hormones and inflammatory mediators. Following venepuncture, arterial stiffness
studies were performed, detailed in Chapter 6.
5.2.4 In vitro culture
Functional EPCs were quantified using the Endocult™CFU-EPC assay as described
in section 2.6.1.
5.2.5 Immunofluorescence
This was performed to confirm endothelial cell lineage of the colonies formed within
the CFU-EPC assay and is described in section 2.7.1.
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5.2.6 Flow cytometric analysis of epcs
This was performed as described in section 2.5.4.
5.2.7 Measurement of circulating hormones
Serum concentrations of oestradiol and progesterone were measured in all women.
Lutenizing hormone and FSH were also measured in the healthy non-pregnant
women. All hormones were measured by automated chemiluminescent microparticle
assays as described in section 2.9.1-4.
5.2.8 Measurement of inflammatory markers
ELISAs were used to measure plasma concentrations of TNF-a, IL-6 and soluble
ICAM-1 in all women, as described in section 2.8.3-5. In addition, plasma VEGF
was measured by ELISA in the healthy non-pregnant women, as described in section
2.8.6.
5.2.9 Statistical analysis
The distribution of data was determined using the Kolmogorov-Smirnov test for
normality. Continuous variables are reported as mean±SEM, or median+interquartile
range for parametric and non-parametric data respectively. Statistical analyses were
performed using two-tailed Student's /-tests or Mann-Whitney tests for parametric
and non-parametric data respectively. For multiple comparisons, one-way ANOVA
with repeated measures and Bonferroni's post-tests or non-parametric Friedman
analyses were used. Correlation coefficients were calculated using Pearson or
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Spearman analyses for parametric and non-parametric data respectively. All
calculations were performed using GraphPad Prism, (GraphPad Software, USA).




In six of sixteen non-pregnant women, ovulation could not be confirmed leaving a
final study group of ten women with a confirmed regular ovulatory cycle (cycle
length 28±0.4 days; luteal phase serum progesterone >30 nmol/L). All women (age,
31.4±2.0 yr) were of normal body composition (BMI, 23.4±0.7 kg/m2). Baseline
systolic and diastolic blood pressures and heart rate, measured at D 1-3 of the cycle,
were 110±2 mmHg, 67±2 mmHg and 60±2 bpm, respectively.
Pregnant women
In the healthy pregnant group, four of thirty women developed complications in their
pregnancy, for example intra-uterine growth restriction, pre-term labour or pre¬
eclampsia and a further five were unable to complete the full schedule of visits. In
addition technical problems with the flow cytometer resulted in samples from two
women being unanalysed. Overall, the final study group consisted of complete
samples from nineteen women. In the pre-eclamptic group, women were categorised
according to gestation at presentation, into pre-term (n=8; mean 30 (range 24-34
141
weeks)) and term (n=8; mean 38 (range 36-40 weeks)). Women with pre-eclampsia
were delivered earlier than women with uncomplicated pregnancies and had
offspring of lower birth weight (Table 5).
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TABLE5.Baselinecharacteristicsofstudyp rticipants Health}nonHealthypregnantgroupPr -eclampticr(n=16)pregnantgroupJr<=&v/ (n=10)9Pre-term(n=8T r ) Age(years)31±2 Height(m)1.70±0.02 Weight(Kg)68±3 BodyMassIndex(kg/m2)23±1 Gestationatdelivery(weeks)N/A Birthweight(g)N/A30±1 1.65±0.02* 72±4 27±1 41±0.3 3430±120
28±3 1.63±0.02* 64±4 24±2 31±1.4X 1366±192§
30±2 1.62±0.02* 75±4 29±1* 39±0.4t 3231±252
Dataexpressedmean±SEM.Bodysind xwar corddu ingfi sttrim sterpr gnantom . p<0.05versushealthynon-pregnantgro p,tp .0 09ve susltnon-pregnantg o p,Jp<0. 03ush althyp eg ,
§p<0.0001versushealthypregnantandte mpr -eclamp icgro s,(two-tailedu p ireStud nt's/-t s). SEM-standarderrorofthemean.
There was no difference in first trimester blood pressures between women with
healthy and pre-eclamptic pregnancies (113±2/69±2 mmHg versus
117±3/73±2 mmHg, p>0.9). As expected women, with pre-term and term pre¬
eclampsia had higher blood pressures at the time of study compared to those women
with uncomplicated pregnancies at similar gestations (Pre-term pre-eclampsia, (30
weeks) versus healthy pregnancy, (32 weeks) 140±2/87±3 mmHg versus
112± 1/70±1 mmHg respectively; term pre-eclampsia (38 weeks) versus healthy
pregnancy (37 weeks) 147±2/96±2 mmHg versus 117±2/76±1 mmHg respectively;
all p<0.0001). The women with pre-eclampsia were no longer hypertensive at the
post-partum visit, but still had higher blood pressures than the women with
uncomplicated pregnancies (pre-eclampsia versus healthy pregnancy post-partum;
123±3/77±2 mmHg versus 113±1/69±1 mmHg, both p<0.002).
Medication use
In women with pre-term pre-eclampsia, five were taking regular labetalol and
nifedipine, two were taking regular methyldopa and nifedipine, and one was
receiving no anti-hypertensive therapy. Seven of these women received antenatal
betamethasone. In women with term pre-eclampsia, one was taking regular labetalol
with the remaining seven women not receiving anti-hypertensive therapy. None
received antenatal betamethasone. Post-partum, out of the original sixteen women
who had developed pre-eclampsia, only three women were taking labetalol, and one,
methyldopa.
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5.3.2 The concentration of circulating triple positive cd34+cd133+kdr+
epcs varied throughout the menstrual cycle
Concentrations of circulating triple positive CD34+CD133+KDR+ EPCs varied
throughout the menstrual cycle (p=0.04, one-way ANOVA with repeated measures)
with mid-follicular levels (0.99±0.3 xlO6 cells L"1) being 3-fold higher than peri-
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Figure 30. Concentration (mean±SEM) of leucocytes co-expressing CD34, CD133 and KDR varied
throughout the menstrual cycle (n=10, p=0.04, one-way ANOVA with repeated measures). Mid-
follicular levels were higher than peri-ovulatory levels (p<0.05, Bonferroni's post-test for multiple
comparisons).
SEM - standard error of the mean; CD - cluster of differentiation; KDR - kinase insert domain
receptor; ANOVA - anlaysis of variance.
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5.3.3 The number of cfu-epcs formed did not vary throughout the
menstrual cycle
In contrast, there was no variation in numbers of CFU-EPCs formed during the
menstrual cycle (p=0.6; Figure 31). Direct staining confirmed that CFU-EPCs, like
mature endothelial cells, bind lectin, integrate AcLDL and are positive for the
endothelial markers CD105 and CD146 (Chapter 2, Figure 14). There was no
correlation between EPCs quantified by phenotype (CD34+CD133+KDR+) and
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Figure 31. Number (mean±SEM) of CFU-EPCs formed per 1x10 mononuclear cells plated,
throughout the menstrual cycle. (n=10, p=0.6, one-way ANOVA with repeated measures).
SEM - standard error of the mean; CFU-EPCs - colony forming unit-endothelial progenitor cells;
ANOVA - anlaysis of variance.
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5.3.4 Sex steroids and inflammatorymediators
There was normal cyclical variation in circulating pituitary and ovarian hormones
with peri-ovulatory peaks in serum LH and FSH concentrations, and peri-ovulatory
and mid-luteal peaks in serum oestradiol and progesterone concentrations
respectively (Table 6). Concentrations of plasma TNF-a (p=0.05) but not IL-6,
soluble ICAM-1 or VEGF (p=0.51, p=0.36, p=0.84, respectively) varied over the
menstrual cycle. There was no relationship between functional or phenotypic EPCs
and circulating levels of oestradiol, progesterone, soluble ICAM-1, IL-6 or VEGF at
any phase of the menstrual cycle. A weak correlation was seen between plasma
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5.3.5 The concentration of circulating triple positive cd34+cd133+kdr+
epcs did not vary significantly in normal pregnancy and was not
affected by pre-eclampsia
There was no significant variation in concentrations of leucocytes co-expressing
CD34, CD133 and KDR with gestation in healthy pregnancy (p=0.6; Figure 32).
Although numbers appear to be higher in the pre-term pre-eclamptic women, this
was not significant and was due to their increased total leucocyte concentration,
(1.3xl010 ±1.5 x 109 versus 9.3±4.2 x 109 L"1, p=0.005, two-tailed, unpaired
Student's /-test). Six of these women had received antenatal betamethasone, which
increases the granulocyte fraction of the circulating white count [Kadanali et al,
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Figure 32. Concentration (mean±SEM) of leucocytes co-expressing CD34, CD133 and KDR in
healthy non-pregnant, pregnant and pre-eclamptic women. No difference was seen within healthy
pregnancy (p=0.6, one-way ANOVA with repeated measures). Apart from the variation within the
menstrual cycle (described earlier in Figure 30), no other differences were observed between healthy
non-pregnant women, healthy pregnant and pre-eclamptic women. There was no difference in
concentration between women with pre-term or term pre-eclampsia at the post-partum visit (two-
tailed unpaired Student's Mest; p=0.3)
SEM - standard error of the mean; CD - cluster of differentiation; KDR - kinase insert domain
receptor; ANOVA - analysis of variance; PP - post-partum..
5.3.6 The number of cfu-epcs formed in normal pregnancy and in pre¬
eclampsia varied widely
The numbers of CFU-EPCs formed from mononuclear cells from pregnant women
varied widely. There was no difference in numbers of CFU-EPCs formed throughout
pregnancy (p=0.42, Friedman test; Figure 33). In addition, numbers formed were not
different between healthy pregnant women and those with pre-eclampsia (p>0.1 for
all, Mann-Whitney test). There was no relationship between functional or phenotypic









▼ Healthy non-pregnant n= 10
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Figure 33. Number (median±interquartile range) of CFU-EPCs formed per 1 x 106 mononuclear cells
plated, throughout the menstrual cycle, healthy and pre-eclamptic pregnancies. Data for menstrual
cycle is expressed as median±interquartile range to allow for comparison between groups. There was
no significant variation within pregnancy (p=0.42, Friedman test) or between the healthy pregnant and
pre-eclamptic groups (p>0.1 for all, Mann-Whitney test). There was no difference in numbers formed
between women with pre-term or term pre-eclampsia at the post-partum visit (Mann-Whitney test;
p>0.05). Numbers of CFU-EPCs were lower in pregnancy, from 24 weeks and post-partum (both
groups), than in the early follicular phase of the menstrual cycle (p<0.04 for all, Mann-Whitney test).
CFU-EPCs - colony forming units-endothelial progenitor cells; PP - post-partum.
The number of CFU-EPCs formed was lower in healthy pregnancy (from 24 weeks)
and post-partum (healthy pregnant and pre-eclamptic groups), than the early
follicular phase of the menstrual cycle (p<0.04 for all, Mann-Whitney test). Log
transformation of the data reveals similar results with a lower number of CFU-EPCs
formed in the third trimester of healthy pregnancy than in the early follicular phase
of the menstrual cycle (p<0.02, Mann-Whitney test). We observed a greater
proportion of samples from healthy pregnant women to be poorly proliferative
compared to samples from healthy non-pregnant women. Fifty-one per cent of all
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samples taken in pregnancy from healthy pregnant women grew five colonies or
fewer compared to 15% of samples from the healthy non-pregnant women, from
throughout the cycle (p<0.05, Chi-squared test).
5.3.7 There was no consistent correlation between triple positive
CD34+CDl33+KDR+ EPCS, CFU-EPCS AND CIRCULATING SEX STEROIDS OR
INFLAMMATORY MEDIATORS
Serum oestradiol and progesterone
Expected increases with gestation were observed in pregnant women in serum
oestradiol and progesterone concentrations (Table 7). Women with pre-term pre¬
eclampsia had lower serum oestradiol levels than healthy pregnant women at 32
weeks gestation (29950±9876 versus 50297±2683 pmol L"1, p=0.009, two-tailed
unpaired Student's Mest). There was no relationship between phenotypic EPCs and
circulating levels of oestradiol or progesterone. A positive correlation was seen
between number of CFU-EPCs and oestradiol (r=0.48, p=0.04) and progesterone
(r=0.6, p=0.0093) in samples from the 24-week visit only.
Plasma TNF-a
Concentrations of plasma TNF-a were not different in pregnancy compared to the
non-pregnant state (at any phase of the cycle) or the post-partum visit.
Concentrations of plasma TNF-a did not vary significantly within pregnancy, nor
were they different in the women with pre-eclampsia compared to the healthy
pregnant women (p>0.2 for all, Freidman and Mann-Whitney tests; Table 7).
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A negative correlation was seen between plasma levels of TNF-a and concentration
of phenotypic EPCs in samples obtained from women at 16 and 24 weeks gestation
(r=-0.47, p=0.04 and r=-0.5, p=0.03, Spearman). There was no relationship between
functional EPCs and circulating levels ofTNF-a.
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Plasma IL-6
Concentrations of plasma IL-6 were raised in pregnancy compared to healthy non¬
pregnant women (pooled data across the cycle, as no cyclical variation) and this
persisted post-partum (pooled non-pregnant versus 16, 24, 32, 37 weeks and 7 weeks
post-partum, p<0.003 for all, Mann-Whitney tests). However, concentrations of
plasma, IL-6 did not vary significantly within pregnancy, nor were they different in
the women with pre-eclampsia compared to the healthy pregnant women (p>0.2 for
all, Freidman and Mann-Whitney tests; Table 7).
There was no relationship between phenotypic or functional EPCs and circulating
levels of IL-6.
Plasma soluble ICAM-1
Levels of soluble ICAM-1 were greater in the healthy pregnant group, than in the
healthy non-pregnant women (pooled data across the cycle, as no cyclical variation)
at 24 and 37 weeks gestation (237±14.2 and 227±11.8 versus 202±5.9 ngmL"1,
p<0.04, two-tailed unpaired Student's Mests). Post-partum levels of soluble ICAM-1
remained higher than in healthy pregnancy (post-partum versus 37 weeks, 273±11.8
versus 227±11.8 ngmL"1, p=0.0004, two-tailed, paired Student's t-test) and higher
than in the healthy non-pregnant women (post-partum versus pooled non-pregnant,
273±11.8 versus 202±5.9 ngmL"1, pO.OOOl, two tailed, unpaired Student's t-test).
However, like TNF-a and IL-6, concentrations of soluble ICAM-1 did not vary
significantly within pregnancy, nor were they different in the women with pre-
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eclampsia compared to the healthy pregnant women (p>0.08 for all, one-way
ANOVA with repeated measures and two-tailed unpaired Student's /-tests; Table 7).
Soluble ICAM-1 levels were correlated with phenotypic EPCs in samples from the
32-week visit only (r=0.46, p=0.04, r2=0.21, Pearson's test). There was no
relationship between functional EPCs and circulating levels of soluble ICAM-1.
5.4 DISCUSSION
This study demonstrates that numbers of circulating EPCs quantified by phenotype
(CD34+CD133+KDR+ cells) vary during the menstrual cycle, peaking in the mid-
follicular phase. In contrast, EPCs quantified by the functional CFU-EPC assay did
not vary during the menstrual cycle, though numbers formed from samples taken in
the early-follicular phase were higher than samples taken in the second and third
trimesters of healthy pregnancy. During the normal menstrual cycle, mobilised
CD34+CD133+KDR+ cells may have the potential to contribute to endometrial
angiogenesis during the mid-follicular phase of the cycle [Girling and Rogers, 2005].
Given the lack of correlation between EPCs quantified by phenotype or function and
the levels of circulating sex hormones or inflammatory mediators measured during
the menstrual cycle, this raises the possibility of an endometrial specific factor being
present in mid-follicular phase endometrium, which has the potential to mobilise
EPCs and/or remove them from the peripheral circulation into endometrium. There
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was no difference in circulating EPCs, quantified either by phenotype or the
functional CFU-EPC assay, during healthy or pre-eclamptic pregnancies.
5.4.1 EPCS AND THE MENSTRUAL CYCLE
During the normal menstrual cycle, the uterine endometrium undergoes a unique
cycle of physiological angiogenesis and endothelial repair. These processes begin in
the proliferative and continue into the secretory phase of the cycle and are under tight
hormonal and inflammatory control [Jabbour et al, 2006]. Previously, endometrial
angiogenesis was thought to occur primarily from new vessels sprouting via
recruitment of local endothelial cells from neighbouring blood vessels [Risau and
Flamme, 1995; Gambino et al, 2002], However recently, an alternative or
complementary mechanism involving circulating EPCs has been proposed in the
control and regulation of endometrial angiogenesis [Mints et al, 2008]. In support, in
mice, an average 6% of endometrial endothelial cells were found to be donor derived
after a haematological stem cell transplant [Bratincsak et al, 2007],
The present study is the first to investigate the influence of the menstrual cycle on
both phenotypic and functional EPCs. The finding that CD34+CD133+KDR+ EPCs
peak during the mid-follicular phase differs from two recent studies of EPCs during
the menstrual cycle [Matsubara et al, 2006; Fadini et al, 2008]. A variety of factors
may account for these seemingly discrepant findings, but in particular the differing
methodologies employed and timing of sampling Fadini et al [2008] demonstrated a
similar 2-fold increase in CD34+KDR+ numbers during the menstrual cycle, but the
peak seemed to occur in the peri-ovulatory phase rather than earlier during the
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follicular phase as in our study. However, Fadini et al [2008] did not specify the day
of sampling so it is possible that this peak occurred between days 6 to 12 of the
menstrual cycle, which would therefore be entirely consistent with our findings. In
the cross-sectional study by Matsubara et al [2006], EPCs were increased in the
luteal phase compared to the follicular phase of the cycle in women. The discrepancy
in findings is most likely due to the different methodology and study design
employed. They quantified the proliferative capacity of EPCs using adherent
peripheral blood mononuclear cells that tested positive for AcLDL and lectin after
7 days in culture, and did not use the EPC-CFU assay described here. Moreover,
although Matsubara et al [2006] compared EPCs during the follicular and luteal
phase of the cycle, it is again unclear on which day the samples were taken in their
cross-sectional study. From this longitudinal study, in which samples were taken on
four consecutive time-points within a single cycle, there are clear differences in
concentrations of CD34+CD133+KDR+ EPCs depending on the day of sampling.
This variation will be magnified if a broader time window of sampling was used, and
by the use ofmultiple subjects because of the potential for inter-subject variability.
5.4.2 EPCS AND HEALTHY PREGNANCY
The results in this chapter demonstrate that neither CD34+CD133+KDR+ EPCs nor
CFU-EPCs vary throughout healthy pregnancy. In healthy pregnant women, the
formation of CFU-EPCs, was lower in samples from women in the early-follicular
phase of the menstrual cycle. This finding is consistent with the inflammatory state
of pregnancy. Although the exact phenotype of EPCs is still under debate (discussed
below) and varies widely in the literature, recent reports demonstrate that induced
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human endotoxaemia decreases EPCs, measured within the EPC-CFU assay [Spiel et
al, 2008],
Elowever, our findings contrast to nearly all the other studies performed in
pregnancy. The first published studies employed a cross-sectional design [Gussin et
al, 2002; Sugawara et al, 2005a; Matsubara et al, 2006] and demonstrated both
increases [Sugawara et al, 2005a] and decreases [Matsubara et al, 2006] of EPCs
with gestation. The only other longitudinal study, by Buemi et al [2007], of seven
women, reported an increase in double positive (CD133+/KDR+) cells. Our findings
are supportive of the most recent study by Savvidou et al [2008] who also found no
change in numbers of EPCs with gestation, and lower levels in healthy pregnant
women compared to non-pregnant women, though they used different methods,
performing flow cytometry on an adherent population of mononuclear cells after
7 days in culture.
It is difficult to make straightforward comparisons between all these studies, as
different methods have been used to quantify putative EPCs. In particular,
discordance between flow cytometry and cell culture will be discussed below.
However, a limitation of all of these studies, except Buemi et al [Buemi et al 2007],
is also the cross-sectional study design. Many factors affecting circulating EPC
numbers were not described for the study subjects. A strength of this current study
therefore is its prospective design following women through gestation and post¬
partum. This has demonstrated that in pregnancy, CFU-EPCs are lower than in the
follicular phase of the menstrual cycle. Due to the difficulties in recruiting women
159
for a longitudinal study before they have had a booking ultrasound scan, we were
unable to obtain data on circulating EPCs in the first trimester. If EPCs play an active
role within the uterus at the time of placentation, our study would have missed this
sampling opportunity.
5,4.3 EPCS AND PRE-ECLAMPSIA
The finding that CD34+CD133+KDR+ EPCs and CFU-EPC numbers are no different
in women with pre-eclampsia compared to healthy pregnant women at similar
gestations partly supports and differs from the only other studies of EPCs in pre¬
eclamptic women [Sugawara et al, 2005b; Matsubara et al, 2006]. As with the
studies in normal pregnancy, the published data are conflicting. Sugawara et al
demonstrated decreased numbers of CFU-EPCs and increased senescence of EPCs in
patients with pre-eclampsia compared to gestationally matched controls [Sugawara et
al 2005b]. In contrast, Matsubara et al [2006] reported no difference in the number
of circulating CD34+CD133+KDR+ EPCs measured by flow cytometry in pre¬
eclamptic women, supporting this similar finding. However, they also performed
culture of fibronectin-adherent mononuclear cells, not the non-adherent fraction as in
the CFU-EPC assay. In their method, the samples from women with pre-eclampsia
resulted in more endothelial-like cells, which had increased proliferative response
following stimulation with TNF-a and angiotensin II compared with cells from
women without pre-eclampsia [Matsubara et al, 2006], This increase may be a
physiological response to ischaemia in the placenta and other organs, similar to that
seen in myocardial infarction [Leone et al, 2005; Massa et al, 2005], These studies
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are not easily comparable because of the different methods used, and it is difficult to
draw a conclusion from the discordant observations.
Although the CFU-EPC assay quantifies colony forming units, different assays are
emerging, which further assess cell function, proliferative ability and endothelial
tube formation. It is likely that EPC function is more important than quantity, and
ideally a subsequent study of EPCs in pre-eclampsia would assess number and
function prospectively prior to the onset of disease.
5.4.4 Quantification of epcs
The exact phenotype of EPCs has been debated since the original publication by
Asahara et al [1999] in which it was demonstrated that CD34+ cells extracted from
circulating peripheral blood formed new blood vessels in culture and contributed to
angiogenesis in a mouse model of ischaemia. The purity of this cell population was
only 15% raising the possibility that a variety of other circulating cell types may also
have angiogenic potential. The current consensus is that mononuclear cells co-
expressing CD34, CD 133, and KDR (so-called 'triple positive' cells) constitute the
most likely phenotype of circulating endothelial progenitors. However, these cells
are rare in normal peripheral blood, constituting between 0.01% and 0.0001% of the
circulating leukocyte population, making their accurate quantification by flow
cytometry difficult. As a result, assays based on the quantification of functional
populations of EPCs with colony forming activity in cell culture (CFU-EPCs) have
emerged as alternatives [Hill et al, 2003].
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However, the validity of the CFU-EPC assay in quantifying EPCs has recently been
challenged by studies showing that the CFU-EPC cells are derived from monocyte-
like cells and not the circulating CD34+ haemangioblast [Prater et al, 2007;
Rohde et al, 2007; Yoder et al, 2007], Recent work, performed by other members of
our group, is consistent with that of Rhode et al [2007] where it has been
demonstrated that there are substantial numbers of CD 14 expressing cells in the non¬
adherent population replated at 48 hours in the CFU-EPC assay. This expression of
CD 14 is gradually reduced during culture in endothelial medium. Using flow
cytometric sorting, CFU-EPCs only develop in the presence of CD 14 cells. Isolated
CD34+ or CD133+ cells are not able to form CFU-EPC in this assay (personal
communication, Dr Olga Tura, The Univeristy ofEdinburgh).
Therefore, a strength of this study design was the simultaneous measurement of
CD34+CD133+KDR+ cells using flow cytometry and quantification of colony
forming units in the CFU-EPC assay. Both remain the most established and widely
used techniques in the field, though our group [Tura et al, 2007] and others have now
confirmed that these techniques are measuring quite different cell populations.
The finding of a lack of correlation between concentrations of CD34+CD133+KDR+
EPCs and EPCs quantified by the CFU-EPC assay is therefore important. Currently,
these two methods are used interchangeably in clinical studies and are in general
thought to be measuring the same endothelial progenitor derived from CD34+
pluripotent cells using different techniques. This is clearly not the case as our study
demonstrates. Thus, cells quantified by flow cytometry (phenotype) and cell culture
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(CFU-EPCs) are likely to have different biological functions and progenitor potential
[Tura et al, 2007]. Ingram et al [2004] described a new EPC population in human
umbilical cord blood called the 'late outgrowth endothelial progenitor cell' with a
high proliferative capacity and the ability to express endothelial markers and form
tubules in vitro [Ingram et al, 2004]. This population arises from CD34+ cells. Thus,
the CD34+CD133+KDR+ EPCs may correlate with this late-outgrowth assay.
5.4.5 Hormonal regulation of epcs
This research has demonstrated that CD34+CD133+KDR+ EPCs peak during the mid-
follicular phase of the menstrual cycle. Neither healthy pregnancy, nor pre-eclampsia
appeared to affect the absolute concentrations of EPCs. Colony forming unit-
endothelial progenitor cell formation was not different across the menstrual cycle,
but was greater in the early follicular phase than in healthy pregnancy. Again, neither
gestation, nor pre-eclampsia appeared to further affect CFU-EPC formation. In this
study, these effects do not appear to be driven by the circulating oestradiol or
progesterone. The lack of correlation of EPCs with serum oestradiol concentrations
differs from the study by Sugawara et al [2005a] in which they found that during
pregnancy, there was a clear correlation between oestradiol and EPCs quantified by a
modified CFU-EPC assay [Sugawara et al. 2005a], However, unlike their study the
results presented here do not demonstrate any change within pregnancy in CFU-
EPCs or CD34+CD133+KDR+ EPCs. There was a positive correlation between
number of CFU-EPCs and circulating oestradiol and progesterone concentrations in
samples from the 24-week visit only. This correlation did not exist for
CD34+CD133+KDR+ EPCs and it is difficult to understand the significance of this
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relationship at a single time point in pregnancy. Differences in methodology are most
likely to account for the differences between this study and that of Sugawara et al
[2005a],
It was surprising not to find a consistent relationship between EPC concentrations
and oestradiol, as oestrogens are known to have vasculoprotective effects, in part due
to increasing production of nitric oxide and by decreasing reactive oxygen species
[Mendelsohn and Karas, 1999]. Outwith pregnancy, oestrogens mobilise EPCs from
the bone marrow in vivo and inhibit the senescence of EPCs and stimulate VEGF
production in vitro [Strehlow et al, 2003; Imanishi et al, 2005b]. These findings
suggest that factors other than oestrogens may be involved in EPC mobilisation in
non-pregnant and pregnant women.
5.4.6 EPCS AND INFLAMMATORY MEDIATORS
In this study, there was no consistent correlation between concentrations of the
circulating inflammatory mediators studied and EPCs. A number of factors may
explain this. First, unlike CD34+CD133+KDR+ EPCs in the menstrual cycle, there
was no variation in CD34+CD133+KDR+ EPCs in healthy pregnancy or pre¬
eclampsia. In addition, CFU-EPC formation did not vary across the cycle, within
healthy pregnancy or in pre-eclampsia. Secondly, there was no cyclical variation in
concentration of the inflammatory mediators IL-6, soluble ICAM-1 and VEGF over
the menstrual cycle. Although, there was a decrease in soluble TNF-a concentration
over the cycle and a weak correlation with numbers of CD34+CD133+KDR+ EPCs,
the absolute levels of TNF-a were almost ten times lower than in conditions such as
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rheumatoid arthritis and cardiac failure, where strong correlations with EPCs have
been demonstrated [Valgimigli et al, 2004; Grisar et al, 2007]. Moreover, the small
numbers in our menstrual cycle study may also be a contributing factor.
Circulating levels of IL-6 and soluble ICAM-1 were higher in pregnancy than in
healthy non-pregnant women, reflecting the systemic inflammatory state, and this
persisted post-partum. TNF-a though was not significantly different in pregnancy
compared to the non-pregnant state. None of the inflammatory markers measured
increased with gestation, and perhaps most surprisingly, none were affected by pre¬
eclampsia. Our women were well matched gestationally and fulfilled ISSHP criteria
for the diagnosis of pre-eclampsia. A recent study that reported no difference in the
circulating concentrations of seventeen cytokines between pre-eclamptic and
gestationally matched women [Brewster et al, 2008],
There were some isolated correlations in healthy pregnancy, negative between
plasma TNF-a and CD34+CD133+KDR+ EPCs at 16 and 24 weeks gestation and a
positive correlation between soluble ICAM-1 and CD34+CD133+KDR+ EPCs at
32 weeks gestation, the significance of these is uncertain. Therefore, local rather than
systemic levels of inflammatory mediators may control mobilisation of EPCs.
Mobilisation of EPCs in response to increased local but not systemic concentrations
of VEGF and SDF-1 has recently been demonstrated in animal and human limb
ischaemia models [Hur et al, 2007; Oh et al, 2007]. Within the menstrual cycle, this
study measured systemic and not local levels of VEGF, which may account for the
lack of correlation between VEGF and EPCs. Finally, other factors thought to be
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involved in regulation of endometrial angiogenesis including the angiopoietins
[Girling and Rogers, 2005; Saito et al, 2007], may play a role in EPC mobilisation
and recruitment [Mints et al, 2007] during the mid-follicular phase of the menstrual
cycle and possibly pregnancy.
5.5 SUMMARY
In summary, during the normal menstrual cycle there is cyclical variation of
phenotypic triple positive EPCs. Their peak in the mid-follicular phase suggests a
potential role for circulating EPCs in the normal cycle of physiological angiogenesis
and repair of the uterine endometrium. It would be of interest to determine whether
pathologies such as heavy menstrual bleeding and endometriosis [Mints et al, 2007]
are associated with abnormalities of EPC number or function. Colony forming unit-
endothelial progenitor cells but not 'triple positive' EPCs were higher in the
follicular phase of the menstrual cycle than in pregnancy, though there was no
variation in EPCs measured by either assay with pre-eclampsia; suggesting that
systemic involvement of these cells is affected by pregnancy, but not altered in pre¬
eclampsia. This work has mainly focused on quantification of these cells. Areas of
interest for future studies would examine their role in the first trimester of pregnancy,
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Arterial stiffness is a key determinant of central aortic pressure and is an independent
predictor of adverse cardiovascular outcomes and organ damage [Laurent et al, 2001;
Wilkinson et al, 2001a]. Female gender affects arterial stiffness, mediated in part via
the influence of both oestrogen and progesterone on arterial structure and function
[Natoli et al, 2005], In the pre-pubertal and post-menopausal years when female sex
steroids are low, women have stiffer arteries than age-matched men [Waddell et al,
2001; Ahimastos et al, 2003]. During the reproductive years, female sex steroids
fluctuate cyclically during the menstrual cycle and increase dramatically in
pregnancy. The initial effect of pregnancy increasing arterial compliance is well
documented in both animal and human studies [Hart et al, 1986; Poppas et al, 1997;
Slangen et al, 1997; Edouard et al, 1998; Smith et al, 2004; Mersich et al, 2005].
However data are conflicting, concerning the effect of the menstrual cycle, (where
circulating concentrations of sex steroids are lower), and the effect of later gestation
on arterial compliance.
Augmentation index and PWV are the principal measures of central arterial pressure
and stiffness that can be determined noninvasively using applanation tonometry.
Analysis of peripheral pressure waveforms allows the derivation of central arterial
pressure and its augmentation by pulse wave reflection; often expressed as the Al
and provides a measure of systemic arterial stiffness. Pulse wave velocity is the 'gold
standard' technique for assessing large vessel stiffness and is usually performed at
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the carotid and femoral or carotid and radial arteries to measure aortic and brachial
stiffness respectively.
Within normotensive pregnancy, PWV is more closely associated with low birth-
weight than mean arterial pressure, suggesting that arterial stiffness may represent
maternal adaptation to pregnancy better than blood pressure [Elvan-Taspinar et al,
2005]. Pre-eclampsia is a common hypertensive complication of pregnancy, which
causes significant maternal and foetal morbidity. Inadequate cardiovascular
adaptation in early pregnancy may predate its clinical presentation [De Paco et al,
2008], and it is associated with an increased long-term risk of maternal
cardiovascular disease. Understanding the relationship between pre-eclampsia and
arterial stiffness may therefore not only inform understanding of its pathogenesis, but
may also increase our understanding of the association between pre-eclampsia and
later cardiovascular disease.
The aim of the research presented in this chapter was to evaluate the effect of the




All equipment used is detailed in Appendix 1.
6.2.1 Subject recruitment
Women were identified, recruited and consented to this study (study 2, Reference
number 05/S1104/48), as described in section 2.1.
Non-pregnant women
Healthy pre-menopausal non-smoking nulliparous women (n=16) with at least a
2-month history of normal regular menstrual cycles were recruited to the study.
Exclusion criteria are listed in section 2.1.2.
Pregnant women
Healthy, non-smoking primigravida women with an uncomplicated pregnancy
(n=30) or with pre-eclampsia (n=16) were recruited in the first trimester of
pregnancy or at diagnosis respectively. Women were given a minimum of 24 hours
to consider participating in the study. Exclusion criteria are listed in section 2.1.3.
6.2.2 Visit schedule
Non-pregnant women
Women attended for four visits during a single menstrual cycle (D 1-3 (early-




Women with uncomplicated pregnancies attended for four visits during pregnancy at
16, 24, 32 and 37 weeks and at 7 weeks post-partum. Women with pre-eclampsia
attended following diagnosis and at 7 weeks post-partum.
6.2.3 Study protocol
At each visit, all women abstained from alcohol and caffeine for 12 hours and fasted
for 4 hours prior to attendance. Height and weight were measured to allow
calculation of BMI. Women with pre-eclampsia continued to take their
antihypertensive medication as prescribed. This is detailed in section 6.3.2. All
studies were performed in a quiet, temperature controlled room with women resting
in the supine position or 30° left lateral position for pregnant women (to avoid
inferior vena cava compression by the uterus). All subsequent measurements were
done in the supine position. Following a 30-minute rest period (during which
venepuncture was performed as detailed in chapters 4 and 5), blood pressure and
heart rate were recorded in duplicate using an automated sphygmomanometer
validated for use in pregnancy and pre-eclampsia [Reinders et al, 2005].
Pulse wave analysis
This was performed on all women at every visit as detailed in section 2.2.1.
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Pulse wave velocity
Pulse wave velocity was performed in the early-follicular visit for the non-pregnant
women and at every visit (pregnant and post-partum) for the healthy pregnant and
pre-eclamptic women as detailed in section 2.2.2.
6.2.4 Measurement of circulating hormones
Serum concentrations of oestradiol and progesterone were measured in all women.
Lutenizing hormone, and FSH were also measured in the healthy non-pregnant
women. All hormones were measured by automated chemiluminescent microparticle
assays as described in section 2.9.1-4.
6.2.5 Statistical analysis
Continuous variables are reported as mean±SEM for parametric data. Statistical
analyses were performed using paired and unpaired two-tailed Student's t-tests. For
multiple comparisons, one-way ANOVA with repeated measures was used. All
calculations were performed using GraphPad Prism, (GraphPad Software, USA).





In six of sixteen non-pregnant women, ovulation could not be confirmed leaving a
final study group of ten women with a confirmed regular ovulatory cycle (cycle
length 28±0.4 days; luteal phase serum progesterone >30 nmol/L).
Pregnant women
In the healthy pregnant group, four of thirty women developed complications in their
pregnancy, for example intra-uterine growth restriction, pre-term labour or pre¬
eclampsia and a further four were unable to complete the full schedule of visits,
leaving a final study group of twenty-two women for analysis. In the group of pre¬
eclamptic women, one woman could not complete the study, leaving a final study
group of fifteen women. Women were categorised according to gestation at
presentation, into pre-term (n=7; mean 30 (range 24-34 weeks)) and term (n=8; mean
38 (range 36-40 weeks)). As anticipated, women with pre-eclampsia were delivered
earlier than women with uncomplicated pregnancies and had offspring of lower birth
weight The mean gestation at delivery for women in the pre-term and term group
was 30.3 weeks (range 24-35.8) and 38.6 weeks (range 36.4-40.4), respectively.
Non-pregnant and pregnant groups were well matched for maternal age and BMI.
However, pregnant women were shorter in height than the non-pregnant group
(Table 8).
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Dataexpressedmean±SEM.Bodyindexwrecordedduringfi strim st ropr gna twome .
* p<0.05andt<0.00 9versusnon-pregnantgro p,Jp<0. 3versushe lthypregnantgra d§pO.OOOl versushealthypr gnantandt rmpre- clampticg ou s,(two-t ileunpair dStud t'/-t sts). SEM-standarderroofthemean.
There were no differences in systolic and diastolic blood pressure at booking
between women with healthy and pre-eclamptic pregnancies (pre-term and term
versus healthy pregnant, both p>0.1). However, as expected, women with pre¬
eclampsia had higher systolic and diastolic blood pressures. At the post-partum visit,
although blood pressure had returned to within the normal range in women who had
pre-eclampsia, it was still higher than in those women who had had an
uncomplicated pregnancy (p<0.004, two-tailed unpaired Student's /-test; Table 9).
6.3.2 Medication use
In women with pre-term pre-eclampsia, five were taking regular labetalol and
nifedipine, one was taking regular methyldopa and nifedipine, and one was receiving
no anti-hypertensive therapy. Six of these women received antenatal betamethasone.
In women with term pre-eclampsia, one was taking regular labetalol with the
remaining seven women not receiving anti-hypertensive therapy. None received
antenatal betamethasone. Post-partum, out of the original fifteen women who had
developed pre-eclampsia, only three women were taking labetalol, and one,
methyldopa.
6.3.3 Circulating hormones
Within the menstrual cycle, there was normal cyclical variation in circulating
pituitary and ovarian hormones with peri-ovulatory peaks in serum LH and FSH
concentrations, and peri-ovulatory and mid-luteal peaks in serum oestradiol and
progesterone concentrations respectively (Table 10).
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TABLE 9. Haemodynamic variables of both pregnant groups
Healthy Pregnant Group (n=22) Significance
Ha,,,,,dynamic 16 24 32 37 Po«- Within pregnancy
, , , , partum (4 time points,Variables weeks weeks weeks weeks . __r , .
visit 16 to 37 weeks)
Heart rate (bpm) 69±2 72±2 77±2 77±2 59±1 p<0.0001
Peripheral SBP, mmHg 113±2 lllil 113±1 117±1 113±1 p=0.004
Peripheral DBP, mmHg 65±1 65±1 70±1 76±1 69±1 p<0.0001
Peripheral PP, mmHg 48±2 46±2 43±I 41±1 42±2 p=0.003
Central SBP, mmHg 93±2 92±1 95±1 103±2 98±2 p<0.0001
Central DBP, mmHg 64±1 64±1 69±1 76±1 70±1 p<0.0001
Central PP, mmHg 30±1 28± 1 26±1 27±1 29±2 p=0.13
Mean Arterial

























Heart rate (bpm) 67±3 76±5 65±3 p=0.02 oooIID- p=0.02
Peripheral SBP,
mmHg 140±3 146±2 123±3 p<0.0001 p<0.0001 p=0.002
Peripheral DBP,
mmHg 87±3 95±2 77±3 pO.OOOl p<0.0001 p=0.004
Peripheral PP,
mmHg 52±4 52±4 45±3 p=0.004 p=0.001 p=0.4
Central SBP, mmHg 126±4 135±3 111±3 p<0.0001 pco.0001 p=0.0006
Central DBP, mmHg 89±3 97±2 79±3 p<0.0001 pco.0001 p=0.002
Central PP, mmHg 37±2 38±3 33±2 p<0.0001 p=0.0002 p=0.2
Mean Arterial
Pressure, mmHg 105±2 113±2 92±2 pcO.OOOl pco.0001 p=0.001
Data expressed as mean±SEM.
SBP - systolic blood pressure; DBP - diastolic blood pressure; PP - pulse pressure; bpm - beats per
minute; SEM - standard error of the mean.
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Dataexpressedmean±SEM.CirculatingLH,FSH,oestr diolanprogesteronevari dsi nificantlythrough uthm ns rualcycl .
LH-lutenisinghormone;FSH-f lliclestimulatinghor one;SEM-standarderrorofthme .
Expected increases with gestation were observed in pregnant women in serum
oestradiol and progesterone concentrations (Table 11). Pre-term pre-eclamptic
women had lower serum oestradiol levels than healthy pregnant women at 32 weeks
gestation (29950±9876 versus 49222±2444 pmol L"1, p=0.009, two-tailed unpaired
Student's /-test).
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TABLE11.Hormonalprofilefthehealthypreg ntande-eclamp icw m n HealthyPr gnantGroup(n=22) 16weeks24ks32ee7wPost-partumvisitSignificanceoverpregnancy
(4groups)
Oestradiol(pmoL"1)14995± 05732350 210849222± 44461385 430610 47.1pO.OOOl Progesterone(nm lL"1)178±9.92 46 0 38.6813 44.54±0p<0.0001 Pre-eclampticGroup(n=15) Prete mT r Post-partumSignificancei ific ceSignifi an (38weeks)pre-termvv32terms7betweenpost- /7\(combined)weekspartumgroups Oestradiol(pmolL"1)29950±98767011 10715167±36.2p=0.009NS Progesterone(nm lL"1)653±130.9949±97NS Dataexpressedmean±SEM.Circul tingo str diolprogester neinc sewithgest i . SEM-standarderrorofthem an;NS-n tsig ific nt.
6.3.4 Effect of the menstrual cycle on systemic arterial stiffness
In women with confirmed ovulatory cycles, systemic arterial stiffness, as measured
by AI, varied over the menstrual cycle (p=0.03, one-way ANOVA with repeated
measures) with a fall in the luteal phase compared to the peri-ovulatory phase
(3.5±1.8% versus 9.9±1.8%, p<0.05 Bonferroni's post-test; Figure 34a). There were
no changes in any other recorded haemodynamic variables throughout the menstrual
cycle (Table 12). There was no correlation between AI and serum oestradiol or
progesterone at any time point in the cycle.
Figure 34a. Variation in augmentation index throughout the menstrual cycle. Data (n= 10) are
reported as mean±SEM. Augmentation index varied during the menstrual cycle (p=0.03, one-way
ANOVA with repeated measures), with a fall in the luteal phase compared to the peri-ovulatory phase,
(days 20-22 versus 13-15, p<0.05 Bonferroni's post-test.)
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Figure 34b. Variation in heart rate adjusted augmentation index throughout the menstrual cycle. Data
(n=10) are reported as mean±SEM. There was a trend towards a reduction in heart rate adjusted
Augmentation index, with a fall in the luteal phase compared to the peri-ovulatory phase, (p=0.07,
one-way ANOVA with repeated measures). ANOVA - analysis of variance.
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TABLE12.Haemodynamicsfthehealthynon-pregnantwome Dayofmenstrualcycle 1-36 83-15
20-22
Significance (one-wayANOVA)
Heartr te(bpm) PeripheralSBP,mmHg PeripheralDBP,mmHg PeripheralP,mmHg CentralSBP,mmHg CentralDBP,mmHg CentralPP,mmHg MeanArterialPr ssure, MmHg
60±2 110±2 67±2 42±2 96±2 68±1 28±1 81±2
61±3 108±1 68±1 39±2 93±1 67±2 26±1 81±1
61±3 108±3 68±2 41±1 94±2 67±2 27±1 81±2
63±3 110±2 67±2 41±2 93±2 68±2 25±1 81±2
p=0.5 p=0.7 p=0.9 p=0.7 p=0.3 p=l p=0.5 p=l
Dataexpressedmean±SEM.SBP-ystolicblo dpre ure;Di s olicl r sure;Pulp m-tsrmin tEMt nda d errorofthemean.
6.3.5 Effect of normal pregnancy on systemic arterial stiffness
Augmentation index, was adjusted for heart rate (calculated at a heart rate of 75
bpm) due to variation in heart rate during pregnancy and post-partum (pO.OOOl for
all, unpaired Student's t-test). Heart rate adjusted AI varied with gestation in normal
pregnancy (pO.OOOl, one-way ANOVA with repeated measures; Figure 35) rising
towards term (16 weeks versus 37 weeks, 24 weeks versus 37 weeks and 32 weeks
versus 37 weeks, all p<0.01, Bonferroni's post-tests). Moreover, heart rate-adjusted
AI was persistently elevated at 7 weeks post-partum compared to 16 weeks gestation
(8.7±1.9% versus -3.0±2.5%, p=0.0002, two-tailed paired Student's t-test). There





















Healthy pregnant n= 22
□ Pre-term pre-eclamptic n= 7
□ Term pre-eclamptic n= 8




Figure 35. The effect of pregnancy, gestation and pre-eclampsia on augmentation index (adjusted for
heart rate). Data reported as mean±SEM. Heart rate adjusted augmentation index varied with gestation
in normal pregnancy (p<0.0001) rising towards term (p<0.0l) and was elevated at 7 weeks post¬
partum compared to 16 weeks gestation (p=0.0002). Compared to gestation matched controls,
augmentation index was raised in both pre-eclamptic groups (pre-term and term, both p<0.001) and
remained elevated post-partum (p=0.02). There was no difference in augmentation index, between the
two pre-eclamptic groups (p=0.05).
AI - augmentation index; PP - post-partum; SEM - standard error of the mean.
6.3.6 Effect of normal pregnancy on central arterial stiffness
Both carotid-femoral and carotid-radial PWV varied with gestation in normal
pregnancy (both p=0.01, one-way ANOVA with repeated measures; Figures 36 and
37, respectively). Carotid-femoral PWV increased from 24 weeks to 7 weeks post¬
partum (5.0±0.2 m/s versus 5.5±0.2 m/s, p=0.0008, two-tailed paired Student's t-
test). Carotid-radial PWV rose from 16 and 24 weeks to term (16 weeks versus
37 weeks, and 24 weeks versus 37 weeks, both 6.4±0.2 m/s versus 7.0±0.2 m/s,
p<0.05 Bonferroni's post-tests), and values at 7 weeks post-partum were not
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different to those at term (post-partum versus 37 weeks, 6.6±0.2 m/s versus
7.0±0.2m/s, p=0.07, two-tailed paired Student's /-tests). There was no correlation
between carotid-femoral or carotid-radial PWV and serum oestradiol or progesterone
















Healthy pregnant n= 22
□ Pre-term pre-eclamptic n= 7
□ Term pre-eclamptic n= 8
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Figure 36. The effect of pregnancy, gestation and pre-eclampsia on carotid-femoral PWV. Data
reported as mean±SEM. Carotid-femoral PWV varied with gestation in normal pregnancy (p=0.01).
Compared to gestation matched controls, carotid-femoral PWV was raised in both pre-eclamptic
groups (pre-term and term, both p<0.0l) and remained elevated post-partum (p=0.01). There was no
difference in carotid-femoral PWV between the two pre-eclamptic groups.
















Healthy pregnant n= 22
□ Pre-term pre-eclamptic n= 7
□ Term pre-eclamptic n= 8
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Figure 37. The effect of pregnancy, gestation and pre-eclampsia on carotid-radial PWV. Data
reported as mean±SEM. Carotid-radial PWV varied with gestation during normal pregnancy (p=0.01).
Compared to gestation matched controls, carotid-radial PWV was raised in both pre-eclamptic groups
(pre-term and term, both p<0.006). There was no difference in carotid-radial PWV, between the two
pre-eclamptic groups in pregnancy.
PP - post-partum; PWV - pulse wave velocity; SEM - standard error of the mean.
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6.3.7 Effect of pre-eclampsia on systemic and central arterial
stiffness
All haemodynamic variables differed between the women with pre-eclampsia and the
healthy pregnant women at similar gestations, apart from heart rate in women with
term pre-eclampsia (Table 9).
Augmentation index, carotid-femoral and carotid-radial PWV were raised in women
with both pre-term and term pre-eclampsia compared to gestationally matched
women with uncomplicated pregnancies (AI pre-term 15.1±3.9% versus 1.3±1.7%
and term 25.1±2.5% versus 8.4±2.4%, p<0.001 for both, two-tailed unpaired
Student's Mests (Figure 35); carotid-femoral PWV pre-term 6.3±0.2 m/s versus
5.1±0.2 m/s and term 6.3±0.6 m/s versus 5.2±0.1 m/s, p<0.01 for both, two-tailed
unpaired Student's /-tests (Figure 36) and carotid-radial PWV pre-term 8.7±0.5 m/s
versus 6.7±0.2 m/s and term 8.3±0.4 m/s versus 7.0±0.2 m/s, p<0.006 for both, two-
tailed unpaired Student's /-tests (Figure 37)). There was no difference in AI, carotid-
femoral or carotid-radial PWV between women with pre-term or term pre-eclampsia
either antenatally or at the post-partum visit (all p>0.05). At the post-partum visit,
despite blood pressure returning to within the normal range, AI and carotid-femoral
PWV remained elevated at 7 weeks compared to women with uncomplicated
pregnancies (16.2±2.5% versus 8.7±1.9% and 6.5±0.3 m/s versus 5.5±0.2 m/s
respectively, p<0.02 for both, two-tailed unpaired Student's /-tests (Figures 35 and
36)). In contrast, there was no difference in carotid-radial PWV by 7 weeks post¬
partum between women with pre-eclampsia compared to women with uncomplicated
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pregnancies (7.5±0.3 m/s versus 6.8±0.3 m/s, p=0.08, two-tailed unpaired Student's
t-test (Figure 37)).
6.4 DISCUSSION
Pulse wave velocity and AI are measures of central and systemic arterial stiffness,
which together provide a comprehensive assessment of arterial function. They are
highly reproducible and have been validated in healthy subjects and those with
cardiovascular disease [Chen et al, 1997; Fetics et al, 1999; Wilkinson et al, 2001a],
In this longitudinal study, systemic arterial stiffness decreases during the luteal phase
before rising again at the beginning of the menstrual cycle. Pre-eclampsia is
associated with increased arterial stiffness and, despite blood pressure returning to
within the normal range, this persists in the immediate post-partum period. Increased
arterial stiffness therefore appears to be a feature of pre-eclampsia that extends
beyond pregnancy and may contribute to the adverse cardiovascular outcomes
associated with pre-eclampsia.
6.4.1 Effect of the menstrual cycle
The present study is the first to use AI to determine the effect of the menstrual cycle
on systemic arterial stiffness. This study demonstrates that AI is reduced in the luteal
phase of the cycle indicating decreased systemic arterial stiffness. These findings
differ from previous studies that demonstrate either no change [Willekes et al, 1997]
or an increase in compliance in the ovulatory phase compared to the follicular and
luteal phase [Giannattasio et al, 1999; Williams et al, 2001; Hayashi et al, 2006], A
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variety of factors may account for these seemingly discrepant findings, in particular,
the differing methodologies employed, sample population characteristics and timing
of sampling. This current study used AI as a method of evaluating systemic arterial
stiffness, whereas the other studies assessed whole body arterial compliance, which
combines both central and peripheral measures [Williams et al, 2001], or carotid
artery compliance, a surrogate for aortic compliance [Hayashi et al, 2006]. In this
current longitudinal study, clear differences exist in AI depending on the day of
study. This variation will be magnified if a broader sampling time window is used as
in the study by Giannattasio et al [Giannattasio el al 1999]. The study group
reported in this chapter was well characterised; all women had clear evidence of
ovulation as indicated by a rise in luteal phase progesterone. Despite this, neither
absolute nor change in serum hormone concentrations correlated with change in AI
in this study. This perhaps reflects the small numbers of women in our study.
Alternatively it may imply that these hormones do not directly regulate arterial
stiffness and that other intermediate factors such as the renin-angiotensin
[Chidambaram et al, 2002] or endothelin [Polderman et al, 2000] systems regulate
vascular tone and augmentation pressure during the menstrual cycle.
6.4.2 Effect of healthy pregnancy
Due to the logistical difficulties in obtaining pre-pregnancy data for pregnant
women, pregnancy data was compared to data obtained from the same women
7 weeks post-partum. Although many cardiovascular parameters normalise rapidly
over the first 2 weeks post-delivery, many require a longer time frame to settle and
probably do not fully recover to pre-conceptual values [Duvekot and Peeters, 1994],
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Moreover, Bernstein et al [2005] demonstrate that mean arterial pressure is lower in
subsequent normal pregnancies than in first pregnancies and that a shorter interval
between pregnancies leads to a greater reduction in mean arterial pressure. Together
these studies suggest that structural vascular changes occur in pregnancy and persist
beyond the gestational period [Bernstein et al, 2005], The non-pregnant group of
women were not used as a comparator because, although they were well matched for
potential confounders including age, BMI and parity, these women were taller than
the pregnant group: height being a major determinant ofAl [McEniery et al, 2006],
The findings of a rise in central and systemic arterial stiffness from the second
trimester to term and post-partum are supportive of previous studies by Oyama-Kato
et al who used brachial-ankle PWV, a composite measure of systemic and central
stiffness [Oyama-Kato et al, 2006]. Macedo et al [ 2008] also described this
variation in their recently published cross-sectional study of Al. Other studies report
no change in PWV with gestation [Rang et al, 2007] or a general decrease in PWV
and Al over the whole of pregnancy [Poppas et al, 1997; Edouard et al, 1998; Smith
et al, 2004; Mersich et al, 2005]. A variety of factors may account for these
discrepant findings, but in particular the timing of sampling. All these studies had
limited and wide time points with the third trimester visits performed earlier than in
this study. These previous study limitations potentially explain why the subtle rise in
PWV and Al in the third trimester went undetected.
The relative reduction in arterial stiffness during pregnancy compared to post-partum
is likely to arise from several factors. Oestrogen has favourable effects on the
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endothelium and vascular smooth muscle cells [Mendelsohn and Karas, 1999],
Indeed, many of the haemodynamic changes observed in normal pregnancy can be
mimicked in non-pregnant animals through chronic exposure to oestrogen [Magness
et al, 1993], Both the endothelium and vascular smooth muscle cells express
receptors for oestrogen and progesterone [Orshal and Khalil, 2004] through which
they can regulate vascular tone [Skafar et al, 1997], Therefore, they are likely to
influence arterial stiffness through effects on mean arterial pressure as well as
structural changes to elastin, collagen and smooth muscle in the arterial wall [Natoli
et al, 2005; Payne and Webb, 2006]. Progesterone has often been thought to have
opposing vascular effects to oestradiol although it has favourable vascular effects in
vitro [Natoli et al, 2005] and in vivo [Skafar et al, 1997], However, despite the
increased serum oestradiol and progesterone concentrations with advanced gestation,
arterial stiffness increased in the third trimester, which may be due to mechanisms
other than the action of sex steroids.
6.4.3 Effect of pre-eclampsia
Consistent with previous cross-sectional studies, all the variables of systemic and
central arterial stiffness measured were higher in women with pre-eclampsia [Elvan-
Taspinar et al, 2004; Ronnback et al, 2005; Spasojevic et al, 2005]. The possibility
that medication influenced the collected data cannot be excluded because the effect
of anti-hypertensive agents on PWV and Al has not specifically been studied during
pregnancy. Given calcium channel blockers [Saito et al, 1990] and beta-blockers
[Kelly et al, 1989] reduce PWV in non-pregnant populations, it seems likely that the
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increase in arterial stiffness observed in women with pre-eclampsia, would have been
even greater if these women were not taking anti-hypertensive agents.
The present studies findings contrast with a cross-sectional study by Lampinen et al
[2006] which reported no difference in arterial stiffness assessed by AI in women
with a history of pre-eclampsia. However this study was performed on average
5 to 6 years after the index pregnancy and it is possible that applanation tonometry is
not sensitive enough to detect more subtle remote effects. Similarly,
Spasojevic et al [2005] found no difference in AI between women with pre¬
eclampsia and healthy pregnant women at a 6-week post-partum visit. In this current
study, a comprehensive assessment of arterial function demonstrated that AI and
carotid-femoral PWV remained elevated at 7 weeks in women with pre-eclampsia
compared to women with uncomplicated pregnancies.
Interestingly, carotid-radial PWV, unlike our other measures of arterial stiffness, had
normalised by 7 weeks post-partum. Carotid-radial PWV is partly determined by the
muscular brachial artery whereas carotid-femoral PWV is determined by the more
elastic aorta. Carotid-radial PWV is therefore susceptible to changes in both vascular
smooth muscle tone and smooth muscle remodelling. It is therefore plausible that the
increase in carotid-radial PWV in pre-eclampsia and pregnancy is in part due to an
effect on smooth muscle function that may normalise more rapidly post-partum than
any effect on the extracellular elastin-collagen matrix of the aorta. Other conditions
such as diabetes mellitus and ageing, are known to have preferential effects on
central rather than peripheral arteries [Kimoto et al, 2003] and it is therefore perhaps
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not surprising that vascular remodelling in pregnancy similarly does not occur in a
uniform manner.
Carotid-femoral PWV is recognised as the gold-standard measure of arterial
stiffness, as stated in the recent expert consensus document on the measurement of
arterial stiffness [Laurent et al, 2001], In this cohort, carotid-femoral PWV remained
elevated at 7 weeks post-partum suggesting the effects of pre-eclampsia on vascular
structure and function extend beyond pregnancy. If arterial stiffness remains elevated
in later life, this may in part contribute to the increased risk of cardiovascular and
cerebrovascular disease [Wilson et al, 2003],
Abnormalities of arterial structure and function were associated with higher post¬
partum blood pressures although these women were no longer hypertensive with
blood pressures within the normal range. It is not possible from these studies to
determine whether raised blood pressure during pre-eclampsia is a cause or
consequence of increased arterial stiffness. There is now good evidence to suggest
that aortic stiffness is an independent predictor of progression to hypertension even
in young non-hypertensive individuals [Dernellis et al, 2005] with endothelial
function being inversely related to arterial stiffness in healthy volunteers [McEniery
et al, 2006]. Therefore, it can be postulated that in pre-eclampsia, endothelial
dysfunction increases aortic stiffness, which in turn causes an increase in blood
pressure.
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Alternative interpretation of the data presented in this chapter is possible and it is not
possible to discount that changes in arterial stiffness occur as a consequence of
prolonged hypertension in pre-eclampsia. It is not known that changes in arterial
stiffness at 7 weeks post-partum persist long-term. A prospective study, in which
blood pressure and arterial stiffness were determined in a very large cohort of
pregnant woman prior to the onset of pre-eclampsia with long-term post-partum
follow-up, would be required to address these issues.
6.5 SUMMARY
The data presented in this chapter demonstrates that systemic arterial stiffness
decreases during the luteal phase of the menstrual cycle with arterial stiffness rising
from the mid-trimester of pregnancy to term. The factors regulating these changes in
arterial stiffness have yet to be identified. However, pre-eclampsia is associated with
increased arterial stiffness and this persists into the post-partum period. Increased
arterial stiffness therefore appears to be a feature of pre-eclampsia that extends
beyond pregnancy and suggesls an abnormality of vascular structure and function






7.1 SUMMARY OF FINDINGS
This thesis provides a comprehensive characterisation of markers of thrombosis,
angiogenesis and arterial stiffness during the menstrual cycle, healthy and pre¬
eclamptic pregnancies. These studies are particularly relevant to reproductive
processes where thrombotic events can have devastating outcomes and long-term
vascular health may be influenced by reproductive health. The main findings and
conclusions from this research are summarised below.
7.1.1 Menstrual cycle
Using a panel of cellular and soluble markers of platelet activation, no significant
variation in any of the measured markers of platelet or monocyte activation was
observed within the menstrual cycle. In contrast, circulating EPC concentrations
were increased in the follicular phase of the menstrual cycle suggesting a potential
role for these cells in the normal cycle of physiological angiogenesis and repair of
the endometrium. Finally, arterial stiffness decreases in the luteal phase of the
normal menstrual cycle when both oestrogen and progesterone levels are raised. This
decrease in stiffness is similar to that observed in the second trimester of healthy




In healthy pregnancy, circulating levels of PAI-1, together with cellular and soluble
markers of platelet and monocyte activation; surface P-selectin expression, platelet-
monocyte aggregates, soluble P-selectin concentrations and monocyte expression of
CD1 lb were increased during the third trimester of pregnancy. Net release of active
t-PA from the endothelium was reduced in response to stimulation with bradykinin in
healthy women in the third trimester of pregnancy. The impaired fibrinolytic
capacity in healthy pregnancy together with the increased platelet activation may, in
part, explain the increased thrombotic risk associated with pregnancy.
Consistent with an increase in soluble IL-6 and soluble ICAM-1 concentrations,
CFU-EPCs were reduced during healthy pregnancy compared to non-pregnant
controls. Moreover, the lack of correlation between EPCs identified by surface
marker expression and those identified by CFU-EPC formation suggests that each
assay potentially measures different cell types. Finally, central and systemic arterial
stiffness increased over the second half of pregnancy to term despite the increased
serum oestradiol and progesterone concentrations. This suggests that other
mechanisms, in addition to the action of sex steroids, are involved in determining
compliance in late pregnancy.
These comprehensive studies highlight the functional interplay between platelets,
monocytes, EPCs and the endothelium represented by: increased markers of platelet
activation and inflammation, decreased EPC-CFU formation and decreased
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fibrinolytic capacity, leading to the pro-inflammatory, pro-thrombotic state of
healthy pregnancy (Figure 38).
Figure 38. The functional interplay between platelets, monocytes, EPCs (endothelial progenitor
cells) and the endothelium.
Platelet a-granules contain large quantities of PA1-1 (plasminogen activator inhibitor type 1), which is
released upon activation. Activated platelets also activate endothelial cells by releasing 1L
(interleukin)-l p and monocytes, as demonstrated in our studies by increased monocyte CD (cluster of
differentiation)! lb. Activated monocytes themselves are pro-thrombotic, more migratory and activate
endothelial cells. Activated endothelium expresses ICAMs (intercellular adhesion molecules) and
releases 1L-6 and PA1-1. Soluble P-selectin was measured as a marker of platelet activation, but is
also shed from activated endothelium.
In vivo and in vitro studies suggest that activated platelets have an inhibitory effect on the proliferative
and migratory capacity of EPCs from healthy volunteers [Dernbach et al, 2008]. This supports our
finding of decreased CFU (colony forming unit) formation by mononuclear cells from healthy
pregnant women, in the presence of raised circulating inflammatory markers and platelet activation.
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7.1.3 Pre-eclampsia
Circulating markers of platelet activation (surface P-selectin expression, platelet-
monocyte aggregates, soluble P-selectin), cytokines (IL-6 and soluble ICAM-1),
circulating EPCs and CFU-EPCs were not different in women with established pre¬
eclampsia compared to women at similar gestational ages. However, this does not
exclude the possibility that the local endothelial response to these factors within the
utero-placental unit may differ in women with pre-eclampsia. Moreover, the
demonstration that measures of systemic and central arterial stiffness were increased
in pre-eclamptic women, persisting into the immediate post-partum period; suggests
that an abnormality of vascular structure and function, may underlie the pathogenesis
of this condition and its adverse cardiovascular outcomes.
7.2 DISCUSSION AND FUTURE DIRECTIONS
7.2.1 Menstrual cycle
The normal menstrual cycle provides a state of systemic hormonal fluctuation in
response to physiological activity in the ovary and uterus. Both menstruation and
ovulation are considered to be inflammatory events and the cyclical regeneration of
the endometrium is the largest site of physiological angiogenesis occurring in the
body. It was anticipated that results from these studies would further our
understanding of the temporal variation in myocardial infarction risk during the cycle




Menstruation is an inflammatory event. However, surprisingly, this work found no
difference in markers of platelet activation in peripheral blood throughout the
menstrual cycle. It must be acknowledged though that there was no sampling point in
the late luteal phase of the cycle, just preceding menstruation. It may be that a peak
in platelet activation occurs at this time, prior to the onset of menses. Future studies
would investigate this and also the role of platelets in pathologies such as heavy
menstrual bleeding.
Although there was no difference in markers of platelet activation within peripheral
blood, the endometrium itself was not examined. Further understanding of the role of
platelets in the endometrium, would include the following areas: -
1) Endometrial sampling at various points in the cycle to examine for platelets
and markers of activation within the tissue itself. This could be performed either
using a pipelle endometrial biopsy system or by examining menstrual blood.
2) Examination of sections of uteri obtained at hysterectomy would also
potentially allow identification, localisation and determination of activation status of
platelets within the endometrium.
Angiogenesis
This study lends further support to the hypothesis that circulating cells in the
peripheral blood may contribute to endometrial angiogenesis. If proven, this may
explain the observed failure rates after endometrial ablation techniques, where
despite initial destruction or removal of all endometrial tissue, complete
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amenorrhoea is rare [Lethaby et al, 2005], It may also further our understanding of
endometriosis, whereby endometrial tissue is found outwith the uterus. Traditionally
endometriosis is thought to be caused by retrograde menstruation, through the
fallopian tubes with ectopic deposition of tissue. The involvement of circulating
EPCs would help explain the presence of endometrial tissue at sites distant from the
peritoneal cavity, such as the lung and brain.
Further understanding of EPCs and their role in endometrial angiogenesis, would
include the following areas: -
1) The use of minimally invasive pipelle endometrial sampling with histological
techniques to identify EPCs within endometrial tissue of women at different stages of
the menstrual cycle.
2) Targeted endometrial biopsy under direct vision (using hysteroscopy) or
ultrasound guidance would potentially allow identification and localisation of EPCs
within the endometrium.
3) Histological examination of sections of uteri obtained at hysterectomy would
also potentially allow identification and localisation of EPCs within the
endometrium. Knowledge of the menstrual cycle phase at time of hysterectomy
would be valuable to further understand the role of these cells in the endometrium.
4) The potential identification of EPCs within endometriotic lesions obtained
during pelvic surgery for endometriosis.
5) The measurement of circulating EPCs in the peripheral blood of women
known to have endometriosis or heavy menstrual bleeding.
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6) Identification of women with previous bone marrow transplants and human
leukocyte antigen-mismatch and subsequent endometrial sampling or biopsy to
confirm and determine the extent of involvement of bone marrow derived cells to
endometrial angiogenesis.
Arterial stiffness
This research has demonstrated that the physiological changes associated with the
menstrual cycle affect systemic arterial stiffness. No simple relationship was
identified between the ovarian hormones and arterial stiffness. Therefore, future
work would examine the relationship between other factors such as the renin-
angiotensin system and circulating levels of endothelin-1 with arterial stiffness
during the menstrual cycle.
7.2.2 Healthy pregnancy and pre-eclampsia
Pregnancy, necessitating gross vascular adaptation accompanied by inflammation is
a stressor for the vascular endothelium, similar to that experienced in sepsis [Sacks et
al, 1998]. Overall, this research complements and adds to existing literature
demonstrating that the third trimester of pregnancy is characterised by systemic
inflammation, pro-thrombotic changes and a relative increase in arterial stiffness.
The latter two are likely to be protective for delivery, where haemorrhage is the
greatest threat to the pregnant woman. Indeed, in developing counties, haemorrhage
is still the leading cause of maternal death. However, in developed countries, where
haemorrhage is prevented or treated, thrombosis and thromboembolism are the
leading causes and are increasing [Lewis, 2005]. In particular, in the
202
United Kingdom, relative and absolute numbers of deaths from myocardial infarction
in pregnant and post-partum women are rising. These increases in inflammatory and
thrombotic pregnancy complications are thought to be due to the current changes in
women's health and the subsequent adverse clinical profile of women entering
pregnancy such as increasing maternal age and obesity.
It was anticipated that this research would provide information about vascular
function in the first trimester of pregnancy. Unfortunately, our earliest samples were
from women in the second trimester. Women were recruited from booking clinics
with the hope of getting first trimester samples. However, in these clinics the vast
majority of women were greater than 12 weeks gestation. Recruiting women in their
first trimester is challenging to integrate with traditional clinic design. Future studies
would approach women in different settings such as early pregnancy clinics and
primary care where the majority of women first present. Recruitment of such women
would enable assessment of vascular function in the first trimester.
Similarly, this research provides insights into features of pre-eclampsia. Further work
would measure these indicators of vascular function prospectively, in large numbers
of women, in order to obtain data preceding the clinical diagnostic signs of
hypertension and proteinuria, and also prior to pregnancy. In addition a longer post¬




The third trimester of both healthy and pre-eclamptic pregnancies was associated
with platelet activation. Although there was no difference in circulating cytokines or
markers of platelet activation in the samples obtained from women with pre¬
eclampsia; the endothelium is the critical regulator of platelets, monocytes and their
effects on coagulation. Endothelial cell activation is known to be heterogeneous, for
example: vWF expression is greatest in the heart and lung, low in the kidney and can
vary between neighbouring endothelial cells in same organ. Tissue plasminogen
activator expression is greatest in the brain. In sepsis there is vascular bed-specific
haemostasis and this is likely to exist in pregnancy [Rosenberg and Aird, 1999],
Therefore, although we could not detect systemic platelet activation or raised
cytokine levels in women with pre-eclampsia, the endothelial response to these
platelets, monocytes and cytokines may be different in women with pre-eclampsia,
particularly within the utero-placental circulation. Future work would be directed to
assess this, specifically by examining for the presence of platelet-monocyte
aggregates in the decidua and myometrium. This would be performed by targeted
placental bed biopsies obtained at time of caesarean section in women with
uncomplicated pregnancies and in women with pre-eclampsia.
As discussed in chapter one of this thesis (section 1.7.5) women with pre-eclampsia
are at increased risk of thrombotic events. To date, the endogenous fibrinolytic
capacity of the endothelium has not been assessed. Future studies would aim to
assess this using the technique of forearm venous sampling and plethysmography
during intra-arterial infusion of bradykinin as was performed in Chapter 3. However
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such studies are technically challenging, as is the recruitment and study of women
with pre-eclampsia in the often limited time before delivery.
Angiogenesis
Our study of the role of EPCs in pregnancy was limited to those circulating in
peripheral blood and as mentioned above it was difficult to obtain data for women in
the first trimester of pregnancy. However, if EPCs indeed play a role in endometrial
angiogenesis then it is likely that they may contribute to placentation. Isolated animal
and clinical studies suggest this but further studies are required [Risau 1995; Taylor
2004; Bratincsak et al, 2007],
These would involve: -
1) Obtaining first trimester placental and decidual tissue from women
undergoing surgical termination of pregnancy in order to identify the presence of
these cells - using in situ immunohistochemistry techniques or flow cytometry.
2) Achieving pregnancies in mice following irradiation and subsequent labelled
bone marrow transplantation would enable the potential identification of bone
marrow derived cells within the placenta and decidua.
3) Once techniques are established for reliably identifying EPCs or more
broadly, bone marrow derived cells, future work would focus on their presence in
placental and decidual tissue of women with pre-eclampsia.
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Arterial stiffness
This research has provided important understanding of the changes in arterial
stiffness that occur in normal pregnancy. It has also demonstrated that pre-eclamptic
women have increased arterial stiffness that persists beyond pregnancy. This
complements a wealth of clinical studies, which report abnormal vascular function,
ranging from impaired endothelium-dependent vasodilatation [Lampinen et al, 2006]
and microvascular function to elevated VCAM, ICAM and HbAlC up to 25 years
after a pregnancy complicated by pre-eclampsia [Ramsay et al, 2003; Sattar et al,
2003]. Together these data suggest that increased vascular risk may be an additive
effect of pre-eclampsia to pre-pregnancy endothelial function.
Current clinical practice relies on the measurement of brachial blood pressure in
pregnancy to screen for pre-eclampsia and to assess response to hypertensive therapy
in women with pre-eclampsia. However, the measurement of brachial blood pressure
has its challenges, increasingly so as more pregnant women are classified as obese.
Inappropriate use of a blood pressure cuff that is too small can lead to over
estimation of both systolic and diastolic blood pressures. As aortic compliance is a
determinant of blood pressure, there maybe a future clinical role for measuring PWV
instead of brachial blood pressure in some patient groups. The measurement of PWV
described in this thesis requires an experienced operator and is time consuming, but
alternative operator independent methods, such as the use of neck and thigh cuffs are
already being used in studies of healthy volunteers.
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Large-scale prospective studies are required to determine whether changes in arterial
stiffness precede a rise in brachial blood pressure in pregnancies complicated by pre¬
eclampsia. The effect of anti-hypertensive medication upon measures of arterial
stiffness in pregnancy is unknown. There is data from non-pregnant populations that
suggests PWV is a significant predictor of response to anti-hypertensive therapy
[Protogerou et al, 2009]. In women with pre-eclampsia, blood pressure control is
crucial to reduce the maternal risk of stroke without compromising the utero¬
placental circulation. Therefore PWV may have a role in the clinical management of
these women in assessing response or likelihood or response to therapy.
7.2.3 Pregnancy, pre-eclampsia and cardiovascular risk
It is known that endothelial function can be altered in childhood. Lipid parameters in
childhood are strongly correlated with adult values [Raitakari et al, 2003]. Entering
pregnancy with sub-clinical changes in endothelial function may explain the link
between cardiovascular risk factors and pregnancy complications such as pre¬
eclampsia, gestational diabetes, hypertension, and intra-uterine growth restriction.
Thus pregnancy stresses and unmasks potential endothelial problems; pregnancy
complications can be considered as vascular related events, the first clinical
manifestation of disruption in vascular function [Sattar and Greer, 2002]. This
hypothesis may further explain the association between pregnancy complications and
vascular diseases in later life, both are associated with sub-clinical changes in
endothelial function and inflammation that are revealed by the added insults of
pregnancy or ageing.
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To test this hypothesis, a large-scale prospective study is required, examining
indicators of vascular function, such as those described in this thesis and others such
as high-sensitivity c-reactive protein and lipid profiles in adolescent girls prior to
pregnancy. These subjects would need to be prospectively followed and further data
collected on vascular function if pregnancy was achieved. Relating pre-pregnancy
vascular function to the development of complications in pregnancy is vital to further
understand the pathology of these conditions. Post-partum follow-up would
contribute to our understanding of increased vascular risk in later life. Identifying
and understanding pre-pregnancy vascular function and its subtle changes may
provide the stimulus for lifestyle intervention.
Whilst the epidemiological links between pregnancy complications and increased
vascular disease are widely documented there is also data to suggest that pregnancy
itself increases the risk of cardiovascular disease. Epidemiological data report that
multiparity is associated with increased risk of cardiovascular disease in later life,
but there are multiple confounders such as socioeconomic status and psychological
stress associated with child rearing. Supportive of this, men have increased risks of
cardiovascular disease when fathering more than two children, though their risk is
not as great as women [Lawlor et al, 2003]. Therefore, clinical and animal studies
are likely to be more useful in understanding the sustained effects of uncomplicated
pregnancy on the vasculature. Specifically, to examine the effects of pregnancy on
large arteries such as the aorta, animal models are likely to be the most useful,
allowing for assessment of structural changes within the arterial wall. The effects of
multiparity can also be assessed more easily than in humans.
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In light of an ageing maternal population and general increase in obesity, pregnancy
complications are expected to increase. Unlike vascular disease in the older, non¬
pregnant population, preventative measures and treatment are limited in pregnancy.
Treatment options for pre-eclampsia are limited to immediate anti-hypertensive
therapy and delivery. Neither of these modifies the additive 7-fold risk of vascular
disease in later life in these women. Therefore women who have had pre-eclampsia
represent a susceptible group who should be targeted for lifestyle advice, potentially
vascular risk factor screening and possible intervention.
7.3 CONCLUSION
Using recognised indicators of vascular pathology from studies outwith pregnancy,
this research has demonstrated that normal healthy pregnancy is an inflammatory,
and pro-thrombotic state, particularly in the third trimester. These findings may, in
part, explain the temporal associations between arterial and venous thromboses and
pregnancy. These systemic changes were also present in pre-eclampsia. Increasingly
epidemiological and clinical studies are highlighting the links between vascular
disease, particularly atherosclerosis and pre-eclampsia. Further understanding the
effect of pre-pregnancy vascular function and pregnancy complications could lead to
targeted lifestyle modifications, screening and potentially intervention. This research
also demonstrated that increased arterial stiffness was a feature of pre-eclampsia that
extended beyond pregnancy. This suggests an abnormality of vascular structure and
function that may underlie the pathogenesis of this condition and may contribute to
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the increased immediate and lifetime risk of vascular disease in these women.
Detection of persisting increased arterial stiffness, may allow for targeted treatments
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MATERIALS AND SUPPLEMENTARY INFORMATION
ON METHODS
ARTERIAL STIFFNESS STUDIES SOURCE
Micro life 3BTO-A automated
sphygmomanometer
Micro life AG, Widnau, Switzerland
Micromanometer Millar Instruments, Texas, USA






OMRON 705 IT, Kyoto, Japan
Mercury-in-silastic strain gauges Hokanson, Bellevue, WA 98005 USA
Plethysmograph Hokanson, Bellevue, WA 98005 USA
Bradykinin Clinalfa, Merck Biosciences AG,
Laufelfingen, Switzerland.
Sodium nitroprusside Hospira, Illinois, USA
Noradrenaline Hospira, Illinois, USA
B-9340 Clinalfa, Merck Biosciences AG,
Laufelfingen, Switzerland.
VENOUS BLOOD COLLECTION SOURCE




Cambridge Bioscience, Cambridge, UK.
EDTA tubes, S-Monovette® Sarstedt AG & Co. Niimbrecht
Germany
Sodium Citrate tubes, S-Monovette® Sarstedt AG & Co. Niimbrecht
Germany
Stabilyte tubes (Acidified Bufferred
Citrate)
Biopool International, Ventura, USA.
Serum Gel tubes, S-Monovette® Sarstedt AG & Co. Niimbrecht
Germany
FLOW CYTOMETRIC ANALYSIS SOURCE
MOUSE ANTI-HUMAN CD42a-FITC
(GRP-P, IgGl)
AbD Serotec Ltd, Oxford, UK.
MOUSE lgGl NEGATIVE
CONTROL :FITC
AbD Serotec Ltd, Oxford, UK.
MOUSE ANTI-HUMAN CD14-FITC AbD Serotec Ltd, Oxford, UK.
MOUSE ANTI-HUMAN CD40-RPE AbD Serotec Ltd, Oxford, UK
235
MOUSE ANTI-HUMAN CD1 lb-RPE AbD Serotec Ltd, Oxford, UK
MOUSE ANTI-HUMAN CD14-PE
(Tuk-4, IgG2a)
DakoCytomation UK Ltd, Ely, UK.
MOUSE IgG2a NEGATIVE
CONTROLrPHYCOERYTHRIN
DakoCytomation UK Ltd, Ely, UK.
MOUSE ANTI-HUMAN CD62P-PE
(IgG2a)
DakoCytomation UK Ltd, Ely, UK.
MOUSE IgGl NEGATIVE CONTROL:
PE
DakoCytomation UK Ltd, Ely, UK.
MOUSE ANTI-HUMAN CD34-FITC Becton Dickinson UK Ltd, Oxford, UK
MOUSE ANTI-HUMAN CD133-PE Miltenyi Biotec Ltd, Bisley, UK
Mouse monoclonal anti-humanVEGF R2
(KDR)-APC
R&D Systems Europe Ltd, Abingdon,
UK
Mouse IgGl Isotype Control-APC R&D Systems Europe Ltd, Abingdon,
UK
Uti-Lyse™ Erythrocyte Lysing Reagent DakoCytomation UK Ltd, Ely, UK.
Phosphate buffered saline (PBS) without
cations
Sigma-Aldrich, Poole, UK
FACS-Lysing Solution (See Appendix 2) Becton Dickinson UK Ltd, Oxford, UK
Flow Buffer See Appendix 2
Anti-Mouse Ig,K/Negative Control
Compensation Particles Set
BD Biosciences, Oxford, UK
BD FACSCalibur Flow Cytometer BD Biosciences, Oxford, UK
Flowjo software Tree Star, Inc. Oregon, USA
IN VITRO CULTURE SOURCE
6-well and 24-well fibronectin-coated
plates
Becton Dickinson UK Ltd, Oxford, UK
Histopaque Sigma-Aldrich Company Ltd, Poole, UK
EndoCult™ Liquid Medium Kit StemCell Technologies, Grenoble,
France




Trypan Blue Sigma-Aldrich Company Ltd, Poole, UK
Endothelium Growth Medium-2 Lonza Ltd, Basel, Switzerland.
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IMMUNOFLUORESENCE SOURCE




Biomedical Technologies Inc, MA, USA.
FITC-labelled Lectin from Ulex
europaeus
Sigma-Aldrich Company Ltd, Poole, UK
4',6-Diamidino-2-phenylindole
dihydrochloride (DAPI)
Sigma-Aldrich Company Ltd, Poole, UK
Permafluor Immunotech, High Wycombe, UK
10% goat serum Autogen Bioclear, Calne, UK
1% BOVINE SERUM ALBUMIN Sigma-Aldrich Company Ltd, Poole, UK
0.02% IGEPAL/NP40 Sigma-Aldrich Company Ltd, Poole, UK
Primary murine monoclonal antibodies
against human CD 105
Becton Dickinson UK Ltd, Oxford, UK
Primary murine monoclonal antibodies
against human CD 146
Springbioscience, Heidleberg, Germany
Polyclonal goat anti-mouse biotinylated
antibody
DakoCytomation UK Ltd, Ely, UK
Streptavidin-Alexa Fluor 546 Molecular probes®, Invitrogen,
California, USA
Streptavidin-Alexa Fluor 488 Molecular probes®, Invitrogen,
California, USA
Human Umbilical Vein Endothelial Cells Dr C Shaw, Department of
Cardiovascular Research, University of
Edinburgh
Human colon cell-line (HT29) Dr S Bader, Edinburgh Cancer Research
Centre
Zeiss 'LSM 510 Meta' confocal
microscope
Carl Zeiss, Oberkochen, Germany
ELISAs SOURCE
Oestradiol ELISA Siemens Medical Solutions Centaur,
Camberley, UK
Progesterone ELISA Siemens Medical Solutions Centaur,
Camberley, UK
Lutenising Hormone ELISA Abbott Architect, Illinois, USA
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Follicular-Stimulating Hormone ELISA Abbott Architect, Illinois, USA
Soluble P-Selectin ELISA R&D Systems Europe Ltd, Abingdon,
UK
CD40 Ligand ELISA R&D Systems Europe Ltd, Abingdon,
UK
IL-6 ELISA R&D Systems Europe Ltd, Abingdon,
UK
Soluble ICAM-1 ELISA R&D Systems Europe Ltd, Abingdon,
UK
VEGF-ELISA Calbiochem, Darmstadt, Germany
t-PA ELISA, t-PA Combi Actibind Elisa
Kit
Technoclone, Vienna, Austria










All dilutions are in deionized water, unless otherwise stated
Bradykinin (for in vivo use within venous occlusion plethysmography studies,
Chapter 3)
1 vial contains: 69 pg of bradykinin
Batch No: AC 0556 Molecular weight: 1060.2
Reconstitution of 1 vial using 0.9% NaCl:
1 vial of 69 pg in 65 mL 0.9% saline
= 1000 pmol/mL
Add 15 mL of 1000 pmol/mL to 35 mL of 0.9% saline (total vol 50 mL)
= 300 pmol/mL
Add 15 mL of 300 pmol/mL to 30 mL 0.9% saline (total vol 45 mL)
= 100 pmol/mL
Sodium nitroprusside (SNP, for in vivo use within venous occlusion
plethysmography studies - Chapter 3)
1 vial contains: 50 mg SNP (dry powder)
Reconstitution of 1 vial using 09.% NaCl:
50 mg SNP diluted into 500 mL saline = 100 pg/mL
(use 2 mL of saline from 500 mL bag to dilute powder)
Add 4 mL of 100 pg/mL to 46mL saline (total volume of 50 mL)
= 8 pg/mL
Add 20 mL of 8 pg/mL to 20 mL saline (total volume of 40 mL)
= 4 pg/mL
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Add 20 mL of 4 pg/mL to 20 mL saline (total volume of 40 mL)
= 2 pg/mL
Flow Buffer (for plateletflow cytometric studies,Chapter 4)
Phosphate buffered saline without cations
0.1% Bovine Serum Albumin
0.1% Sodium Azide
1% Paraformaldehyde
EndoCult™ Complete Culture Medium (ECCM, for CFU-EPC assay, Chapter 5)
2 mL EndoCult™ Supplement
8 mL EndoCult™ Basal Medium
Penicillin and Streptomycin Solution added to give final concentration of 100 U/mL
of Penicillin and 100 pg/mL of Streptomycin.
Blocking Serum (for immunofluorescence ofCFUs,Chapter 5)
10 mL Normal Goat Serum
80 mL Phosphate Buffered Saline




STAINING PROTOCOL FOR PLATELET-MONOCYTE AGGREGATES,
PLATELET P-SELECTIN EXPRESSION, MONOCYTE CD40 AND CD11B




Flow buffer (phosphate buffered saline without cations with 0.1% bovine
serum albumin and 0.1% sodium azide).
FACS-lyse solution (Becton Dickinson)
1% paraformaldehyde
Monoclonal antibodies (diluted with flow buffer):
■ IgGl-FITC / CD14-PE 1 :20
■ CD14-PE / CD42a-FITC
■ IgG2a-PE / CD42a-FITC
■ CD42a-FITC / CD62P-PE
■ CD42a-FITC / CD154-PE
■ CD14-FITC / CD40-PE
■ CD14-FITC / CD1 lb-PE
1. Take blood with 19-gauge or larger needle
a. If drawing blood from a cannula try to use minimal tourniquet pressure
during insertion.
b. Blood should come back freely, and with no resistance to avoid
artefactual platelet activation. If blood is sluggish or stop-start consider
trying again.
2. Put 3 mL into PPACK tube and start timer to count down 5 minutes.
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3. After exactly 5 minutess start staining:























Set timer to count down from 20 minutes:




















































CD1 lb:RPE / 60pL 60pL none 120pL
CD14:FITC CD1 lb/CD 14
1:20
4. When timer reaches zero (i.e. 20 mins after staining for PMA) FIX cells as
below:
i. Set timer for 5 minutes then add 500 pL FACS-lyse to all PMB tubes
ii. When timer reaches zero reset for 5 minutes then add 1450 pL
paraformaldehyde to all P-selectin tubes
iii. When timer reaches zero add 500 pi FACS-lyse to all Mono tubes
How to make FACS-lvse
Add 5 mL of neat FACS-lyse to 50 mL Falcon tube. Make up to 50 mL total with
Deionized or Millipore water.
total solution 50 mL of 1:10 FACS-lyse




MCA928F Mouse IgGl-FITC negative control
• MCA1227F Mouse anti-human CD42a-FITC
MCA596F Mouse anti-human CD14-FITC
MCA1590PE Mouse anti-human CD40-PE
MCA551PE Mouse anti-human CD1 lb-PE
DakoCytomation
R0864 Mouse anti-human CD14-PE
X0950 Mouse IgG2a-PE negative control
R7200 Mouse anti-human P-selectin CD62P-PE
• X0928 Mouse IgGl-PE
All antibody mixes are diluted 1:20 with flow buffer. Add 50 pL of each antibody
neat and make it up to 1000 pL with flow buffer for the 1:20 dilution.
For example for the platelet-monocyte panel:
50 pL IgGl-FITC [MCA928F] + 50 pL CD 14-PE [R0864] + 900 pL
flow buffer = 1000 pL of IgGl-FITC / CD 14-PE 1:20
50 pL CD 14-PE [R0864] + 50 pL CD42a-FITC [MCA1227F] + 900 pL
flow buffer = 1000 pL of CD14-PE / CD42a-FITC 1:20
For the platelet P-selectin panel:
50 pL IgG2a-PE [X0950] + 50 pL CD42a-FITC [MCA1227F] + 900 pL
flow buffer = 1000 pL of IgG2a-PE / CD42a-FITC 1:20
50 pL CD42a-FITC [MCA1227F] + 50 pL CD62P-PE [R7200] + 900 pL
flow buffer = 1000 pi of CD42a-FITC/ CD62P-PE 1:20
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For the Monocyte CD40 panel:
50 pL CD14-FITC [MCA596F] + 950 pL
flow buffer = 1000 pi of CD14-FITC 1:20
50 pL CD14-FITC [MCA596F] + 50 pL CD40-PE [MCA1590PE] + 900 pL
flow buffer = 1000 pL ofCD14-FITC/ CD40-PE 1:20
50 pL CD14-FITC [MCA596F] + 50 pL CD1 lb-PE [MCA551PE] + 900 pL
flow buffer = 1000 pL of CD 14-FITC/ CD 11 b-PE 1:20
This amount of stock will be enough for 16 visits.
Flow cytometer set up
For platelet monocyte aggregates, use PMB template with PMB settings. Collect
2500 monocytes.
For P-selectin use pit template and pit settings. Collect 7500 platelets.
For Monocyte CD40 use Mono template and settings. Collect 3000 monocytes
positive for CD 14. There is no isotype control for this panel so please make sure you
collect 3000 monocytes from the unstained sample as well - we will use this as a
control.
Although the templates should be fine, all lasers and flow cytometers differ slightly
and the antibody batches you get may be different to ours. Therefore, the instrument
settings and compensation may need to be adjusted for your flow cytometer.
Adjusting the compensation and instrument settings should only need to be done
once at the beginning when setting up the protocol. Once they are set and saved you
should not have to change them again.
If you are not sure about the compensation it is much better to under-compensate or
not compensate at all. Post-collection compensation can be achieved but is not
possible if the data is over compensated.
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Flow cytometric assay for the quantification of CD133/CD34/KDR progenitor
cells in whole peripheral blood
Requirements
6 BD Falcon tubes with lids and labelled 1 to 6
PBS (without cations)
UTI-lyse reagent (from DAKO) A and B
Monoclonal antibodies:
• Mouse anti-human CD34 (Becton Dickson; FITC conjugated) used neat
• Mouse anti-human CD133 (Miltenyl Biotech; PE conjugated) used neat
• Mouse anti-human CD 14 (Becton Dickson ; APC conjugated) used at 1:20
dilution
• Mouse anti-human IgGl (R&D; APC conjugated) used neat
• Mouse anti-human KDR (R&D; APC conjugated) used neat
Protocol
1. Pipette 200 pL of whole blood (from EDTA tube) into each of the 8 Falcon
tubes. (Use a PI 000 pipette). Send the remainder of the blood in the EDTA
tube to haematology for full blood count.
2. Add antibodies as follows: - pipette up and down 3 times and then gently
vortex tube.
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Tube number Antibodies to be added
1 Blank None
2 CD34 5pL CD34
3 CD34 CD133 5pL CD34
5pL CD 133
4 CD34CD133 ISO 5pL CD34
5pL CD133
5pL ISOTYPE
5 CD34 CD133 KDR 5pL CD34
5pL CD133
5pL KDR
6 CD 14 5pi CD14
(1 IN 20 DILUTION)
3. Incubate in the dark for 20 minutes.
4. At 20 minutes add 200 pL ofUTI-lyse reagent A to each tube. Vortex gently.
Leave for 10 minutes at room temperature in the dark.
5. Stop reaction A at 10 minutes by adding 2 mL of UTI-lyse reagent B to each
tube - put numbered lids on at this stage and vortex gently. Leave for a
minimum of 10 minutes in the dark.
6. Centrifuge for 5 minutes, 1500 g at 20°C.
7. Tip off supernatant onto paper towel - be careful not to cross contaminate the
tops of tubes.
8. Add 1 mL of PBS (from fridge ) to each tube. Replace numbered lids and
vortex gently.
9. Centrifuge for 5 minutes, 1500 g at 20°C.
10. Tip off supernatant onto paper towel - be careful not to cross contaminate the
tops of tubes.
11. Add 500 pL of PBS to each tube. No need to replace lids - they can be
discarded.
Samples are now ready to run through the flow cytometer.
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Abstract
The discovery of endothelial progenitor cells has generated considerable interest in the field of vascular biology. These cells arise
from a population of circulating mononuclear cells and have the capacity to form new blood vessels and contribute to vascular
repair. Circulating endothelial progenitor cell numbers are reduced in patients with cardiovascular risk factors and in the
presence of endothelial dysfunction, but are increased in response to ischaemia, oestrogens and drug therapy. They have been
studied in pathologies from cardiovascular and renal disease to rheumatoid arthritis and pre-eclampsia. Pregnancy is a challenge
to the maternal vascular system, requiring systemic adaptation and pronounced local changes in the uterus. Diseases of
pregnancy such as pre-eclampsia and gestational diabetes increase the risk of pregnancy complications and are associated with
endothelial dysfunction. We propose that endothelial progenitor cells have an important role in the regulation and maintenance
of the vasculature during pregnancy. This review summarises our current understanding of endothelial progenitor cells, with
specific reference to their role in angiogenesis and human pregnancy.
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Introduction
The observation of an affinity between endothelial cells
and haematopoietic cells was first reported in 1920 by
Florence Sabin. Until recently, differentiation of endo¬
thelial cells from angioblasts was thought to exclusively
occur within the developing embryo. In 1997, Asahara
and colleagues isolated a population of bone marrow-
derived cells from human peripheral blood capable of ex
vivo expansion, differentiation into a mature endothelial
phenotype and neovascularisation in response to acute
tissue ischaemia (Asahara et at. 1997). Shortly after this,
Shi and colleagues observed that bone marrow cells
were important for the endothelialisation of intra-aortic
Dacron grafts in dogs (Shi et al. 1998). These studies
suggest the existence of a population of circulating
endothelial progenitor cells (EPCs), which are mono¬
nuclear, cells arising in bone marrow with the capacity
to differentiate into mature endothelial cells.
Normal human pregnancy involves adaptation of
maternal vasculature to accommodate and sustain the
developing foetus. Abnormal adaptation of the uterine
vasculature is associated with deficient placentation and
some diseases of pregnancy including pre-eclampsia
and gestational diabetes are associated with systemic
endothelial dysfunction (Brosens et al. 1972, McCarthy
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et al. 1993, Knock et al. 1997). We postulate that EPCs
play an important role in development, regulation and
maintenance of the vasculature during pregnancy. This
review summarises our current understanding of the
origin and function of EPCs, and highlights their
potential role in angiogenesis and vascular repair in
human pregnancy.
Characterisation of circulating EPCs
EPCs are characterised by their expression of both
haematopoietic and mature endothelial cell antigens,
and by their ability to proliferate, migrate and differ¬
entiate into mature cell types. Asahara and colleagues
exploited two antigens shared by endothelial cells and
haematopoietic stem cells (HSCs) to isolate putative
EPCs from peripheral blood (Asahara et al. 1997). CD34
is expressed by most mature endothelial cells (Fina et al.
1990) as well as all HSCs but is lost by haematopoietic
cells as they differentiate (Civin etal. 1984). Kinase insert
domain receptor (KDR), the extracellular domain of
vascular endothelial growth factor receptor (VEGFR)
(Shalaby et al. 1995), is also expressed by both early
HSCs and endothelial cells but is lost on haematopoietic
cell differentiation (Matthews et al. 1991). CD34+ and
KDR+ cells, isolated from peripheral blood leucocytes
DOI: 10.1530/REP-06-0219
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form vascular structures in vitro and incorporate into the
vessel wall in experimental models of neovascularisation
(Asahara et al. 1997).
Co-expression of CD34 and KDR has been used in a
number of experimental and clinical studies to identify
circulating EPCs. No surface marker unique to endo¬
thelial progenitors has been identified and so it remains
difficult to distinguish EPCs from mature endothelial cells
that have been swept into the circulation or haemato¬
poietic cells. CD133 is expressed by haematopoietic
cells, but not by mature endothelial cells. Identification
of CD133, KDR and CD34 co-expression may differ¬
entiate between circulating mature and progenitor
endothelial cells (Peichev et al. 2000). The rarity of
EPCs in peripheral blood (100-200 cells/ml), has made
their study difficult.
Alternative methods have been described for the
characterisation and quantification of EPCs based on
the culture of endothelial cells from circulating mono¬
nuclear cells. A number of functional assays have been
reported, most Involving the isolation of peripheral
blood mononuclear cells by density centrifugation of
blood and subsequent culture on fibronectin coated
plates. After 5-7 days in culture, adherent colonies are
seen, where spindle shaped cells emerge from a cluster
of round cells (EPC colony forming units, EPC-CFUs).
These adherent cells display a variety of endothelial-like
properties including the uptake of acetylated low density
lipoprotein (AcLDL) and staining with UEA-1 (Fig. 1), a
lectin of Ulex europaeus, specific for endothelial cells in
a variety of tissues binding to the carbohydrate moiety a-
l-fucose (Stephenson et al. 1986).
Whilst counting EPC-CFUs measures the capacity of
circulating mononuclear cells to form endothelial cells,
the colonies may not directly arise from the CD34+ stem
cells. The exact phenotype of EPC-CFUs remains a
matter of debate in part because the purity of CD34 +
cells used in the initial Asahara study was only 15%
(Asahara et al. 1997). Peripheral blood contains several
cell types that can differentiate into endothelial-like cells
in vitro, including haematopoietic stem cells, mono¬
nuclear phagocytes (monocyte-macrophages), and
mature endothelial cells (Ingram etal. 2005). In a recent
methodological paper by George and colleagues no
correlation was found between the number of peripheral
blood CD34+ cells and the number of EPC-CFUs
(George et al. 2006).
Studies addressing the origin of EPCs have demon¬
strated that monocytes express endothelial lineage
markers such as KDR and can differentiate into
endothelial cells (Schmeisser et al. 2001). Rehman
and colleagues found that the majority of EPC-CFUs
expressed monocyte markers such as CD14, Mac-1, and
CD11c, suggesting that peripheral blood EPCs are
derived from monocyte-iike cells (Rehman et al.
2003). The concept that functional endothelial cells
may originate from a CD14+ progenitor is supported by
Figure 1 (A) A typical colony-forming unit (EPC-CFU) with a
characteristic core of round cells and sprouting spindle cells at the
periphery (X 100 magnification). (B) Overlay with immunofluores¬
cence staining of EPC-CFU demonstrating uptake of Dil-acetylated-
LDL (red) (X 100 magnification). (C) Fluorescent micrograph of
cultured EPCs 4 days after isolation from peripheral blood, stained with
lectin Ulex europaeus-FITC (green) and demonstrating uptake of Dil-
acetylated-LDL (red) (X 40 magnification). Figure 1(C) reproduced
with permission from Kalka eta/. (2000).
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reports that mature endothelial cells from human Mobilization and differentiation of EPCs
umbilical vein express CD14 (Jersmann et al. 2001)
and that isolated CD14+ cells can improve neovascu- The vascular endothelium is a monolayer of cells central
larisation after mouse hind limb ischaemia (Urbich totheiegulalioiiufbluudvesseltonedridpeirneabilily.il
et at. 2003). We present a diagram outlining two acts as a non-adhesive surface for leucocytes and
potential ways that endothelial cells might arise from platelets, and produces important factors in the
haematopoietic stem cells via myeloid or endothelial regulation of fibrinolysis and blood flow. Endothelial
progenitor subtypes (Tig. 2). dysfunction caused by mechanical or biochemical stress
In this emerging field, many different methods have and inflammation is characterised by reduced nitric
been used to characterise and quantify putative endo- oxide bioavailability and a progressive loss of endo
thelial progenitors, preventing straightforward compari- thelial cells (Libby 2002, Wassmann & Nickenig 2003).
son. Reduced levels of both phenotypic (Schmidt-Lucke Endothelial denudation is one of the earliest pathophy-
et al. 2005) and functional EPCs (Werner et al. 2005) siological features of vascular disease, with persistent
predict adverse outcome in patients with coronaiy aitery endothelial dysfunction responsible for the piogiessiuu
disease. Whilst questions remain as to the origin and and clinical manifestations of atherothrombosis (Ross
phenotype of EPCs, evidence that they contribute to 1999, Weissberg & Bennett 1999). Integrity of the
vascular repair and neoangiogenesis in animal models is vascular endothelium is a dynamic equilibrium between










Figure 2 Possible pathways by which endothelial cells
may arise from haematopoietic stem ceils. Haeman-
gioblasts give rise to circulating haematopoetic stem
cells of myeloid or endothelial progenitor subtypes,
with endothelial cells potentially derived from either
pathway.
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Table 1 Characteristics of endothelial progenitor cells
Phenotypic Cell-surface expression of haematopoietic stem-cell
(CD34, CD133) and endothelial-cell antigens (KDR)
Functional Produce characteristic colonies and tubular
structures on fibronectin in vitro
Migrate and incorporate into areas of vascular
damage in vivo
Differentiate into mature endothelial cells
The concept of a pool of endothelial progenitors in the
bone-marrow, capable of moving to effect angiogenesis
or vascular repair in response to ischaemia or vascular
injury is supported by both in vitro and in vivo studies. In
a mouse model, Asahara and colleagues demonstrated
differentiation of donor bone marrow cells into endo¬
thelial cells and their subsequent incorporation into the
vasculature during processes such as ovulation, wound
healing, recovery from hind limb ischaemia and
neoplasia (Asahara eta/. 1999).
Reduced circulating EPC levels are observed when
established cardiovascular risk factors are present
suggesting a role for EPCs in the maintenance of
endothelial function. Decreased numbers of EPCs have
been demonstrated in cigarette smokers (Vasa etal. 2001)
and in patients with diabetes mellitus (Topper of a/. 2002)
or rheumatoid arthritis (Grisar et at. 2005). Hill et al.
(2003) observed a strong correlation between the
Framingham cardiovascular risk score (which uses
cardiovascular risk factors to predict future risk of
coronary artery disease (Wilson et al. I9tf/)) and
circulating EPC numbers. EPC numbers predicted sys¬
temic endothelial function more accurately than the
Framingham risk score (Hill et al. 2003). Furthermore,
lower levels of EPCs are associated with adverse outcome
in patients with coronary artery disease (Schmidt-Lucke
etal. 2005, Werner etal. 2005) and impaired myocardial
remodelling after infarction (Leone et al. 2005).
The postulated factors responsible for mobilization of
EPCs from the bone marrow are the subject of an intense
search. Such a factor might form a therapeutic strategy to
enhance vascular repair, EPCs are released in the context
of acute ischaemic injury, such as myocardial infarction
(Leone et al. 2005, Massa et al. 2005) and following
vascular injury as a consequence of coronary artery
bypass grafting (Gill et al. 2001). Vascular endothelial
growth factor (VEGF) and stromal cell-derived factor-1
(SDF-1), both released from ischaemic tissue, are thought
to be important factors in the mobilisation of EPCs. Other
cytokines such as granulocyte-colony stimulating factor
(G-CSF) and granulocyte-macrophage colony stimulating
factor (GM-CSF) mobilise both haematological progeni¬
tors and EPCs. These have been used for many years to
harvest progenitors for autologous bone marrow trans¬
plantation in the context of haematological malignancy.
However, they also induce a pro-inflammatory state
which may limit their therapeutic potential.
Mechanisms of EPC mobilisation in conditions other
than ischaeinia may be more lelevaul to understanding
the role of EPCs in maternal circulation during pregnancy.
The effect of oestrogens in maintaining endothelial
function may be related to EPC mobilisation and
enhanced vascular repair. In a rat-carotid injury model,
exogenous oestradiol accelerates re-endothelialisation
and attenuates medial thickening via mobilization and
proliferation of bone marrow-derived EPCs. This response
was absent in endothelial nitric oxide synthase (eNOS)
knock out animals (Iwakura et al. 2003). Recent mouse
studies with oestrogen receptor (ER) a and (3 knockout
animals demonstrate roles for both receptors a and (3 in
EPC-mediated neovascularisation in response to ischae¬
mia. In addition, ERa messenger RNA expression was
higher than ERP messenger RNA expression in EPCs.
VEGF expression was significantly down-regulated on
EPCs from ERa knockout mice compared with EPCs from
wild type animals (Hamada et al. 2006).
Vascular remodelling in pregnancy
Growth of endometrial vasculature in preparation for
implantation begins in the proliferative phase and
continues in the secretory phase of the menstrual cycle.
This physiological angiogenesis is thought to occur
primarily through elongation and intussusception of
existing small vessels (Gargett & Rogers 2001). Sprouting
is important in placentation and is also a feature of
angiogenesis associated with pathology such as ischaemia
(Reynolds & Redmer 2001) (Fig. 3). A role for EPCs in
physiological endometrial angiogenesis has been impli¬
cated by Asahara and colleagues where EPCs were
demonstrated within vasculature and stroma of the
endometrium and myometrium after induced ovulation
in mice (Asahara etal. 1999). Increased circulating levels
of EPCs are seen during the secretory phase of the
menstrual cycle in human subjects (Matsubara etal. 2006).
The uterine vasculature undergoes dramatic remodel¬
ling during pregnancy. In addition to vasodilation of the
uterine artery, remodelling of maternal spiral arteries
provides a large vascular bed perfusing the placental
intervillous space with maternal blood (Brosens et al.
1967). During placentation, this remodelling is mediated
by interstitial and endovascular trophoblast invading
maternal vessels (for a review see (Pijnenborg et al.
2006)). During the wave of trophoblast invasion,
maternal spiral artery endothelium is extensively
damaged and then repaired. This results in a fresh layer
of endothelium (Pijnenborg et al. 2006). The repair is
thought to be effected by local endothelial cells though it
is plausible that circulating EPCs are involved.
Vascular and endothelial function in pregnancy
Pregnancy necessitates cardiovascular adaptation to
sustain the developing foetus. Initially, peripheral
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vascular resistance falls resulting in an increase in
cardiac output (Cinsburg & Duncan 1967, Ueland
et al. 1969). The plasma volume expands (Pirani et at.
1973). In normal pregnancy, there is enhanced endo¬
thelial function and reactivity with greater production of
endothelium-derived vasodilators (Goodman et al.
1982, Williams et al. 1997, Anumba et al. 1999).
Flow-mediated dilation of the brachial artery increases
with the gestational week suggesting maintenance of
endothelial vascular function (Dorup eta/. 1999).
Endothelial function is preserved in spite of the
systemic inflammatory response associated with normal
pregnancy. There is increased production of pro-inflam¬
matory cytokines, including interleukin (IL)-6, IL-12, and
tumour necrosis factor (TNF)-a with associated leucocy-
tosis. The neutrophil count rises steadily throughout
gestation, to peak at term (Austgulen et al. 1994, Rebelo
etal. 1995, Melczer etal. 2003, Sacks etal. 2003). As well
as being a pro-inflammatory state, normal pregnancy is
associated with increased insulin resistance and hyperli-
pidaemia, controlled by hormonal changes. Pregnancy
might be considered a 'stress' test for the maternal
vascular endothelium (Sattar & Greer 2002).
Potential role of EPCs in normal pregnancy
Only three cross-sectional studies of circulating EPCs
during normal human pregnancy have been reported to
date. Different methods have been used to characterise
and quantify putative endothelial progenitors, prevent¬
ing straightforward comparisons between studies. The
first, by Sugawara et al. (2005a) studied circulating EPCs
in the peripheral blood of 20 pregnant women. They
observed greater numbers of colony-forming units
Figure 3 Proposed mechanisms by which
EPCs may contribute to angiogenesis in
human endometrium. Mature resident endo¬
thelial cells (purple) and proliferating mature
resident mature endothelial cells (blue).
Circulating EPCs (yellow) may incorporate
into endothelial monolayer at points of
elongation and intussusception, or proliferate
to form new micro vessels (sprouting).
Circulating EPCs may have a supportive
paracrine effect on adjacent mature endo¬
thelial cells, through the release of angio¬
genic factors including VECF. EPCs release
VECF in vitro and in in vivo murine studies
(Urbich eta/. 2005). Adapted with per¬
mission from Gargett CE & Rogers PA 2001
Human endometrial angiogenesis. Repro¬
duction 121 181-186.
(EPC-CFUs) at greater gestational age. EPC-CFUs corre¬
lated with serum oestradiol concentrations (Sugawara
et al. 2005a). Oestrogens are known to have vasculo-
protective effects, in part due to increasing production of
nitric oxide and by decreasing reactive oxygen species
(Mendelsohn & Karas 1999). Oestrogens also mobilise
EPCs from the bone marrow in vivo. They inhibit the
senescence of EPCs and stimulate VEGF production
in vitro (Strehlow et al. 2003, Imanishi et al. 2005).
Mobilisation of EPCs may be an important mechanism
by which oestrogens protect the vascular endothelium
during pregnancy.
A second study by Gussin et al. (2002) supports this
hypothesis. They cultured peripheral blood mono¬
nuclear cells from non-pregnant and pregnant women.
Early outgrowth endothelial cells were formed from both
groups. Late outgrowth cells, which have a higher
proliferative potential, were only formed by the cells
from pregnant women. The authors initially
hypothesized that these cells were of fetal origin and
their original intention was to optimise the culture of
fetal cells. To identify fetal cells, they stained for X and Y
chromosomes and discovered that none of the colonies
contained fetal cells. They concluded that endothelial
cells were of maternal origin and that pregnancy is
associated with mobilization of EPCs into the circulation
(Gussin et al. 2002).
In contrast, a study by Matsubara and colleagues of 36
healthy pregnant women observed decreasing numbers
of circulating EPCs with increasing gestational age. They
directly quantified EPCs by flow-cytometry, selecting for
co-expression of CD34, CD133 and KDR. They also
assessed EPC proliferation by counting cells that stained
for both lectin Ulex europaeus and the uptake of
www.reproduction-online.org Reproduction (2007) 133 1-9
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acetylated-LDL after 7 days in culture. With increasing
gestation, they found decreased numbers of these cells
and decreased responses when stimulated by TNF-a and
angiotensin II (Matsubara et al. 2006).
It is difficult to compare the results of these studies
because different methods were used to count EPCs. It
remains uncertain whether the cells measured by flow-
cytometry are responsible for forming endothelial-like
structures in cell culture. It is possible that the reduction
in CD34+/CD133 +/KDR+ cells is caused by dilution in
expanding plasma volume. A limit of all three studies is
the cross-sectional study design. Many factors affect
circulating EPC numbers were not described for the
study subjects. Prospective studies following women
through gestation would provide more information
about EPCs in pregnancy.
Vascular dysfunction and EPCs in diseases of
pregnancy
Pre-eclampsia and gestational diabetes are associated
with maternal endothelial dysfunction (McCarthy et at.
1993, Knock et at. 1997). Pre-eclampsia is the only
disease of pregnancy in which EPCs have been studied.
Pre-eclampsia, occurring in 5-7% of first pregnancies
with 20-25% recurrence is the most common medical
complication of pregnancy. The disease, characterised
by hypertension and proteinuria, is a significant cause of
maternal and perinatal morbidity and mortality world¬
wide (Stone et al. 1994).
Despite recent advances, the pathogenesis of pre¬
eclampsia remains unclear. Deficient placentation
(decreased trophoblast invasion and subsequent spiral
artery remodelling) is seen histologically in most women
with pre-eclampsia (Brosens et al. 1972, Pijnenborg
et al. 1991). Maternal endothelial dysfunction is a core
feature of pre-eclampsia. Vascular cellular adhesion
molecule-1 (VCAM), intercellular adhesion molecule-1
(ICAM), E-selectin, endothelin-1 and cellular fibronec-
tin, all soluble markers of endothelial dysfunction are
raised in the blood of women with pre-eclampsia. Some
are evident before the clinical features of the disease
(Taylor et al. 1991, Schiff et al. 1992, Kraayenbrink et al.
1993, Higgins et al. 1998, Bretelle et al. 2001). Other
markers of endothelial dysfunction including asym¬
metric dimethylarginine (an endogenous inhibitor of
nitric oxide synthesis) (Savvidou et al. 2003), plasmino¬
gen activator inhibitor type 1 (PAI-1) (Roes et al. 2002)
and tissue plasminogen activator (t-PA) (Belo el al.
2002), also rise before clinical symptoms appear with
t-PA correlating with the degree of proteinuria (Belo etal.
2002). Women with pre-eclampsia are more likely to
have impaired uterine artery doppler waveforms (Camp¬
bell et al. 1983) and reduced flow-mediated dilation of
the brachial artery at 23-25 weeks gestation, suggesting
that endothelial dysfunction precedes pre-eclampsia
(Savvidou et al. 2003). Endothelial dysfunction,
observed in pre-eclampsia, persists beyond pregnancy
(Lampinen etal. 2006) and epidemiological data suggest
an increased maternal risk of hypertension, coronary and
cerebro-vascular disease (Wilson et al. 2003).
Pre-existing conditions associated with endothelial
dysfunction, such as hypertension, renal disease, and
diabetes, increase the risk of developing pre-eclampsia.
Although there are extensive studies reporting decreased
levels of EPCs or abnormal function of EPCs in men and
non-pregnant women with these conditions, there are
few available data about EPCs in pre-eclampsia. In
addition, as with the studies in normal pregnancy, the
published data are conflicting. Matsubara and
colleagues reported no difference in the number of
circulating EPCs measured by flow-cytometry in pre¬
eclamptic women although culture of mononuclear cells
resulted in more endothelial-like cells. These cells had
increased proliferative response following stimulation
with TNF-a and angiotensin II compared with cells from
women without pre-eclampsia (Matsubara et al. 2006).
This increase may be a physiological response to
ischaemia in the placenta and other organs, similar to
that seen in myocardial infarction (Leone et al. 2005,
Massa et al. 2005). In contrast, Sugawara et al. (2005b)
demonstrated decreased numbers of EPC-CFUs and
increased senescence of EPCs in patients with pre¬
eclampsia compared with gestationally matched con¬
trols (Sugawara etal. 2005 b). These studies are not easily
comparable because of the different methods used, and it
is difficult to draw a conclusion from the discordant
observations. It is likely that EPC function is more
important than quantity, and ideally a subsequent study
of EPCs in pre-eclampsia would assess number and
function prospectively prior to the onset of disease.
Postulated role of EPCs in pre-eclampsia
The role of EPCs in the pathogenesis of pre-eclampsia is as
yet unknown. However from studies outside of pregnancy,
EPCs have a potential role in maintaining vascular integrity.
Decrease in number and function is associated with
endothelial impairment. We hypothesise that EPCs
represent a common cellular pathway linking cardiovas¬
cular risk factors and endothelial dysfunctional states, with
pre-eclampsia. They may be involved in homeostasis of the
pregnant uterine and systemic vasculature. Their defici¬
ency or impairment may render the individual vulnerable
to the inflammatory and metabolic insults of pregnancy,
leading to widespread endothelial dysfunction and pre¬
eclampsia. Fig. 4 represents this hypothesis schematically.
Future directions
Future research strategies evaluating the role of EPCs in
pregnancy will hopefully address the following
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The discovery of a circulating endothelial progenitor cell
that is capable of contributing to physiological and
pathological angiogenesis has generated intense interest
in the field of vascular biology. To date this has focused
particularly in the areas of vascular injury and athero¬
sclerosis where the therapeutic possibilities of EPCs are
already being explored. We have summarised the
current literature on EPCs in pregnancy and postulate
that these progenitors may have an important role in
regulating vascular homeostasis in pregnancy. Their
impairment or deficiency may underlie maternal suscep¬
tibility to pre-eclampsia.
b. State of maternal susceptibility
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Figure 4 Illustration of proposed hypothesis, (a) Normal pregnancy -
there is a continuous demand for endothelial regeneration with
vascular adaptation, which occurs in the presence of inflammation.
Oestrogens mobilise EPCs from the bone marrow, (b) State of maternal
susceptibility - reduced mobilisation of EPCs from the bone marrow or
their functional impairment results in maternal susceptibility to
endothelial dysfunction, (c) Acute pre-eclampsia - EPCs are mobilised
from the bone marrow in response to ischaemia.
questions: Are EPCs useful markers or predictors for pre¬
eclampsia? Do levels reflect severity of disease?
EPCs may also have a role in other pathologies of
pregnancy such as gestational diabetes. Prospective
longitudinal studies are required to assess EPC quantity
and function during and after pregnancy. In addition,
animal studies and in vitro models will provide us with a
greater understanding of the role of EPCs in the
maintenance of the endometrial vasculature and in
placentation.
References
Anumba DO, Robson SC, Boys RJ & Ford GA 1999 Nitric oxide activity
in the peripheral vasculature during normotensive and preeclamptic
pregnancy. American Journal of Physiology 277 H848-H8S4.
Asahara T, Masuda Ft, Takahashi T, Kalka C, Pastore C, Silver M,
Kearne M, Magner M & Isner JM 1999 Bone marrow origin of EPCs
responsible for postnatal vasculogenesis in physiological and
pathological neovascularization. Circulation Research 85 221-228.
Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R,
Witzenbichler B, Schatteman G & Isner JM 1997 Isolation of
putative progenitor endothelial cells for angiogenesis. Science 275
964-967.
Austgulen R, Lien E, Liabakk NB, Jacobsen G & Arntzen KJ 1994
Increased levels of cytokines and cytokine activity modifiers in
normal pregnane)'. European Journal ofObstetrics, Gynecology, and
Reproductive Biology 57 149-155.
Belo L, Santos-Silva A, Rumley A, Lowe G, Pereira-Leite L,
Quintanilha A & Rebelo I 2002 Elevated tissue plasminogen
activator as a potential marker of endothelial dysfunction in pre¬
eclampsia: correlation with proteinuria. Bjog 109 1250-1255.
Bretelle F, Sabatier F, Blann A, D'Ercole C, Boutiere B, Mutin M,
Boubli L, Sampol J & Dignat-George F 2001 Maternal endothelial
soluble cell adhesion molecules with isolated small for gestational
age fetuses: comparison with pre-eclampsia. Bjog 108 1277-1282.
Brosens I, Robertson WB & Dixon HG 1967 The physiological
response of the vessels of the placental bed to normal pregnancy.
Journal of Pathology and Bacteriology 93 569-579.
Brosens IA, Robertson WB & Dixon HG 1972 The role of the spiral
arteries in the pathogenesis of preeclampsia. Obstetrics and
Gynecology Annual 1 177-191.
Campbell S, Diaz-Recasens J, Griffin DR, Cohen-Overbeek TE,
Pearce JM, Willson K & Teague MJ 1983 New doppler technique
for assessing uteroplacental blood flow. Lancet 1 675-677.
www.reproduction-online.org Reproduction (2007) 133 1-9
8 AO Robb and others
Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz )F & Shaper JH
1984 Antigenic analysis of hematopoiesis. III. A hematopoietic
progenitor cell surface antigen defined by a monoclonal antibody
raised against KG-1a cells, journal of Immunology 133 157-165.
Dorup I, Skajaa K & Sorensen KE 1999 Normal pregnancy is associated
with enhanced endothelium-dependent flow-mediated vasodilation.
American journal ofPhysiology 276 H821-H825.
Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D,
Sutherland DR, Baker MA & Greaves MF 1990 Expression of CD34
gene in vascular endothelial cells. Blood 75 2417-2426.
Gargett CE & Rogers PA 2001 Human endometrial angiogenesis.
Reproduction 121 181-186.
George J, Shmilovich H, Deutsch V, Miller H, Keren G & Roth A 2006
Comparative analysis of methods for assessment of circulating EPCs.
Tissue Engineering 12 331-335.
Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L,
Yurt R, Himel H & Rafii S 2001 Vascular trauma induces rapid but
transient mobilization of VEGFR2( + )AC133( + ) endothelial pre¬
cursor cells. Circulation Research 88 167-174.
Ginsburg J & Duncan SL 1967 Peripheral blood flow in normal
pregnancy. Cardiovascular Research 1 132-137.
Goodman RP, Killam AP, Brash AR & Branch RA 1982 Prostacyclin
production during pregnancy: comparison of production during
normal pregnancy and pregnancy complicated by hypertension.
American journal of Obstetrics and Gynecology 142 817-822.
Grisar ], Aletaha D, Steiner CW, Kapral T, Steiner S, Seidinger D,
Weigel G, Schwarzinger I, Wolozcszuk W, Steiner G et al. 2005
Depletion of EPCs in the peripheral blood of patients with
rheumatoid arthritis. Circulation 111 204-211.
Gussin HA, Bischoff FZ, Hoffman R & Elias S 2002 Endothelial
precursor cells in the peripheral blood of pregnant women.
Journal for the Society for Gynecologic Investigation 9 357-361.
Hamada H, Kim MK, Iwakura A, li M, Thorne T, Qin G, Asai ),
Tsutsumi Y, Sekiguchi H, Silver M et al. 2006 Estrogen Receptors
(alpha) and (beta) Mediate Contribution of Bone Marrow-Derived
Endothelial Progenitor Cells to Functional Recovery After Myo¬
cardial Infarction. Circulation 114 2261-2270.
Higgins )R, Papayianni A, Brady HR, Darling MR & Walshe I) 1998
Circulating vascular cell adhesion molecule-1 in pre-eclampsia,
gestational hypertension, and normal pregnancy: evidence of
selective dysregulation of vascular cell adhesion molecule-1
homeostasis in pre-eclampsia. American journal of Obstetrics and
Gynecology 179 464-469.
Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA
& Finkel T 2003 Circulating EPCs, vascular function, and cardiovas¬
cular risk. New EnglandJournal ofMedicine 348 593-600.
Imanishi T, Hano T & Nishio I 2005 Estrogen reduces endothelial
progenitor cell senescence through augmentation of telomerase
activity, journal of Hypertension 23 1 699-1 706.
Ingram DA, Caplice NM & Yoder MC 2005 Unresolved questions,
changing definitions, and novel paradigms for defining EPCs. Blood
106 1525-1531.
Iwakura A, Luedemann C, Shastry S, Hanley A, Kearney M, Aikawa R,
Isner JM, Asahara T & Losordo DW 2003 Estrogen-mediated,
endothelial nitric oxide synthase-dependent mobilization of bone
marrow-derived EPCs contributes to reendothelialization after
arterial injury. Circulation 108 3115-3121.
Jersmann HP, Hii CS, Hodge GL & Ferrante A 2001 Synthesis and
surface expression of CD14 by human endothelial cells. Infection
and Immunity 69 479-485.
Kalka C, Masuda H, Takahashi T, Gordon R, Tepper O, Gravereaux E,
Pieczek A, Iwaguro H, Hayashi SI, Isner JM et al. 2000 Vascular
endothelial growth factor(165) gene transfer augments circulating
EPCs in human subjects. Circulation Research 86 1198-1202.
Karter Y, Aydin S, Curgunlu A, Uzun H, Erturk N, Vehid S, Kutlu A,
Simsek G, Yucel R, Arat A et al. 2004 Endothelium and angiogenesis
in white coat hypertension, journal of Human Hypertension 18
809-814.
Knock GA, McCarthy AL, Lowy C & Poston L 1997 Association of
gestational diabetes with abnormal maternal vascular endothelial
function. British Journal of Obstetrics and Gynaecology 104
229-234.
Kraayenbrink AA, Dekker GA, van Kamp GJ & van Geijn HP 1993
Endothelial vasoactive mediators in preeclampsia. American
Journal of Obstetrics and Gynecology 169 160-165.
Lampinen KH, Ronnback M, Kaaja RJ & Groop PH 2006 Impaired
vascular dilatation in women with a history of pre-eclampsia.
journal ofHypertension 24 751-756.
Leone AM, Rutella S, Bonanno G, Abbate A, Rebuzzi AG, Giovannini S,
Lombardi M, Galiuto L, Liuzzo G, Andreotti F et al. 2005
Mobilization of bone marrow-derived stem cells after myocardial
infarction and left ventricular function. European Heart journal 26
1196-1204.
Libby P 2002 Inflammation in atherosclerosis. Nature 420 868-874.
Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, De
Ferrari GM, Ferlini M, Goffredo L, Bertoletti A etal. 2005 Increased
circulating hematopoietic and EPCs in the early phase of acute
myocardial infarction. Blood 105 199-206.
Matsubara K, Abe E, Matsubara Y, Kameda K & Ito M 2006 Circulating
EPCs during normal pregnancy and pre-eclampsia. American
journal of Reproductive Immunology 56 79-85.
Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG &
Lemischka IR 1991 A receptor tyrosine kinase cDNA isolated from a
population of enriched primitive hematopoietic cells and exhibiting
close genetic linkage to c-kit. PNAS 88 9026-9030.
McCarthy AL, Woolfson RG, Raju SK & Poston L 1993 Abnormal
endothelial cell function of resistance arteries from women with
preeclampsia. American journal of Obstetrics and Gynecology 168
1323-1330.
Melczer Z, Banhidy F, Csomor S, Toth P, Kovacs M, Winkler G &
Cseh K 2003 Influence of leptin and the TNF system on insulin
resistance in pregnancy and their effect on anthropometric
parameters of newborns. Acta Obstetricia et Gynecologica Scandi-
navica 82 432-438.
Mendelsohn ME & Karas RH 1999 The protective effects of estrogen on
the cardiovascular system. New England journal of Medicine 340
1801-1811.
Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC,
Hicklin DJ, Witte L, Moore MA et al. 2000 Expression of VEGFR-2
and AC133 by circulating human CD34( + ) cells identifies a
population of functional endothelial precursors. Blood95 952-958.
Pijnenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L &
van Assche A 1991 A Placental bed spiral arteries in the hypertensive
disorders of pregnancy. British jounal ofObstetrics and Gynaecology
98 648-655.
Pijnenborg R, Vercruysse L & Hanssens M 2006 The Uterine Spiral
Arteries In Human Pregnancy: Facts and Controversies. Placenta 27
939-958.
Pirani BB, Campbell DM & MacGillivray I 1973 Plasma volume in
normal first pregnancy. The journal of Obstetrics and Gynaecology
of the British Commonwealth 80 884-887.
Rebelo I, Carvalho-Guerra F, Pereira-Leite L & Quintanilha A 1995
Lactoferrin as a sensitive blood marker of neutrophil activation in
normal pregnancies. European Journal of Obstetrics, Gynecology,
and Reproductive Biology 62 189-194.
Rehman J, Li J, Orschell CM & March KL 2003 Peripheral blood 'EPCs'
are derived from monocyte/macrophages and secrete angiogenic
growth factors. Circulation 107 1164 -1169.
Reynolds LP & Redmer DA 2001 Angiogenesis in the placenta. Biology
of Reproduction 64 1033-1040.
Roes EM, Sweep CG, Thomas CM, Zusterzeel PL, Geurts-Moespot A,
Peters WH & Steegers EA 2002 Levels of plasminogen activators and
their inhibitors in maternal and umbilical cord plasma in severe
preeclampsia. American journal of Obstetrics and Gynecology 187
1019-1025.
Ross R 1999 Atherosclerosis-an inflammatory disease. New England
journal of Medicine 340 115-126.
Reproduction (2007) 133 1-9 www.reproduction-online.org
EPCs in pregnancy 9
Sacks CP, Redman CW & Sargent IL 2003 Monocytes are primed to
produce the Th1 type cytokine IL-12 in normal human pregnancy: an
intracellular flow cytometric analysis of peripheral blood mono¬
nuclear cells. Clinical and Experimental Immunology 131 490-497.
Sattar N & Greer IA 2002 Pregnancy complications and maternal
cardiovascular risk: opportunities for intervention and screening?.
BMJ 325 157-160.
Savvidou MD, Hingorani AD, Tsikas D, Frolich )C, Vallance P &
Nicolaides KH 2003 Endothelial dysfunction and raised plasma
concentrations of asymmetric dimethylarginine in pregnant women
who subsequently develop pre-eclampsia. Lancet 361 1511-1517.
Schiff E, Ben-Baruch G, Peleg E, Rosenthal T, Alcalay M, Devir M &
Mashiach S 1992 Immunoreactive circulating endothelin-1 in
normal and hypertensive pregnancies. American Journal of Obste¬
trics and Gynecology 166 624-628.
Schmeisser A, Garlichs CD, Zhang H, Eskafl S, Graffy C, Ludwig ),
Strasser RH & Daniel WG 2001 Monocytes coexpress endothelial
and macrophagocytic lineage markers and form cord-like structures
in Matrigel under angiogenic conditions. Cardiovascular Research
49 671-680.
Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M,
Kamper U, Dimmeler S & Zeiher AM 2005 Reduced number of
circulating EPCs predicts future cardiovascular events: proof of
concept for the clinical importance of endogenous vascular repair.
Circulation in 2981-2987.
Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML
& Schuh AC 1995 Failure of blood-island formation and vasculogenesis
in Flk-1 -deficient mice. Nature 376 62-66.
Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S,
Mohle R, Sauvage LR et al. 1998 Evidence for circulating bone
marrow-derived endothelial cells. Blood92 362-367.
Stephenson TJ, Griffiths DW & Mills PM 1986 Comparison of Ulex
europaeus I lectin binding and factor VIIl-related antigen as markers
of vascular endothelium in follicular carcinoma of the thyroid.
Histopathology 10 251-260.
Stone JL, Lockwood CJ, Berkowitz GS, Alvarez M, Lapinski R &
Berkowitz RL 1994 Risk factors for severe preeclampsia. Obstetrics
and Gynecology 83 357-361.
Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller), Laufs K,
Ghaeni L, Milosevic M, Bohm M etal. 2003 Estrogen increases bone
marrow-derived endothelial progenitor cell production and
diminishes neointima formation. Circulation 107 3059-3065.
Sugawara ), Mitsui-Saito M, Hoshiai T, Hayashi C, Kimura Y &
Okamura K 2005a Circulating EPCs during human pregnancy.
Journal of Clinical Endocrinology and Metabolism 90 1845-1848.
Sugawara), Mitsui-Saito M, Hayashi C, Hoshiai T, Senoo M, Chisaka H,
Yaegashi N & Okamura K 2005b Decrease and senescence of EPCs
in patients with preeclampsia. Journal ofClinical Endocrinology and
Metabolism 90 5329-5332.
Taylor RN, Crombleholme WR, Friedman SA, Jones LA, Casal DC &
Roberts JM 1991 High plasma cellular fibronectin levels correlate
with biochemical and clinical features of preeclampsia but cannot
be attributed to hypertension alone. American Journal of Obstetrics
and Gynecology 165 895-901.
Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR,
Levine JP & Gurtner GC 2002 Human EPCs from type II diabetics
exhibit impaired proliferation, adhesion, and incorporation into
vascular structures. Circulation 106 2781-2786.
Ueland K, Novy MJ, Peterson EN & Metcalfe J 1969 Maternal
cardiovascular dynamics. IV. The influence of gestational age on the
maternal cardiovascular response to posture and exercise. American
Journal of Obstetrics and Gynecology 104 856-864.
Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK,
Zeiher AM & Dimmeler S 2005 Soluble factors released by EPCs
promote migration of endothelial cells and cardiac resident
progenitor cells. Journal of Molecular and Cellular Cardiology 39
733-742.
Urbich C, Heeschen C, Aicher A, Dernbach E, Zeiher AM &
Dimmeler S 2003 Relevance of monocytic features for
neovascularization capacity of circulating EPCs. Circulation
108 2511-2516.
Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H,
Zeiher AM & Dimmeler S 2001 Number and migratory activity of
circulating EPCs inversely correlate with risk factors for coronary
artery disease. Circulation Research 89 E1-E7.
Wassmann S & Nickenig G 2003 Interrelationship of free oxygen
radicals and endothelial dysfunction-modulation by statins. Endo¬
thelium 10 23-33.
Weissberg PL & Bennett MR 1999 Atherosclerosis-an inflammatory
disease. New England Journal of Medicine 340 1928-1929.
Werner N, Kosioi S, Schiegl T, Ahlers P, Walenta K, Link A, Bohm M &
Nickenig G 2005 Circulating EPCs and cardiovascular outcomes.
New England Journal of Medicine 353 999-1007.
Williams DJ, Vallance PJ, Neild GH, Spencer JA & Imms FJ 1997 Nitric
oxide-mediated vasodilation in human pregnancy. American
Journal of Physiology 272 H748-H752.
Wilson PW, Castelli WP & Kannel WB 1987 Coronary risk prediction in
adults (the Framingham Heart Study). AmericanJournal ofCardiology
59 91G-94G.
Wilson BJ, Watson MS, Prescott GJ, Sunderland S, Campbell DM,
Hannaford P & Smith WC 2003 Elypertensive diseases of pregnancy
and risk of hypertension and stroke in later life: results from cohort
study. BMJ 326 845.
Received 1 8 September 2006
First decision 30 October 2006
Accepted 30 November 2006
www.reproduction-online.org Reproduction (2007) 133 1-9
Fibrinolytic potential in pregnancy 139
Methods
Subjects
Ten healthy primigravida women in the third trimester of
pregnancy were recruited from community antenatal clinics.
Twenty healthy non-pregnant women with at least a 2-month
history of normal regular menstrual cycles were recruited from
the University of Edinburgh stuff and student populations.
Exclusion criteria included current or past hypertension,
diabetes mcllitus, and the use of regular medication other than
antacids, inhaled medication for asthma or vitamin supple¬
mentation. Non-pregnant women were also excluded if they
used hormonal contraception, or had a history of monorrhagia
or dysmennorhoea.
All subjects gave written informed consent and the study was
approved by the Lothian Research Ethics Committee and
undertaken in accordance with the Declaration of Helsinki.
Study protocol
Non-pregnant women attended for a single visit in the mid-
follicular phase (day 9.8 ± 0.3) of their menstrual cycle.
Pregnant women attended for a single visit during the third
trimester of pregnancy (week 36 ± l).
Studies were carried out in a quiet temperature controlled
room (22-25 °C). Subjects fasted for 4 h prior to the study and
avoided cigarettes, caffeine and alcohol for the preceding 24 h.
The study was conducted in the supine position for non¬
pregnant women but pregnant women had a slight left lateral
tilt to minimize caval compression by the gravid uterus. Blood
pressure and heart rate were recorded throughout the study
using a semi automated non invasive oocillomctric sphygmo
manometer (OMRON 705 IT, Kyoto, Japan).
Venous occlusion plethysmography
Forearm blood flow was measured in the infused and non-
infused arms by venous occlusion plethysmography rising
mercury-in-silastic strain gauges as described previously [7].
All subjects underwent unilateral brachial artery cannulation
with a 27-standard wire gauge steel needle under controlled
conditions. Following a 20-min saline infusion, bradykinin at
100, 300 and 1000 prnol min~' (cndothelium-dcpcndcnt vaso¬
dilator that stimulates the release of t-PA) and sodium
nitroprussidc at 2,4 and 8 pg min_l (endothelium-independent
vasodilator that docs not stimulate release of t-PA) weic
infused [7], The two vasodilators were separated by a 20-min
saline infusion and given in a randomized order.
Assessment of acute t-PA release
Venous cannulae (17 gauge) were inserted into large subcuta¬
neous veins of the antecubital fossa in both arms as described
previously [7], Blood (10 mL) was drawn simultaneously from
both arms at baseline and after each dose ol bradykuiiu into
acidified buffered citrate (Stabilytc tubes, Biopool International,
Bray, Ireland; for t-PA assays) and into citrate (BD Vacutainer;
for PALI assays). Samples were kept on ice before being
centrifuged at 2000 x g for 30 min at 4 °C. Platelet-free plasma
was decanted and stored at 80 °C before assay. Plasma t PA
antigen and activity (t-PA Conibi Actibind Elisa Kit; Tcchno-
clone, Vienna, Austria) and PAI-1 antigen and activity (Elitest
PAI-I Antigen and Zymutest PAI-1 Activity; Hyphen Biorned,
Ncuvillc Sur Oisc. France) concentrations were determined by
enzyme-linked immunosorbent assays.
Serum hormonal assays
Venous blood (10 mL) collected in a serum gel tube (Sarstedt
Monovotte, Germany), was centrifuged and scrum samples
were stored at 80 C until analysis. Scrum concentrations of
estradiol, progesterone, lutcnizing hormone (LH) and follicle
stimulating hormone (FSII) were measured using immunoas¬
say systems (Siemens Medical Solutions Centaur, Cambcrley,
UK, and Abbott Architect. North Chicago, IL, USA).
Data and statistical analysis
Plethysmography data and net t-PA release were deter¬
mined as described previously [4,7]. In brief, data were
extracted from the Chart data files and forearm blood flows
were calculated for individual venous occlusion cull infla¬
tions by use of a template spreadsheet (Excel version 11.3;
Microsoft Corp., Redmond, WA, USA). Recordings from
the first 60 s after wrist cull inflation were not used because
of the reflex vasoconstriction this causes. The last five linear
flow recordings in each 3-min measurement period were
calculated and averaged for each arm. Estimated not release
of t PA activity and antigen was defined as the product of
the infused forearm plasma flow (based on the hematocrit.
Hot and the infused forearm blood flow, FBF) and the
concentration difference between the infused ([t PA],llt) and
non-infused ([t-PA]N„nin|-) arms:
Estimated net t-PA release = FBF x (1 - Hct)
X([t"f>A]lnf — [t-PA]Noninr)
The t-PA/PAI-1 ratio was calculated from the respective
antigen concentrations. Continuous variables are reported as
mean ± SEM. Statistical analyses were performed with
GraphPad Prism (Graph Pad Software, La Jolla, CA. USA)
using analysis of variance (anova) with repeated measures and
two tailed Student's / test where appropriate. Statistical signif
icance was taken at two-sided P < 0.05.
Results
Baseline characteristics
Due to technical problems, one pregnant woman and three
non pregnant women were unable to complete the complex
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vascular studies. Pregnant (;; = 9) and non-pregnant (n = 17)
women were well matched for age (26 ± 3 vs. 27 ± l,
P = 0.67) and body mass index (24 ± I vs. 24 ± l kg m~2,
P = 0.77). Serum hormonal assays confirmed that the non¬
pregnant women were studied in the mid-follicular phase of
their menstrual cycle (data not shown). All pregnant women
had uncomplicated pregnancies and delivered at term (mean
gestational age at delivery of40 ± I weeks) with average birth
weights (3144 ± 186 g). Three pregnant and three non¬
pregnant women were unable to complete the fibrinolytic
studies due to technical problems with simultaneous venous
access, leaving a final study group of six pregnant and 14 non¬
pregnant women for fibrinolytic analysis. These women were
well matched for age (26 ± 4 vs. 27 ±2, P = 0.94). body
mass index (24 ±1 vs. 24 ± 1 kg m~2, P = 0.85) and
current smoking status (2/6 vs. 3/14, P = 0.6).
Vasomotor function There were no differences in resting
systolic (122 ± 3 vs. ± 2. P = 0.14) or diastolic blood
pressure (76 ± 3 vs. 73 ± 2, P = 0.39) between pregnant and
non-pregnant women. Similarly, there was no difference in
basal infused (3.1 ± 0.5 vs. 2.1 ± 0.2, P = 0.07) or non-
infused (2.4 ± 0.4 vs. 1.8 ± 0.2. P = 0.11) forearm blood
(low between pregnant and non-pregnant women. I Iowever,
consistent with a hyperdynamic circulation, pregnant women
had increased resting heart rates compared with non-pregnant
women (80 ± 3 vs. 67 ± 2 beats min-1, P = 0.002).
There was a dose-dependent increase in forearm blood flow
with bradykinin (P < 0.0001 for both) and sodium nitroprus-
side (P < 0.002 for both). Endothelium-dependent and endo-
thelium-independent vasodilatation was similar between the
two groups ofwomen (P = 0.6 and P = 0.8 respectively, two-
way anova with repeated measures; Table 1).
Fibrinolytic function Baseline plasma PAI-I antigen
concentrations were higher in pregnant women (77 1 T 12.4
vs. 21.5 A 9.8 ng mL"1 in non-prcgnant women; P ~ 0.004,
unpaired r-test; Table 2) whilst apparently higher plasma t-PA
antigen concentrations did not achieve statistical significance
(13.5 ± 2.4 vs. 7.5 A 2.0 ng mL respectively; P = 0.10,
impaired r-test). Consistent with this, t-PA/PAI-1 ratios
(0.2 A 0.1 vs. 0.6 A 0.1; P = 0.02) and plasma
t-PA activity concentrations (0.17 A 0.02 vs.
0.58 A 0.06 IU mL-1; P < 0.0004, unpaired r-test) were
lower in pregnant women.
Bradykinin caused a dose-dependent increase in plasma t-
PA antigen and activity concentrations in the infused arm of
both pregnant and non-pregnant women (P < 0.005 for all;
Table 2). The increase in t-PA activity was greater in the non¬
pregnant women (P = 0.02 vs. pregnant; two-way anova;
Fig. 1). Bradykinin increased the net release of t-PA antigen
and activity in both pregnant women and non-pregnant
women (P < 0.05 for all; Table 2). Both net release of active
t-PA and plasma t-PA/PAI-1 ratios were markedly reduced in
pregnant women (P < 0.05 for both; Table 2 and Fig. 2).
Compared with the non-pregnant women, the area under the
curve for net active t-PA release was reduced by 36% in the
pregnant women.
Discussion
In the third trimester of pregnancy, we have demonstrated that
there is perturbation of the fibrinolytic system. Consistent with
previous work [8,9], we report a marked increase in basal
plasma PAI-I concentrations leading to a reduction in t-PA
activity and t-PA/PAl-l ratios. For the first time, we have
assessed acute endothelial t PA release in pregnant women.
Despite normal bradykinin induced vasodilatation and release
of t-PA antigen, there was a major inhibition of the acute
increase in t-PA activity that was primarily attributable to an
excess of PAI-1. We conclude that this inadequate acute
fibrinolytic activity contributes to the prothrombotic conse
quences of pregnancy.
Pregnancy is associated with a marked elevation in plasma
PAI-I concentrations that in our study, were 4 5-fold higher
than age matched non pregnant women and comparable with
concentrations found in previous studies [1], Although there
appeared to be a modest concomitant rise in t PA antigen, this
Table 1 Absolute forearm blood flow responses to endothelium-dependent and independent vasodilators
Non-pregnant Pregnant
Bradykinin pmol min 1 0 100 300 1000 0 100 300 1000





A 0.2 2.0 A 0.3





2.0 a 0.3 3.1 A 0.6












Sodium nitroprusside pg min ' 0 2 4 8 0 2 4 8
FBF, mL 100 mL"1 min"'
Non-infused arm
Infused arm
2.4 A 0.4 2.4 A





0.4 2.1 a 0.4 2.9 a 1,1











Data expressed as mean A SEM for nine pregnant and 17 non-pregnant women. *P < 0.0001 for bradykinin, *P = 0.002 and P < 0.0001 for
sodium nitroprusside (pregnant and non-pregnant groups, respectively) one-way anova.
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Table 2 Plasma t-PA and PAI-I antigen and activity concentrations in both forearms
Non-pregnant (// - 14) Pregnant (/? = 6)
Bradykinin pmol min ' 0 100 300 1000 0 100 300 1000
t-PA Antigen, ng mL"'
Non-infused arm 7.45 ± 2.0 7.6 ± 2.0 8.0 ± 2.3 9.0 ± 2.8 13.5 ± 2.4 13.6 ± 2.6 14.6 ± 3 15.8 ± 3.2
Infused arm 6.95 ± 2.0 8.6 ± 2.0 11 2 ± 2.5 16.0 ± 3.0 13.4 2.7 12.9 ± 2.4 13.7 ± 2.3 19.2 ± 2.0
t-PA Activity, IU ml..."'
Non-infused arm 0.58 ± 0.06 0.6 ± 0.08 0.79 ± 0.09 1.1 ± 0.14 0.17 ± 0.02 0.26 ± 0.06 0.43 ± 0.2 0.53 ±0.12
Infused arm 0.5 ± 0.06 1.6 ± 0.19 2.8 H- o OJ 4.3 ± 0.6 0.51 ± 0.32 0.51 ± 0.1 1.3 0.15 2.4 ± 0.31
PAI-1 Antigen, ng ml"1 mL"'
Non-infused arm 21.5 ± 9.8 23.2 ± 10.3 22.9 ± 9.6 26.9 ± 10.0 77.1 ± 12.4 71.8 ± 6.3 80.5 ± 11.4 78.5 ± 5.8
Infused arm 19.2 ± 7.7 18 ± 7.3 18.8 ± 7.32 19.8 ± 7.4 72.6 ± 9.0 87.1 ± 16.3 82.8 ± 14.0 82.9 ± 3.1
PAI-1 Activity, ng ml"1 mL"1
Non-infused arm 2.1 ± 1.8 1.4 ± 1.0 I.I ± 0.9 I.I ± 0.8 5.7 ± 1.4 6.1 ± 1.7 6.2 ± 1.7 5.8 ± 1.6
Infused arm 1.36 ± 1.0 1.31 ± 1.0 1.9 ± 1.7 1.1 ± 0.9 5.7 ± 1.5 5.9 ± 1.7 5.8 ± 1.7 6.6 ± 2.5
Net l-PA Antigen release -0.05 ± 0.8 12.2 ± 3.19 62.3 ± 13 150.3 ± 32.6 -2.8 ± 3.03 0.07 ± 8.0 6.63 ± 15.8 101.6 ± 59
ng 100 mL"1 of tissue mm"'
Net tPA activity release 0.17 ± 0.07 8.8 ± 1.3 24.7 ± 2.7 60.8 ± 11.2 0.85 ± 1.0 3.4 ± 2.0 17.2 ± 7.4 41.3 ± 13.1
IU 100 niL 1 of tissue mm '
Data expressed as mean ± SEM for six pregnant and 14 non-pregnant subjects. Fibrinolytic data not available or incomplete for three pregnant
and three non-pregnant subjects due to technical difficulties with simultaneous cannulation during study.
Bradykinin
(pmol mirr1)
Fig. 1. Plasma tissue plasminogen activator (t-PA) activity concentrations
in the infused (solid symbols and lines) and non-infused (open symbols and
dashed lines) arms of pregnant (circles) and non-pregnant (squares) wo¬
men during intra-arterial bradykinin infusion. Plasma t-PA activity in¬
creased in the infused arm of both pregnant and non-pregnant women
(P < 0.001 for both; one-way anova) but was greater in non-pregnant
women (P = 0.02 vs. pregnant women; two-way anova).
was unable to compensate for the dominance of PA 1-1 as
demonstrated by the adverse effect on the ratio of t-PA to PAI-
1. Thus, while we were able to stimulate the release of t-PA
from the endothelium using intra arterial bradykinin. the
overwhelming effect of PA1-1 markedly inhibited the plasma
activity of both basal and stimulated t-PA. This marked shift in
fibrinolytic potential, and the associated dramatic reduction in
active t-PA. will have prothrombotic consequences for
pregnant women.
Pregnancy is associated with an increased risk of systemic
thrombotic events including thromboembolism and myocar¬
dial infarction. Although rare (six per 100 000 pregnancies), the
age-adjusted incidence of acute myocardial infarction is
increased 4-fold by pregnancy. Acute myocardial infarction
2-i
1 1 1 1
0 100 300 1000
Bradykinin
(pmol min~1)
Fig. 2. Ratio of tissue plasminogen activator (t-PA) and plasminogen
activator inhibitor type 1 (PAI-1) in the infused (solid symbols and lines)
and non infused (open symbols and dashed lines) arms of pregnant (cir
cles) and non pregnant (squares) women during intra arterial bradykinin
infusion. Plasma t-PA/PAI-1 ratios were markedly lower in pregnant
women (P = 0.04, vs. non-pregnant women; two-way anova).
in women has several features that distinguish it from those
seen in men. In a half of women, myocardial infarction results
from plaque erosion rather than rupture and, in some
instances, endothelial erosion and coronary thrombosis can
occur in the absence of atherosclerosis [10]. Thus, thrombosis
and prothronibotic states are more likely to be implicated in the
pathogenesis of acute myocardial infarction in women and this
may be mediated through changes in fibrinolytic function.
In the current study we have demonstrated a reduction of
bradykinin-induced release of active t-PA and t-PA/PAl-1
ratio in normal pregnancy compared with non-pregnant
women. This is consistent with a study by Segar et al. [11]
that demonstrated reduced t-PA activity in pregnant compared
with non-pregnant women after the venous occlusion test.
© 2008 International Society on Thrombosis and Haemostasis
142 A. O. Rohb et al
Moreover these findings mirror that of a previous study in
whieh we demonstrated that current smokers had elevated
basal plasma t-PA and PAI-l antigen concentrations that were
associated with reduced basal and stimulated active t-PA
release [12]. Coronary thrombosis is one of the major causes of
sudden cardiac death in both smokers [13] and myocardial
infarction during pregnancy [14], The alteration in fibrinolytic
function that we have demonstrated may therefore provide a
common pathogenic mechanism underlying coronary throm¬
bosis in both patient populations. Moreover, it may in part
explain the strong association of myocardial infarction with
hypertension during pregnancy [5].
In conclusion, pregnancy is associated with perturbations of
endogenous fibrinolytic capacity that is due an overwhelming
increase in plasma PAI-l concentrations, in the presence of
unchanged t-PA antigen release leading to inadequate active t-
PA. These pro-thrombotic effects may. in part, explain the
increased risk of arterial and venous thrombosis both system-
ically and locally within the feto-placental unit in pregnant
women.
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Influence of the Menstrual Cycle, Pregnancy, and
Preeclampsia on Arterial Stiffness
Amy O. Robb, Nicholas L. Mills, Jehangir N. Din, Imogen B.J. Smith, Finny Paterson,
David E. Newby, Fiona C. Denison
Abstract Arterial stiffness and compliance are major predictors of adverse cardiovascular events and are influenced by
female sex hormones, including estrogen and progesterone. The aim of this longitudinal study was to evaluate the effect
of the menstrual cycle, normal pregnancy, and preeclampsia on central and systemic arterial stiffness. Ten healthy
nulliparous women with regular menses were studied in the early and midfollicular, pcriovulatory, and luteal phases of
a single menstrual cycle. Twenty-two primigravida pregnant women were studied throughout pregnancy at 16, 24, 32,
and 37 weeks gestation and at 7 weeks postpartum. Fifteen primigravida women with preeclampsia were studied at
diagnosis and 7 weeks postpartum. Augmentation index and carotid radial and carotid-femoral pulse wave velocities
were measured using applanation tonometry. Augmentation index fell during the luteal phase of the menstrual cycle
(luteal phase versus periovulatory phase; P<0.05). In normal pregnancy, pulse wave velocity and augmentation index
increased from 24 weeks over the third trimester (P^O.Ol for both). All of the measures were increased in women with
preeclampsia (PrSO.Ol), with augmentation index and carotid femoral pulse wave velocity remaining elevated 7 weeks
postpartum (P^0.02). We conclude that systemic arterial stiffness undergoes major changes during the menstrual cycle
and pregnancy and that preeclampsia is associated with greater and more prolonged increases in arterial stiffness. These
effects may contribute to adverse cardiovascular outcomes of pregnancy and preeclampsia. (Hypertension. 2009;53:
00-00.)
Key Words: hypertension ■ arterial stiffness ■ pregnancy ■ preeclampsia ■ menstrual cycle
Arterial stiffness is a key determinant of central aorticpressure and is; an independent predictor of adverse
cardiovascular outcomes; and organ damage.1- Female sex
affects arterial stiffness that is mediated in part via the
influence of both estrogen and progesterone on arterial
structure and function.' In the prepubertal and postmeno¬
pausal years, when female sex steroids are low, women have
stiffer arteries than age matched men.4-5 During the reprod
uctive years, female sex steroids fluctuate cyclically during
the menstrual cycle and increase dramatically in pregnancy.
The initial effect of pregnancy reducing arterial stiffness is
well documented in both animal and human studies." "
However, data are conflicting concerning the effect of sex
steroids on arterial stiffness during the menstrual cycle1213
and the effect of later gestation.1415
Augmentation index and pulse wave velocity (PWV) are
the principal measures of central arterial pressure and stiff¬
ness that can be determined noninvasivcly using applanation
tonometry. Within normotensive pregnancy, PWV is more
closely associated with birth weight than mean arterial
pressure, suggesting that arterial stiffness may represent
maternal adaptation to pregnancy better than blood prcs
sure.1" Preeclampsia is a common hypertensive complication
of pregnancy, which causes significant maternal and fetal
morbidity. Inadequate cardiovascular adaptation in early
pregnancy may predate its clinical presentation,17 and it is
associated with an increased long-term risk of maternal
cardiovascular disease. Understanding the relationship be
tween preeclampsia and arterial stiffness may. therefore, not
only inform understanding of its pathogenesis but may also
increase our understanding of the association between pre
eclampsia and later cardiovascular disease. The aim of the
current longitudinal study was, therefore, to evaluate the
effects of the menstrual cycle, normal pregnancy, and pre
eclampsia on central and systemic arterial stiffness.
Methods
Subjects
Healthy premenopausal nonsmoking nulliparous women (n=10)
with at least a 2-month history of normal regular menstrual cycles
were recruited to the study. All of the study group had confirmed
ovulation, defined as day 21 serum progesterone >30 nmol/L (please
ceo the online data supplement at http://hyper.ahajournals.org).
Exclusion criteria included current or past hypertension, use of hor
monal contraception, or use of regular medication. Nonsmoking healthy
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primigravida women with an uncomplicated singleton pregnancy
(n=22) were recruited in the first trimester of pregnancy. Exclusion
criteria included current or past hypertension, the use of regular
medication, and the development of complications during pregnancy.
Women with a singleton pregnancy who fulfilled the diagnostic criteria
for preeclampsia, as defined by the International Society for the Study of
Hypertension in Pregnancy, were recruited at diagnosis (n=15).is
Exclusion criteria included pre-existing hypertension.
All of the subjects gave written informed consent, and the study
was approved by the Lothian Research Ethics Committee and
undertaken in accordance with the Declaration of Helsinki. All of the
procedures followed were in accordance with institutional
guidelines.
Visit Schedule
Nonpregnant women attended for 4 visits during a single menstrual
cycle: early follicular (days 1 to 3), midlbllicular (days 6 to 8),
periovulatory (days 13 to 15). and luteal (days 20 to 22) phases.
Women with uncomplicated pregnancies attended for 4 visits during
pregnancy (16, 24, 32, and 37 weeks) and I visit at 7 weeks
postpartum. Women with preeclampsia attended after diagnosis and
at 7 weeks postpartum.
Study Protocol
At each visit, all of the subjects abstained from alcohol and caffeine
for 12 hours and fasted for 4 hours before attendance. All of the
subjects had an initial rest period of 30 minutes in a quiet,
temperature-controlled room. Nonpregnant subjects rested in the
supine position, whereas pregnant subjects rested in the 30° left
lateral position to avoid inferior vena cava compression by the gravid
uterus. In both groups, all of the subsequent measurements were
done in the supine position. Heart rate, blood pressure (recorded in
duplicate using an automated sphygmomanometer; Microlife
3BTO-A, validated for use in pregnancy and preeclampsia),19 and
augmentation index were measured on all of the subjects at every
visit. PWV was performed at the early follicular visit for nonpreg¬
nant subjects and at every visit in women with an uncomplicated
pregnancy or with preeclampsia.
Augmentation Index
Applanation tonometry of the radial artery was performed using a
micromanometer (Millar Instruments) and the SphygmoCor system
(AtCor Medical) in accordance with the manufacturer's recommen¬
dations. An aortic pulse pressure waveform was derived from the
radial artery waveform via a mathematical transfer function. From
this, the augmentation index (defined as the difference between the
second and first systolic peaks, expressed as a percentage of the
pulse pressure) was calculated (please see the online data supple¬
ment). The SphygmoCor system also reports augmentation index
corrected for a heart rate of 75 bpm. The augmentation index is a
measure of systemic arterial stiffness and wave reflection. Arterial
blood pressure varies with respiration; thus, to cover a complete
respiratory cycle, £2 independent analyses, incorporating 10 arterial
waveforms each, were obtained and averaged from each subject.
Pulse Wave Velocity
Using the same equipment, carotid-femoral PWV and carotid-radial
PWV were determined by sequential acquisition of pressure wave¬
forms from the carotid, femoral, and radial arteries. The timing of
these waveforms was compared with the R wave on the simulta¬
neously recorded ECG to calculate the time delay. For each subject,
a total of 2 consecutive waveform recordings was obtained, and the
mean of 2 PWV readings was recorded.
Staff specifically trained in the technique performed all of the
vascular measurements. Our interobserver and intraobserver vari¬
abilities have been described previously.30 Only measurements
meeting SphygmoCor quality control criteria were accepted.
Table 1. Baseline Characteristics of Study Population
Healthy Preeclamptic Group (n=15)
Nonpregnant Pregnant
Baseline Group Group Preterm Term
Characteristics (n=10) (n=22) (n=7) (n=8)
Age, y 31 ±2 30±1 30±4 CM-OCO
Height, m 1.70±0.02 1.65±0.02* 1.63±0.02* 1.62+0.02*
Weight, kg 68+3 73±3 66±4 75+4
Body mass 23 ±1 27 + 1 25+2 29±1f
index, kg/m2
Gestation at NA 285 + 2 213±10t 270 ±34
delivery, d
Gestation at NA 41 ±0.3 30 + 1.44 39±0.44
delivery, wk
Birth weight, g NA 3497+112 1371 ±222§ 3231 ±252
Body maoG index wao rocordod during first trimester for pregnant subjects.
Data are reported as mean±SEM. NA indicates not applicable.
*P<0.05 vs nonpregnant group.
tRs0.0009 vs nonpregnant group.
fPsO.0003 vs healthy pregnant group.
§P<0.0001 vs healthy pregnant and term groups.
Measurement of Soluble Hormones
At each visit, poriphoral venous blood was drawn from a large
antecubital vein. Serum was prepared from blood collected into
serum gel tubes (Sarstedt Monovette) and stored at — 80°C until
analysis. Estradiol and progesterone were measured using the Sie¬
mens Modical Solutions Centaur immunoassay system, and lutein
izing hormone and follicle stimulating hormone concentrations were
measured in sampler, from the nonpregnant women using the Abbott
Architect immunoassay system.
Statistical Analysis
Continuous variables were analyzed using the Kolmogorov-Smirnov
test for normality and reported as mean±SEM. For comparisons
across the menstrual cycle and within healthy pregnancy, analyses
were performed using 1 way ANOVA with repeated measures and
Bonferroni's post-tests. Two-tailed paired Student t tests were used
when comparing pregnant and postpartum data within a subject
group. Two-tailed unpaired Student t tests were used when compar¬
ing data between different subject groups. All of the calculations
were performed using Graphl'ad Prism (GraphPad Software). Sla
tistical significance was taken at 5%.
Results
Baseline Characteristics
Baseline demographics for the nonpregnant (n= 10) and
pregnant (women with uncomplicated pregnancy: n=22;
women with preeclampsia; n—15) study groups, and longi
tudinal hemodynamic variables are presented in Table 1.
Women with preeclampsia were classified according to ges
tation at presentation, into preterm (n=7; presented before 34
weeks; mean: 30; range: 24 to 34 weeks) and term (n=8;
presented after 34 weeks; mean: 38; range: 36 to 40 weeks)
groups, respectively.21 The mean gestations at delivery for
women in the preterm and term groups were 30.3 weeks
(range: 24.0 to 35.8) and 38.6 weeks (range: 36.4 to 40.4),
respectively. Nonpregnant and pregnant groups were well
matched for maternal age and body mass index; however,
pregnant women were shorter in height than those in the
nonpregnant group. There were no differences in systolic and
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Figure 1. A, Augmentation index throughout
menstrual cycle. Augmentation index varied
during the menstrual cycle (P=0.03) with a
fall in the luteal phase compared with the
periovulatory phase (*P<0.05). Data are
reported as mean±SEM. B, Heart rate-ad¬
justed augmentation index throughout men¬
strual cycle. There was a trend toward a
reduction in heart rate adjusted (at 75 bpm)
in the luteal compared with the periovulatory
phase (P==0.07). Data are reported as
mean±SEM.
diastolic blood pressures in the first trimester in women who
subsequently had an uncomplicated pregnancy or developed
preeclampsia (data not shown). At the postpartum visit,
although blood pressure had returned to within the normal
range in women who had preeclampsia, it was still higher
than in those women who had had an uncomplicated preg¬
nancy (P<0.00'1).
In women with preterm preeclampsia, 5 were taking
regular labetalol and nifedipine. 1 was taking regular meth-
yldopa and nifedipine, and I was receiving no antihyperten¬
sive therapy. Six of these women received antenatal beta¬
methasone. In women with term preeclampsia, 1 was taking
regular labetalol. with the remaining 7 women not receiving
amihyperiensive therapy. None received antenatal betametha¬
sone. Postpartum, of the original 13 women who had devel¬
oped preeclampsia, only 3 women were taking labetalol, and
I was taking methyldopa.
Effect of Menstrual Cycle oil Augmentation Index
Augmentation index. varied over the menstrual cycle
(P=0.03), with a fall in the luteal phase compared with the
periovulatory phase (3.5±1.8% versus 9.9±1;.8%; P<0.05:
Figure 1A and IB). There were no changes in any other
recorded hemodynamic variables throughout the menstrual
cycle. There was no correlation between augmentation index
and serum estradiol or progesterone at any time point in the
cycle.
Effect of Normal Pregnancy on Augmentation
Index and PWV
Augmentation index was adjusted for heart rate (calculated at
a heart rate of 75 bpm) because of variation in heart rate
during pregnancy and postpartum (PCO.OOOl). Heart rate-
corrected augmentation index varied with gestation in normal
pregnancy (P<0.0001; Figure 2) rising toward term (16
weeks versus 37 weeks, 24 weeks versus 37 weeks, and 32
weeks versus 37 weeks: all P<0.01). Moreover, heart rate-
corrected augmentation index was persistently elevated at 7
weeks postpartum compared with 16 weeks gestation
(8.7±1.9% versus -3.0±2.5%; P=0.0002).
Both carotid-femoral and carotid-radial PWVs varied with
gestation in nonnal pregnancy (both P—0.01; Figure 3A and
3B). Carotid-femoral PWV increased from 24 weeks to 7
weeks postpartum (5.0±0.2 m/s versus 5.5±0.2 m/s;
P=0.0008). Carotid-radial PWV rose from 16 and 24 weeks
to term (16 weeks versus 37 weeks and 24 weeks versus 37
weeks, both 6.4±0.2 m/s versus 7.0±0.2 m/s; PC0.05), and
values at 7 weeks postpartum were not different from those at
term (postpartum versus 37 weeks. 6.6±0.2 m/s versus
7.0±0.2 m/s; P=0.07). There was no correlation among
augmentation index, carotid femoral PWV. or carotid radial
PWV and serum estradiol or progesterone concentrations at
any time point in pregnancy.
Effect of Preeclampsia on Augmentation Index
and Pulse Wave Analysis
All of the hemodynamic variables differed between the
women with preeclampsia and women with uncomplicated
pregnancies at similar gestation, apart from heart rate in
women with term preeclampsia (Table 2). Augmentation
index, carotid femoral PWV, and carotid-radial PWV were
raised in women with both preterm and term preeclampsia
compared with gestationally matched women with uncompli
cated pregnancies (P<0.001 for both, Figure 2; P<0.01 for
both. Figure 3A. and PS0.006 for both. Figure 3B. respec¬
tively). There were no differences in augmentation index,
30-i
Gestation (weeks)
Figure 2. Effect of pregnancy, gestation, and preeclampsia on
augmentation index (adjusted for heart rate). Heart rate-adjusted
augmentation index varied with gestation in normal pregnancy
(circles; P<0.0001) rising toward term (P<0.01) and was ele¬
vated at 7 weeks postpartum compared with 16 weeks gesta¬
tion (P=0.0002). Compared with gestation-matched controls,
augmentation index was raised in both preeclamptic groups
(preterm and term, white and hatched columns, respectively;
both P-J0.001) and remained elovatod postpartum (gray oolumn;
P=0.02). There was no difference in the augmentation index
between the 2 preeclamptic groups (P=0.05). Data are reported
as mean±SEM.
Downloaded from hyper.ahajournals.org by on May 8, 2009











24 32 37 +7 PP
Gestation (weeks)
24 32 37 +7 PP
Gestation (weeks)
Figure 3. A, Effect of pregnancy, gestation, and preeclampsia
on carotid-femoral PWV. Carotid-femoral PWV varied with ges¬
tation in normal pregnancy (circles; P=0.01). Compared with
gestation-matched controls, carotid-femoral PWV was raised in
both preeclamptic groups (preterm and term, white and hatched
columns, respectively; both Ps0.01) and remained elevated
postpartum (gray column; P=0.01). There was no difference in
carotid-femoral PWV between the 2 preeclamptic groups. Data
are reported as meaniSEM. B, Effect of pregnancy, gestation,
and preeclampsia on carotid-radial PWV. Carotid-radial PWV
varied with gestation during normal pregnancy (circles; P=0.01).
Compared with gestation-matched controls, carotid-radial PWV
was raised in both preeclamptic groups (preterm and term,
white and hatched columns, respectively; both P<0.006). There
was no difference in carotid-radial PWV between the 2 pre¬
eclamptic groups in pregnancy. Data are reported as
mean±SEM.
carotid-femoral PWV, or carotid-radial PWV between
women with preterm or term preeclampsia (all P>0.05). At
the postpartum visit, despite blood pressure returning to
within the normal range, augmentation index and carotid-
femoral PWV remained elevated at 7 weeks compared with
women with uncomplicated pregnancies (I6.2±2.5% versus
8.7± 1.9% and 6.5±0.3 m/s versus 5.5±0.2 m/s. respectively,
P-&0.02 for both; Figures 2 and 3A). In contrast, there was no
difference in carotid-radial PWV by 7 weeks postpartum
between women with preeclampsia compared with women
with uncomplicated pregnancies (7.5±0.3 m/s versus
6.8±0.3 m/s; P=0.08; Figure 3B).
Discussion
PWV and augmentation index together provide a comprehen¬
sive assessment of arterial function that is highly reproducible
and validated in healthy subjects and those with cardiovas¬
cular disease.20 In this longitudinal study, we have demon¬
strated that augmentation index decreases during the luteal
phase of the menstrual cycle before rising at the beginning of
the menstrual cycle. During normal pregnancy, arterial stiff¬
ness increases from the midtrimester to term. Preeclampsia is
associated with increased arterial stiffness and, despite blood
pressure returning to within the normal range, this persists in
the immediate postpartum period. Increased arterial stiffness,
therefore, seems to be a feature of preeclampsia that extends
beyond pregnancy and may contribute to the adverse cardio¬
vascular outcomes associated with preeclampsia.
The present study is the first to use the augmentation index
to determine the effect of the menstrual cycle on systemic
arterial stiffness. We demonstrated that augmentation index is
reduced in the luteal phase of the cycle, indicating decreased
systemic arterial stiffness. Previous studies have demon¬
strated either no change22 or an increase in compliance in the
ovulatory phase compared with the follicular and luteal
phases.12'13-23 A variety of factors may account for these
seemingly discrepant findings but, in particular, the differing
methodologies used, sample population characteristics, and
timing of sampling. Our study used the augmentation index as
a method of evaluating systemic arterial stiffness, whereas
other studies have assessed whole body arterial compliance
that combines both central and peripheral measures," or
carotid artery compliance, a surrogate for aortic compli¬
ance.12 In our longitudinal study, we demonstrated clear
differences in the augmentation index depending on the day
of study. This variation will be magnified if a broader
sampling window is used, as in the study by Giannattasio et
al.23 Our study group was well characterized, with all of the
women ovulating, as indicated by a rise in luteal phase
progesterone. Despite this, neither absolute nor change in
serum hormone concentrations correlated with change in
augmentation index in our study. This perhaps reflects the
small numbers of women in our study. Alternatively, it may
imply that these hormones do not directly regulate arterial
stiffness and that other intermediate factors, eg. the renin-an¬
giotensin24 or endothelin25 systems, regulate vascular tone
and augmentation pressure during the menstrual cycle.
Because of the logistical difficulties in obtaining prepreg¬
nancy data for pregnant women, we compared our pregnancy
data with those obtained from the same women 7 weeks
postpartum. Although many cardiovascular parameters nor¬
malize rapidly over the first 2 weeks postdelivery, many
require a longer time frame to settle and probably do not fully
recover to preconceptual values.26 Moreover, Bernstein et al27
demonstrated that mean arterial pressure is lower in subse¬
quent normal pregnancies than in first pregnancies and that a
shorter interpregnancy interval leads to a greater reduction in
mean arterial pressure. Together these studies suggest that
structural vascular' changes occur in pregnancy and persist
beyond the gestational period.27
Our findings of a rise in arterial stiffness from the second
trimester to term and postnatally are supportive of previous
studies using brachial ankle PWV as a composite measure of
systemic and central stiffness28 and augmentation index.29
Other studies report no change in PWV with gestation30 or a
general decrease in PWV and augmentation index during
pregnancy.6-8'9-11 All of these studies had limited and wide
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Table 2. Hemodynamic Variables of Healthy Pregnant Women and Women With Preeclampsia Longitudinally During Pregnancy and
Postpartum
Healthy Pregnant Group (n=22) Preeclamptic Group (n=15)
Significance, Preterm Term
Within Pregnancy Preterm Term vs Pregnant vs Pregnant Significance,
Hemodynamic 16 wk 24 wk 32 wk 37 wk Postpartum (4 Time Points, (30 wk) (38 wk) Postpartum Control at Control at Postpartum
Variables Gestation Gestation Gestation Gestation Visit 16 to 37 wk) (n=7) (n=8) Visit 32 wk 37 wk Comparisons*
Heart rate, 69 ±2 72±2 77 + 2 77±2 59±1 PC0.0001 67±3 76+5 65±3 P—0.02 P—0.8 P=0.02
bpm
Peripheral 113±2 111 ±1 113±1 117± 1 113±1 P= 0.004 140±3 146±2 123±3 PcO.0001 P<0.0001 P= 0.002
SBP, mm Hg
Peripheral 65±1 65±1 70± 1 76±1 69±1 P<0.0001 87±3 95±2 77+3 PcO.0001 P-C0.0001 P-0.004
DBP, mm Hg
Peripheral 48±2 46±2 43±1 41 ±1 42±2 P=0.003 52±4 52±4 45±3 P=0.004 P=0.001 P=0.4
PP, mm Hg
Central 93±2 92 ±1 95±1 103±2 98±2 P<0.0001 126 + 4 135±3 111+3 P<0.0001 P<0.0001 P= 0.0006
SBP, mm Hg
Central 64±1 64±1 69±1 76+1 70±1 P<0.0001 89±3 97+2 79±3 P<0.0001 P<0.0001 P= 0.002
DBP, mm Hg
Central 30±1 28±1 26±1 27±1 29±2 P-0.13 37±2 38±3 33±2 PC0.0001 P= 0.0002 P=0.2
PP, mm Hg
Mean arterial 81 ±1 80±1 84 ±1 90 ±1 84±1 P<0.0001 105+2 113±2 92 ±2 P<0.0001 PC0.0001 P= 0.001
pressure,
mm Hg
PP indicates pulse pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure. Data are reported as mean+SEM.
•Postpartum comparison between all of the women with preeclampsia and healthy pregnant women at 7 weeks postpartum.
time points, with the third-trimester visits performed earlier
than in our study. These limitations may potentially explain
why the subtle rise in PWV and augmentation index in the
third trimester went undetected in these studies.
The relative reduction in arterial stiffness during pregnancy
compared with postpartum is likely to arise from several
factors. Estrogen has favorable effects on the endothelium
and vascular smooth muscle cells.3' with many of the
hemodynamic changes observed in normal pregnancy being
mimicked in nonpregnant animals chronically exposed to
estrogen.32 Both the endothelium and vascular smooth muscle
cells express receptors for estrogen and progesterone33
through which they can regulate vascular tone.34 Therefore,
they are likely to influence arterial stiffness through effects
on mean arterial pressure, as well as structural changes to
elastin, collagen, and smooth muscle in the arterial wall.3-35
Progesterone has often be thought to have opposing vascular
effects to estradiol, although it has favorable vascular effects
in vitro3 and in vivo.34 However, despite the increased serum
estradiol and progesterone concentrations with advanced
gestation, we report an increase in arterial stiffness in the
third trimester that we postulate is attributed to factors other
titan sex steroids.
Consistent with previous cross-sectional studies, all of the
variables of systemic and central arterial stiffness measured
were higher in women with preeclampsia.I5J6-36 We cannot
exclude the possibility that medication influenced the col¬
lected data, because the effect of antihypertensive agents on
PWV and augmentation index has not specifically been
studied during pregnancy. Given that calcium channel block¬
ers37 and /3-blockers38 reduce PWV in nonpregnant popula¬
tions, it seems likely that the increase in arterial stiffness
observed in women with preeclampsia would have been even
greater if these women were not taking antihypertensive
agents.
The present study contrasts with a cross-sectional study
that reported no difference in arterial stiffness assessed by
augmentation index in women with a history of preeclamp¬
sia.3'3 However this study was performed on average 5 to 6
years after the index; pregnancy, and it is possible that
applanation tonomeuy is not sensitive enough to detect more
subtle remote effects. Similarly, Spasojevic et al15 found no
difference in the augmentation index between women with
preeclampsia and healthy pregnant women at a 6-week
postpartum visit. In our study, we performed a comprehen¬
sive assessment of arterial function and demonstrated that
augmentation index and carotid-femoral PWV remained ele¬
vated at 7 weeks in women with preeclampsia compared with
women with uncomplicated pregnancies.
Interestingly, carotid-radial PWV, unlike our other mea¬
sures of arterial stiffness, had normalized by 7 weeks post¬
partum. Carotid-radial PWV is partly determined by the
muscular brachial artery, whereas carotid-femoral PWV is
determined by the more elastic aorta. Carotid-radial PWV is,
therefore, susceptible to changes in both vascular smooth
muscle tone and smooth muscle remodeling. It is, therefore,
plausible that the increase in carotid-radial PWV in pre¬
eclampsia and pregnancy is in part attributed to an effect on
smooth muscle function that may normalize more rapidly
postpartum than any effect on the extracellular elastin-
collagen matrix of the aorta. Other conditions, eg, diabetes
mellitus and ageing, are known to have preferential effects on
central rather than peripheral arteries,40 and it is. therefore,
perhaps not surprising that vascular remodeling in pregnancy
similarly does not occur in a uniform manner.
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Carotid-femoral PWV is recognized as the gold standard
measure of arterial stiffness, as stated in the recent expert
consensus document on the measurement of arterial stiff¬
ness.1 In our cohort, carotid-femoral PWV remained elevated
at 7 weeks postpartum, suggesting that the effects of pre¬
eclampsia on vascular structure and function extend beyond
pregnancy. If arterial stiffness remains elevated in later life,
this may in part contribute to the increased risk of cardiovas¬
cular and cerebrovascular diseases.41
Abnormalities of arterial structure and function were asso¬
ciated with higher postpartum blood pressures, although these
women were no longer hypertensive, with blood pressures
within the normal range. It is not possible from our studies to
determine whether raised blood pressure during preeclampsia
is a cause or a consequence of increased arterial stiffness.
There is now good evidence to suggest that aortic stiffness is
an independent predictor of progression to hypertension even
in young nonhypertensive individuals,42 with endothelial
function being inversely related to arterial stiffness in healthy
volunteers.43 We, therefore, believe that in preeclampsia
endothelial dysfunction increases aortic stiffness, which, in
turn, causes an increase in blood pressure.
Alternative interpretations of our findings are possible,
and. in particular, we cannot discount that changes in arterial
stiffness occur as a consequence of prolonged hypertension in
preeclampsia, nor can we be certain that changes in arterial
stiffness at 7 weeks postpartum persist long term. A prospec¬
tive study in which blood pressure and arterial stiffness were
determined in a very large cohort of pregnant woman before
the onset of preeclampsia with long-term postpartum
follow-up would be required to address these issues.
Perspectives
In this longitudinal study, we have demonstrated that the
augmentation index decreases during the lineal phase of die
menstrual cycle widi arterial stiffness rising from the midtri-
mester of pregnancy to term. The factors regulating these
changes in arterial stiffness have yet to be identified. How¬
ever. preeclampsia is associated with increased arterial stiff¬
ness, and this persists into die postpartum period. Increased
arterial stiffness, therefore, appears to be a feature of pre¬
eclampsia that extends beyond pregnancy and suggests an
abnormality of vascular structure and function associated
widi this condition, perhaps contributing to its adverse
cardiovascular outcomes.
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BACKGROUND: Endothelial progenitor cells (EPCs) are circulating mononuclear cells that participate in angiogcncsis. The aim of this
study was to determine the influence of the menstrual cycle on the number and function of EPCs, and to investigate their relationship
with circulating concentrations of sex steroids and inflammatory mediators.
METHODS: Ten healthy nulliparous, premenopausal, non-smoking women with regular menses were studied over a single menstrual cycle.
Venepuncture was performed in the menstrual, follicular, peri-ovulatory and luteal phases. EPCs were quantified by flow cytometry
(CDI33+CD34+KDR~ phenotype) and the colony-forming unit (CFU-EPC) functional assay. Circulating concentrations of estradiol,
progesterone and inflammatory mediators (TNF-a, IL-6, sICAM-l and VEGF) were measured by immunoassays.
RESULTS: The numbers of CD 133+CD34+KDR+ cells were higher in the follicular phase (0.99 ± 0.3 x I06 cells/1) compared with the
peri-ovulatory phase (0.29 + 0.1 x I06 cells/I; P< 0.05). In contrast, the numbers of CFU-EPCs did not vary over the menstrual cycle.
There were no correlations between EPCs and concentrations of either circulating sex steroids or inflammatory mediators.
CONCLUSIONS: CD 133+CD34^KDR' cells but not CFU-EPCs vary during the menstrual cycle. Our findings suggest a potential role for
circulating EPCs in the normal cycle of physiological angiogenesis and repair of the uterine endometrium that is independent of circulating sex
steroids or inflammatory mediators.









During the normal menstrual cycle, the uterine endometrium
undergoes a unique cycle of physiological angiogenesis and endothelial
repair. These processes begin in the proliferative phase and continue
into the secretory phase of the cycle and are under tight hormonal and
inflammatory control (jabbour et a/.. 2006). Until recently, endo¬
metrial angiogenesis was thought to occur primarily from new
vessels sprouting via recruitment of local endothelial cells from neigh¬
bouring blood vessels (Risau, 1995; Gambino et al., 2002). However
recently, an alternative or complementary mechanism involving circu¬
lating endothelial progenitor cells (EPCs) has been proposed in the
control and regulation of endometrial angiogenesis (Mints et a/., 2008).
EPCs are circulating mononuclear cells derived from the bone
marrow, which have the potential to proliferate, migrate and
differentiate into mature endothelial cells. Increasingly they are recog¬
nized as having an important role in mediating vascular endothelial
repair and angiogenesis (Urbich and Dimmeler, 2004; Robb et o/..
2007). A role for EPCs in physiological endometrial angiogenesis
was first implicated by Asahara et al. (1999) who demonstrated local¬
ization of EPCs within endometrial vasculature and stroma after
induced ovulation in mice. More recently, an average 6% of endo¬
metrial endothelial cells were found to be donor derived after a hae-
matological stem cell transplant in a mouse model (Bratincsak et al..
2007). These animal studies are supported by clinical studies in
women demonstrating that stromal and endothelial endometrial cells
can originate from donor-derived bone marrow cells (Risau, 1995;
Taylor, 2004).
Currently there is a lack of consensus on the definitive EPC pheno¬
type and a variety of surface markers and functional assays are being
© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
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used to assess this progenitor population. This makes comparison
between different clinical studies difficult. Although groups are increas¬
ingly quantifying EPCs by surface expression of phenotypic markers
(CDI33+CD34+KDR+), the colony-forming unit endothelial progeni¬
tor cell assay (CFU-EPC) represents a functional assessment that
quantifies the ability of putative endothelial progenitors to form colo¬
nies (Hill et of., 2003). To date, relatively few clinical studies have
either used both approaches or compared EPC phenotype and
function.
Local factors including estradiol, tumour necrosis factor-a (TNF-a),
interleukin (IL)-6, vascular endothelial growth factor (VEGF) and inter¬
cellular adhesion molecule (ICAM)-1 are implicated in the regulation
of endometrial angiogenesis (Kapiteijn et a/„ 2001; Jabbour et of,,
2006; Jasper et of., 2007). Many of these factors also appear to be
involved in EPC mobilization and trafficking in mice models (Rafii
et o/„ 2002; Iwakura et a/., 2003; Hamada et a/., 2006; Iwakura
et al., 2006) and human studies (Naiyer et al., 1999; Kalka et al.,
2000; Bulut et al., 2007; Foresta et al., 2007; Grisar et al., 2007; Fan
et al., 2008). However, whether cyclical systemic variation of these
factors during the menstrual cycle is associated with changes in pheno¬
typic or functional circulating EPCs is unknown. The aims of this study
were therefore to determine the influence of the menstrual cycle on
the number and function of circulating EPCs, and to investigate how
their number and function vary with cyclical variation of circulating
sex steroids or inflammatory mediators.
Materials and Methods
Subjects
Ten healthy, non-smoking, nulliparous women with at least a 2 month
history of normal regular menstrual cycles gave written informed
consent and were recruited to the study. Exclusion criteria included use
of hormonal contraception, infection, hypertension or other significant
past medical history, regular medication, or a history of heavy menstrual
bleeding or dysmennorhoea. All the study group had confirmed ovulation,
defined as Day (D) 21 serum progesterone >30 nmol/l. The study was
approved by the local research ethics committee and undertaken in
accordance with the Declaration of Helsinki.
Visit schedule
Volunteers abstained from alcohol, caffeine and tobacco for 12 h and
fasted for 4 h prior to attendance. Participants attended for four visits
during a single menstrual cycle [D I -3 (menstrual), D 6-8 (mid-follicular),
D 13-15 (peri-ovulatory) and D 20-22 (mid-luteal)]. At the first visit,
blood pressure and heart rate were recorded in duplicate using an auto¬
mated sphygmomanometer (Micro life 3BTO-A) following a I5min
supine rest. Height (m) and weight (kg) were also measured to allow
calculation of body mass index (BMI; kg/m2). At each visit, 50 ml of per¬
ipheral venous blood was collected from the antecubital fossa: 30 ml was
anti-coagulated with EDTA (Sarstedt-Monovette, Germany) for full blood
count, flow cytometric analysis and CFU-EPCs culture; 10 ml was
anti-coagulated with EDTA and centrifuged at 2000g with plasma being
stored at -80"C until subsequent analysis; and the remaining 10 ml was
collected in a serum tube for hormonal analysis.
Flow cytometry
EPCs were quantified by phenotype in whole blood samples using flow
cytometry. Briefly, cells were directly stained and analysed for phenotypic
expression of surface antigens using anti human monoclonal antibodies
conjugated to phycoerythrin (PE), fluorescein isothiocynate (FITC) or allo-
phycocyanin (APC). Whole blood (200 fxl) was stained with antibodies
[anti-CD34-FITC (Becton Dickinson, Oxford, UK), anti-CD 133-PE
(Miltenyl Biotech, Germany) and anti-KDR(VEGFR2)-APC (R&D
Systems, Minneapolis, USA)] for 20 min in the dark at room temperature.
Appropriate negative unstained controls and isotype-matched anti-IgG i -
APC (R&D Systems) were used to establish positive stain boundaries.
Erythrocytes were lysed (UTI-lyse™, Dako). Next, samples were centri¬
fuged at 1500g for 5 min at room temperature, and cells were washed
and re-suspended in 500 jxl of phosphate-buffered saline (PBS) without
cations (Sigma-Aldrich, Poole, UK). For FACS analysis, 80 000 events
were acquired in the lymphocyte region (as determined by characteristic
forward and side scatter profile) using a FACSCalibur00 analyser (Becton
Dickinson). EPCs were quantified based on the percentage of CD34+
CDI33+KDR+ triple positive leucocytes and expressed as number of
cells per litre of blood.
CFU-EPC assay
Based on the assay described by Hill et al. (2003), functional EPCs were
quantified using the CFU-EPC assay and commercial kit reagents according
to the manufacturer's recommendations (StemCell Technologies, UK).
Briefly, blood samples were diluted with PBS without cations
(Sigma-Aldrich) and peripheral blood mononuclear cells (PBMCs) were
isolated by centrifugation using Ficoll-Paque (Histopaque, Sigma-Aldrich).
PBMCs were washed twice with PBS and once with culture medium and
re-suspended at 5 x I06 cells/ml in Complete Culture Medium (EndoCult
Supplement mixed with EndoCult Basal Medium and PenStrep, containing
penicillin and streptomycin, Stem Cell Technologies, UK). Cells were then
plated at 2 ml/well in a 6-well fibronectin-coated plate (Becton Dickinson)
and incubated at 37°C, 5% C02 with 95% humidity for 2 days. The non¬
adherent cells were then harvested and transferred to fibronectin-coated
24-well plate at I x I06 cells/well (Becton Dickinson) for a further 3 days.
Colonies (CFU-EPC. early outgrowth colony-forming endothelial progeni¬
tor cells; Stem Cell Technologies) were defined using the published
method as a central core of'round' cells surrounded by elongated 'sprout¬
ing' cells at the periphery. Colonies were counted in a minimum of two
wells per sample by observers unaware of the subjects' clinical profiles
and the results were expressed as mean numbers of CFU-EPCs per I x
I06 cells plated.
Uptake of acetyiated LDL
and immunophenotyping
To confirm endothelial-cell lineage, colonies were stained directly using
acetyiated LDL and co-stained with Lectin (Ulex europaeus I agglutinin) as
previously described (Kalka et al., 2000). Briefly, cells were incubated
with I. I '-dioctadecyl-3,3,3',3'-tetramethylcarbocyanine-labelled acetyiated
LDL (Dil-AcLDL (Serotech); 1: 100 in Endocult) for 4 h, washed in PBS and
fixed with ice-cold methanol for 10 min. Colonies were stained for I h with
FITC-labelled lectin from Ulex europaeus (Sigma; 1:100 in PBS), counter-
stained with DAPI (Sigma) and mounted with Permafluor (Immunotech).
For CD 105 (endoglin) and CD 146 staining, fixed colonies were per-
meabilized and blocked in a solution of 10% goat serum (Autogen Bio-
clear), 1% BSA (Sigma) and 0.02% IGEPAL/NP40 (Sigma). Next,
colonies were incubated with primary murine monoclonal antibodies
against human CD 105 (1:500, BD Transduction Laboratories) or CD 146
(1:200, Springbioscience) for 2 h at room temperature. A secondary poly¬
clonal goat anti-mouse biotinylated antibody (DAKO) was added for
30 min followed by streptavidin-Alexa Fluor 546 or streptavidin-Alexa
Fluor 488 (Molecular probes) for I h in the dark. Nuclei were counter-
stained and colonies were mounted as above. Between each step the
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slides were washed with PBS for 5 min. Human umbilical vein endothelial
cells (HUVECs) were used as positive controls for all of the endothelial
markers. Staining was performed without the primary antibody as a nega¬
tive control for each antibody. In addition, a human colon cell-line (HT29)
population was used as a negative control for the endothelial markers.
Phase-contrast images of the same CFU-EPCs were used to confirm
colony morphology. All images are representative of at least three different
subjects. A Zeiss 'LSM 510 Meta' confocal microscope, with x40 oil
immersion objective was used to visualize the stained cells. Image
capture was performed with LSM 510 meta-analysis computer software.
Hormone and inflammatory marker assays
Serum concentrations of estradiol, progesterone, lutenizing hormone (LH)
and follicle-stimulating hormone (FSH) were measured using the Siemens
Medical Solutions Centaur and Abbott Architect immunoassay systems.
Commercial enzyme-linked immunosorbent assays (ELISAs) were used
to measure plasma concentrations of TNF-a (measures total TNF-a com¬
prising free TNF-a and TNF-a bound to its soluble receptors). IL-6,
sICAM-l (all R&D Systems, detection limits 0.1 pg/ml, 0.039 pg/ml and
0.35 ng/ml, respectively) and VEGF (Calbiochem, Darmstadt. Germany,
detection limit 9.0 pg/ml).
Statistical analysis
Continuous variables are reported as mean + SEM. Statistical analyses
were performed using one-way ANOVA with repeated measures and
Bonferroni's post-tests for multiple comparisons. Non-parametric
Friedman analyses were used where appropriate. Correlation coefficients
were calculated using Pearson or Spearman analyses for parametric and
non-parametric data, respectively. All calculations were performed using
GraphPad Prism (GraphPad Software, USA). Statistical significance was
taken at 5%.
Results
All women (age, 31.4 + 2.0 year) were of normal body composition
(BMI, 23.4 + 0.7 kg/m2) and had regular menstrual cycles (cycle
length 28 ± 0.4 days). Baseline systolic and diastolic blood pressures
and heart rate, measured at D 1-3 of the cycle, were 110 +
2 mmHg, 67 + 2 mmHg and 60 + 2 bpm, respectively.
Phenotypic and functional EPCs during the
menstrual cycle
Triple positive (CD34+CDI33+KDR+) EPCs varied during the men¬
strual cycle (P = 0.04) with mid-follicular levels (0.99 + 0.3 x I06
cells/1) being 3-fold higher than peri-ovulatory levels (0.29 + 0.1 x
I06 cells/1) (Fig. I A; P<0.05). A similar trend was seen for
CD34+KDR+ cells (data not shown).
In contrast, there was no variation in numbers of CFU-EPCs during
the menstrual cycle (Fig. I B; P > 0.05). Direct staining confirmed that
CFU-EPCs, like mature endothelial cells, bind lectin, integrate acetyl-
ated LDL and are positive for the endothelial markers CD 105 and
CDI46 (Figs 2 and 3, respectively). There was no correlation
between EPCs quantified by phenotype (CD34+CD133~KDR"r) and
number of functional CFU-EPCs during the menstrual cycle.
Sex steroids arid inflammatory mediators
There was normal cyclical variation in circulating pituitary and ovarian
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Figure I (A) Concentrations of circulating triple positive CD 133+"
CD34+KDR+ EPCs varied throughout the menstrual cycle (P = 0.04,
one-way ANOVA with repeated measures) with mid-follicular levels
(0.99 + 0.3 x I06 cells/l) being 3-fold higher than peri-ovulatory
levels (0.29 + 0.1 x I06 cells/l, P< 0.05, Bonferroni's post-test for
multiple comparisons),
(B) Numbers of CFU-EPCs do not vary throughout the menstrual
cycle (one-way ANOVA with repeated measures) (P > 0.05).
concentrations, and peri-ovulatory and mid-luteal peaks in serum
estradiol and progesterone concentrations, respectively (Table I).
Concentrations of plasma TNF-ot (P= 0.05) but not IL-6, sICAM-l
or VEGF (P = 0,5 I, P = 0.36, P = 0.84, respectively) varied over the
menstrual cycle. There was no relationship between functional or phe¬
notypic EPCs and circulating levels of estradiol, progesterone,
sICAM-l (all r2 < 0.06), IL-6 (r=0.06) or VEGF (r = 0.01) at any
phase of the menstrual cycle. A weak correlation was seen between
plasma levels of TNF-a and concentration of phenotypic EPCs (r =
0.33, P = 0.04).
Discussion
This study demonstrates that numbers of circulating EPCs quantified
by phenotype (CD34+CD133+KDR+ cells) vary during the menstrual
cycle, peaking in the mid-follicular phase. In contrast, EPCs quantified
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by the functional CFU-EPC assay did not vary during the menstrual
cycle. During the normal menstrual cycle, we propose that mobilized
CD34+CDI 33TKDR+ cells have the potential to contribute to endo¬
metrial angiogenesis during the mid-follicular phase of the cycle
(Girling and Rogers, 2005). Given that there was no correlation
between EPCs quantified by phenotype or function and the levels of
circulating sex hormones or inflammatory mediators measured, this
raises the possibility of an endometrial specific factor being present
in mid-follicular phase endometrium, which has either the potential
Figure 2 Typical colony forming unit.
A typical colony-forming unit (CFU EPC) with a characteristic core of
round cells and sprouting spindle cells at the periphery (x 100
magnification).
to mobilize EPCs or to remove them from the peripheral circulation
into endometrium.
The present study is the first to investigate the influence of the men¬
strual cycle on both phenotypic and functional EPCs. Our finding that
CD34+CD133~KDR"^ EPCs peak during the mid-follicular phase
differs from two recent studies of EPCs during the menstrual cycle
(Matsubara et at., 2006; Fadini et at.. 2008). A variety of factors, in par¬
ticular the differing methodologies employed and timing of sampling,
may account for these seemingly discrepant findings. Fadini et at.
(2008) demonstrated a similar 2-fold increase in CD34+KDR^
numbers during the menstrual cycle, but the peak seemed to occur
in the peri-ovulatory phase rather than earlier during the follicular
phase as in our study. However, Fadini et at. (2008) did not specify
the day of sampling so it is possible that this peak occurred
between Day 6 and 12 of the menstrual cycle which would therefore
be entirely consistent with our findings. In the cross-sectional study by
Matsubara et at. (2006), they found that EPCs were increased in the
luteal phase compared with the follicular phase of the cycle in
women. They quantified the proliferative capacity of EPCs using adher¬
ent peripheral blood mononuclear cells that tested positive for
Ac-LDL and lectin after 7 days in culture, and did not use the
EPC-CFU assay that we have described here. Moreover, although
Matsubara et at. (2006) compared EPCs during the follicular and
luteal phase of the cycle, it is again unclear on which day the
samples were taken in their cross-sectional study. From our longitudi¬
nal study, in which samples were taken at four consecutive time-points
within a single cycle, there are clear differences in concentrations of
CD34+CD133^KDR~ EPCs depending on the day of sampling. This
variation will be magnified if a broader time window of sampling
E \
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Figure 3 Characterization of CFU-EPCs.
Live CFU-EPCs exposed to Dil-AcLDL (A), stained with FITC-lectin (Ulex europeaus) (B), nuclear counterstain DAPI (C) and merged image (D). Fixed
CFU-EPCs immunostained for the endothelial cell marker CD 105 (E), nuclear counterstain (F) and merged image (G) and for CD 146 (H), nuclear
counterstain (I) and merged image (J) (x 40 magnification).
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Table I Hormonal and inflammatory profile of participants
Day of menstrual cycle Significance
1-3 6-8 13-15 20-22
Day at sampling 2 + 0.2 7 ±0.2 14 ± 0.3 21 + 0.2
LH (U/l) 5 ± 0.4 7 ± 0.4 32 + 7.2 5 ±0.5 P< 0.0001
FSH (U/l) 6 ± 0.4 6 ± 0.4 9+1.9 3 ±0.2 P = 0.002
Estradiol (pmol/l) 180 + 21.1 318 + 68.4 1342 ± 274.4 827 ± 93.4 P< 0.0001
Progesterone (nmol/l) 4 + 0.3 3 + 0.2 7 ±2.1 47 + 4.5 P< 0.0001
sICAM-l (ng/ml) 214 ± 15.2 193 ± 11.6 203 ± 8.1 199 ± 1 1.8 P= 0.36
VEGF (pg/ml) 42 ± 16.0 44 + 14.8 39 ± 11.3 93 ± 60.4 P = 0.84
TNF-a (pg/ml)" 0.73 (0-3) 0.41 (0-0.9) 0.075 (0-1) 0.0 (0-0.4) P = 0.05
IL-6 (pg/ml)" 0.13 (0.1-0.2) 0.1 1 (0.1-0.2) 0.095 (0.06- 1) 0.14 (0.07-0.5) P = 0.51
Circulating LH. FSH, estradiol and progesterone varied significantly throughout the menstrual cycle. Plasma TNF cv concentrations decreased, while levels of IL-6. sICAM-l and VEGF did
not vary significantly. Values reported as mean + SEM or "median with inter-quartile ranges.
was used, and by the use of multiple subjects because of the potential
for inter-subject variability.
The exact phenotype of EPCs has been debated since the original
publication by Asahara et al. (1999) in which it was demonstrated
that CD34+ cells extracted from circulating peripheral blood formed
new blood vessels in culture and contributed to angiogenesis in a
mouse model of ischaemia. The purity of this cell population was
only 15% raising the possibility that a variety of other circulating cell
types may also have angiogenic potential. The current consensus is
that mononuclear cells co-expressing CD34, CD 133 and KDR
(so-called 'triple positive' cells) constitute the most likely phenotype
of circulating endothelial progenitors. However, these cells are rare
in normal peripheral blood, constituting between 0.01 and 0.0001%
of the circulating leukocyte population, making their accurate quantifi¬
cation by flow cytometry difficult. As a result, assays based on the
quantification of functional populations of EPCs with colony-forming
activity in cell culture (CFU-EPC) have emerged as alternatives (Hill
et o/„ 2003).
The validity of the CFU-EPC assay in quantifying EPCs has recently
been challenged by studies showing that the CFU-EPC cells are
derived from monocyte-like cells and not the circulating CD34" hae-
mangioblast (Prater et al.. 2007; Rohde et al.. 2007: Yoder et a/.,
2007). Our finding of a lack of correlation between concentrations
of CD34+CD133+KDR+ EPCs and EPCs quantified by the CPU
assay is therefore important. Currently, these two methods are
used interchangeably in clinical studies and are in general thought to
be measuring the same endothelial progenitor, derived from CD34+
pluripotent cells, using different techniques. This is clearly not the
case as our study demonstrates. Thus, cells quantified by flow cytome¬
try (phenotype) and cell culture (CFU-EPC) are likely to be different
cell populations with differing biological functions and progenitor
potential (Tura et al., 2007). Ingram et al. (2004) recently have
described a new EPC population in human umbilical cord blood
called the 'late outgrowth endothelial progenitor cell' with a high
proliferative capacity and the ability to express endothelial markers
and form tubules in vitro. This population arises from CD34~ cells.
Thus, the CD34+CD133^KDR^ EPCs may correlate with this
late outgrowth assay.
We demonstrate that CD34^CD 133+KDR~ EPCs peak during the
mid-follicular phase of the menstrual cycle. In our study, this effect
does not appear to be driven by the circulating sex hormones or
inflammatory factors studied. The lack of correlation of EPCs with
serum estradiol concentrations differs from a study by Sugawara
et al. in which they found that during pregnancy, there was a clear
correlation between estradiol and EPCs quantified by a modified
CFU-EPC assay (Sugawara et al.. 2005). Differences in methodology
or the higher serum concentrations of estradiol in pregnancy com¬
pared with the menstrual cycle could account for these differences.
In our study, there was no correlation between concentrations of
the circulating inflammatory mediators studied and EPCs. A number
of factors may explain this. First, unlike CD34TCD133+KDR+ EPCs.
there was no cyclical variation in concentration of the inflammatory
mediators IL-6, sICAM-l and VEGF studied over the menstrual
cycle. Although, there was a decrease in soluble TNF-a concentration
over the cycle and a weak correlation with numbers of CD34+
CDI33+KDR+ EPCs, the absolute levels of TNF-a were almost
10 x lower than in conditions such as rheumatoid arthritis and
cardiac failure, where strong correlations with EPCs have been
demonstrated (Valgimigli et al., 2004; Grisar et al., 2005). It is there¬
fore not surprising that concentrations of the circulating inflammatory
mediators and EPCs were not correlated. Moreover, the small
numbers in our study may also be a contributing factor. Second,
mobilization of EPCs may be controlled by local rather than systemic
levels of inflammatory mediators. Mobilization of EPCs in response to
increased local but not systemic concentrations of VEGF and stromal
cell-derived growth factor has recently been demonstrated in animal
and human limb ischaemia models (Hur et al.. 2007: Oh et of.,
2007). We measured systemic and not local levels of VEGF. This
may account for the lack of correlation between VEGF and EPCs
demonstrated in this study. Finally, other factors thought to be
involved in regulation of endometrial angiogenesis. including the angio-
poetins (Girling and Rogers, 2005; Saito et al., 2007), may play a role in
EPC mobilization and recruitment (Mints et al., 2007) during the mid-
follicular phase of the menstrual cycle.
In summary, we have demonstrated that during the normal
menstrual cycle, there is cyclical variation of phenotypic triple positive
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EPCs. Their peak in the mid-follicular phase suggests a potential role
for circulating EPCs in the normal cycle of physiological angiogenesis
and repair of the uterine endometrium. It would be of interest to
determine whether pathologies such as heavy menstrual bleeding
and endometriosis are associated with dysregulation of EPC number
or function.
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